P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.168e-09 | -20.57 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 17 | 19454 | 50 |
ABLIM1,SLC4A4,ATP1A2,LSAMP,TRPS1,GJA1,GPM6A,AHCYL2,MSI2,SORBS1,NHSL1,CPE,SLC1A3,AQP4,MACF1,PTPRZ1,SPARCL1 |
6.200e-09 | -18.90 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 45 | 16828 | 49 |
NEBL,SPON1,PARD3,MACF1,ZBTB20,CTNND2,SLC1A2,PTPRZ1,BMPR1B,FGFR3,PON2,NTM,NPAS3,ABLIM1,NFIA,NKAIN3,LSAMP,SOX5,TNIK,SLC4A4,ZNRF3,MEIS2,ATP13A4,NHSL1,PITPNC1,SFXN5,SORBS1,RFX4,MSI2,GPM6A,GPC5,LRIG1,CPE,FBXL7,SLC1A3,TRPS1,ITPR2,LIFR,CDH20,AHCYL2,PARD3B,RYR3,DTNA,SPARCL1,PREX2 |
9.497e-09 | -18.47 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 27 | 16828 | 49 |
TNIK,SOX5,PREX2,RYR3,LSAMP,ITPR2,LIFR,CDH20,AHCYL2,NKAIN3,NPAS3,FBXL7,SLC1A3,CPE,GPM6A,GPC5,SLC1A2,CTNND2,PTPRZ1,FGFR3,SFXN5,ZBTB20,PARD3,ATP13A4,ZNRF3,SPON1,MEIS2 |
1.086e-08 | -18.34 | cell periphery | cellular component | GO:0071944 | 6020 | 35 | 19108 | 49 |
FGFR3,CTNNA2,LSAMP,TNIK,ATP13A4,GLUL,SORBS1,SPON1,LRIG1,LIFR,AQP4,CPE,PARD3,SPARCL1,MACF1,ITPR2,ATP1A2,GJA1,GPC5,PON2,GPM6A,NTM,DTNA,CTNND2,RYR3,PREX2,NKAIN3,PARD3B,CDH20,PTPRZ1,SLC1A2,BMPR1B,SLC1A3,ZNRF3,SLC4A4 |
2.195e-08 | -17.63 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 24 | 16828 | 49 |
SLC1A3,FBXL7,CPE,GPC5,GPM6A,PREX2,SOX5,TNIK,LSAMP,RYR3,NKAIN3,CDH20,AHCYL2,LIFR,ITPR2,PARD3,ATP13A4,MEIS2,SPON1,ZNRF3,PTPRZ1,CTNND2,SFXN5,ZBTB20 |
2.351e-08 | -17.57 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 22 | 16828 | 49 |
GPC5,SPON1,GPM6A,LRIG1,ATP13A4,SLC1A3,PARD3,CPE,FBXL7,NPAS3,NHSL1,NKAIN3,AHCYL2,ITPR2,LSAMP,RYR3,BMPR1B,PREX2,RFX4,CTNND2,SOX5,SLC1A2 |
2.351e-08 | -17.57 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 22 | 16828 | 49 |
LSAMP,RYR3,PREX2,SOX5,NKAIN3,AHCYL2,ITPR2,FBXL7,CPE,SLC1A3,NPAS3,GPC5,GPM6A,LRIG1,BMPR1B,RFX4,CTNND2,SLC1A2,NHSL1,ATP13A4,PARD3,SPON1 |
2.942e-08 | -17.34 | plasma membrane | cellular component | GO:0005886 | 5538 | 33 | 19108 | 49 |
SLC1A2,PTPRZ1,ZNRF3,SLC4A4,SLC1A3,BMPR1B,NKAIN3,CDH20,PARD3B,PREX2,NTM,GPM6A,RYR3,CTNND2,DTNA,GJA1,ATP1A2,PON2,GPC5,ITPR2,MACF1,CPE,AQP4,LIFR,LRIG1,PARD3,ATP13A4,LSAMP,TNIK,CTNNA2,FGFR3,SORBS1,GLUL |
4.446e-08 | -16.93 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 25 | 16828 | 49 |
LRIG1,GPM6A,GPC5,TRPS1,SLC1A3,FBXL7,CPE,NKAIN3,ITPR2,LIFR,RYR3,LSAMP,PARD3B,PREX2,SOX5,NEBL,MEIS2,ZNRF3,SPON1,ATP13A4,PARD3,SFXN5,RFX4,SLC1A2,CTNND2 |
8.941e-08 | -16.23 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 3 | 10285 | 30 |
SLC1A3,GLUL,SLC1A2 |
8.941e-08 | -16.23 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 3 | 10285 | 30 |
SLC1A2,GLUL,SLC1A3 |
1.027e-07 | -16.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 24 | 16828 | 49 |
MEIS2,ZNRF3,SPON1,NEBL,PARD3,SFXN5,RFX4,SLC1A2,CTNND2,LRIG1,GPM6A,GPC5,TRPS1,FBXL7,CPE,SLC1A3,NKAIN3,ITPR2,LIFR,PREX2,SOX5,LSAMP,RYR3,PARD3B |
1.086e-07 | -16.04 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 19 | 16828 | 49 |
ITPR2,LIFR,SFXN5,PARD3B,LSAMP,DTNA,RYR3,CTNND2,SOX5,TNIK,FGFR3,NEBL,GPC5,GPM6A,MEIS2,ATP13A4,PARD3,SLC1A3,TRPS1 |
1.245e-07 | -15.90 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 9 | 19454 | 50 |
CTNNA2,NEBL,MACF1,DTNA,PARD3,NHSL1,SORBS1,TNIK,ABLIM1 |
1.551e-07 | -15.68 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 39 | 16828 | 49 |
SLC1A2,CTNND2,RFX4,PTPRZ1,FGFR3,SORBS1,SFXN5,MACF1,ZBTB20,NHSL1,PITPNC1,PARD3,ATP13A4,SLC4A4,SPON1,MEIS2,NEBL,TNIK,SOX5,PREX2,PARD3B,RYR3,LSAMP,LIFR,ITPR2,AHCYL2,NKAIN3,NFIA,TRPS1,NPAS3,CPE,FBXL7,SLC1A3,ABLIM1,LRIG1,NTM,GPM6A,GPC5,PON2 |
2.803e-07 | -15.09 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 29 | 16828 | 49 |
ATP13A4,PARD3,NEBL,SPON1,MEIS2,CTNND2,SLC1A2,FGFR3,MACF1,FBXL7,CPE,SLC1A3,TRPS1,GPM6A,GPC5,LSAMP,DTNA,RYR3,SOX5,SPARCL1,TNIK,PREX2,ATP1A2,ITPR2,LIFR,NKAIN3,AQP4,CDH20,AHCYL2 |
4.615e-07 | -14.59 | nervous system development | biological process | GO:0007399 | 2185 | 20 | 18204 | 50 |
TNIK,RFX4,BMPR1B,LSAMP,SOX5,PTPRZ1,CTNND2,CTNNA2,PARD3,SLC1A2,LRIG1,MEIS2,NTM,NFIA,GJA1,GPM6A,MSI2,ATP1A2,SLC1A3,PREX2 |
6.051e-07 | -14.32 | multicellular organism development | biological process | GO:0007275 | 3957 | 27 | 18204 | 50 |
NFIA,CPE,LRIG1,MEIS2,CTNNA2,TNIK,RFX4,LSAMP,SLC1A3,ZNRF3,PREX2,FGFR3,ATP1A2,GLUL,TRPS1,GJA1,GPM6A,NTM,SLC1A2,PARD3,NEBL,SOX5,BMPR1B,PTPRZ1,CTNND2,CDH20,MSI2 |
6.193e-07 | -14.29 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 20 | 18204 | 50 |
LRIG1,MEIS2,CPE,ABLIM1,NFIA,CTNND2,TNIK,NEBL,SOX5,PTPRZ1,BMPR1B,PARD3,CTNNA2,FGFR3,PREX2,SLC1A3,GJA1,GPM6A,GLUL,CDH20 |
1.129e-06 | -13.69 | system development | biological process | GO:0048731 | 3533 | 25 | 18204 | 50 |
NFIA,CPE,LRIG1,MEIS2,CTNNA2,TNIK,RFX4,LSAMP,SLC1A3,PREX2,FGFR3,ATP1A2,GLUL,TRPS1,GJA1,GPM6A,NTM,SLC1A2,PARD3,NEBL,PTPRZ1,BMPR1B,SOX5,CTNND2,MSI2 |
1.153e-06 | -13.67 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 26 | 16828 | 49 |
RYR3,LSAMP,PREX2,TNIK,SPARCL1,SOX5,CDH20,AHCYL2,NKAIN3,AQP4,LIFR,ITPR2,ATP1A2,FBXL7,CPE,GPM6A,GPC5,FGFR3,SLC1A2,CTNND2,MACF1,ATP13A4,PARD3,NEBL,MEIS2,SPON1 |
1.475e-06 | -13.43 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 12 | 16828 | 49 |
MEIS2,ITPR2,GPC5,NEBL,PTPRZ1,ABLIM1,NPAS3,CPE,CTNND2,PARD3,RYR3,PARD3B |
1.990e-06 | -13.13 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 50 |
NFIA,SLC1A3,PREX2,PTPRZ1,BMPR1B,GPM6A,TNIK,CTNND2,CTNNA2,PARD3,CDH20 |
2.095e-06 | -13.08 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 11 | 16828 | 49 |
NPAS3,CPE,PARD3,CTNND2,PTPRZ1,ABLIM1,PARD3B,RYR3,ITPR2,MEIS2,NEBL |
2.127e-06 | -13.06 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 11 | 16828 | 49 |
PARD3B,RYR3,CTNND2,PTPRZ1,ITPR2,NPAS3,CPE,PARD3,ABLIM1,NEBL,MEIS2 |
3.650e-06 | -12.52 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 12 | 19454 | 50 |
CTNND2,TNIK,NTM,LSAMP,SORBS1,SLC1A2,ATP1A2,ABLIM1,CTNNA2,NEBL,GPM6A,SLC1A3 |
3.755e-06 | -12.49 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 49 |
ZBTB20,PTPRZ1,BMPR1B,CTNND2,SLC1A2,MEIS2,SPON1,SLC4A4,NEBL,PARD3,ATP13A4,NKAIN3,ITPR2,LIFR,NFIA,PREX2,SOX5,TNIK,LSAMP,RYR3,GPC5,GPM6A,NTM,SLC1A3,FBXL7,CPE |
3.755e-06 | -12.49 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 49 |
GPC5,GPM6A,NTM,FBXL7,CPE,SLC1A3,NKAIN3,ITPR2,LIFR,NFIA,PREX2,SOX5,TNIK,LSAMP,RYR3,MEIS2,SPON1,SLC4A4,NEBL,PARD3,ATP13A4,ZBTB20,PTPRZ1,BMPR1B,CTNND2,SLC1A2 |
4.001e-06 | -12.43 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 14 | 16828 | 49 |
PARD3,FBXL7,NPAS3,NKAIN3,ATP1A2,NFIA,FGFR3,BMPR1B,PREX2,SOX5,SLC1A2,TNIK,RYR3,LSAMP |
4.001e-06 | -12.43 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 14 | 16828 | 49 |
LSAMP,RYR3,SOX5,SLC1A2,TNIK,PREX2,FGFR3,BMPR1B,NFIA,ATP1A2,NKAIN3,FBXL7,PARD3,NPAS3 |
6.091e-06 | -12.01 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 19 | 16828 | 49 |
SOX5,CTNND2,SLC1A2,PTPRZ1,PREX2,FGFR3,RYR3,LSAMP,ITPR2,NKAIN3,CDH20,PARD3,FBXL7,SLC1A3,SPON1,GPM6A,GPC5,MEIS2,NEBL |
7.143e-06 | -11.85 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 2 | 18521 | 50 |
PARD3B,PARD3 |
7.737e-06 | -11.77 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 2 | 17795 | 50 |
PARD3B,PARD3 |
8.240e-06 | -11.71 | adherens junction | cellular component | GO:0005912 | 188 | 6 | 19108 | 49 |
CTNNA2,SORBS1,CDH20,PARD3B,CTNND2,PARD3 |
1.014e-05 | -11.50 | generation of neurons | biological process | GO:0048699 | 1158 | 13 | 18204 | 50 |
NTM,NFIA,CTNNA2,PARD3,TNIK,BMPR1B,SOX5,PTPRZ1,CTNND2,SLC1A3,PREX2,GJA1,GPM6A |
1.071e-05 | -11.44 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 44 | 16828 | 49 |
PON2,NTM,ABLIM1,NPAS3,NFIA,NKAIN3,ATP1A2,LSAMP,TNIK,SOX5,NEBL,SPON1,GLUL,PARD3,ZBTB20,MACF1,PTPRZ1,BMPR1B,FGFR3,SLC1A2,CTNND2,LRIG1,GPC5,GPM6A,TRPS1,SLC1A3,FBXL7,CPE,CDH20,AHCYL2,LIFR,ITPR2,DTNA,RYR3,PARD3B,PREX2,MEIS2,SLC4A4,ZNRF3,ATP13A4,PITPNC1,SORBS1,SFXN5,RFX4 |
1.071e-05 | -11.44 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 44 | 16828 | 49 |
RFX4,PITPNC1,SORBS1,SFXN5,ATP13A4,ZNRF3,SLC4A4,MEIS2,PARD3B,RYR3,DTNA,PREX2,LIFR,ITPR2,AHCYL2,CDH20,TRPS1,CPE,FBXL7,SLC1A3,LRIG1,GPM6A,GPC5,SLC1A2,CTNND2,PTPRZ1,FGFR3,BMPR1B,MACF1,ZBTB20,GLUL,PARD3,NEBL,SPON1,LSAMP,TNIK,SOX5,NFIA,ATP1A2,NKAIN3,NPAS3,ABLIM1,PON2,NTM |
1.311e-05 | -11.24 | anatomical structure development | biological process | GO:0048856 | 5207 | 29 | 18204 | 50 |
CDH20,MSI2,PARD3,NEBL,SOX5,BMPR1B,PTPRZ1,CTNND2,NTM,ABLIM1,SLC1A2,GLUL,GJA1,TRPS1,GPM6A,SLC1A3,SPARCL1,PREX2,ZNRF3,FGFR3,ATP1A2,CTNNA2,TNIK,LSAMP,RFX4,NFIA,CPE,LRIG1,MEIS2 |
1.324e-05 | -11.23 | multicellular organismal process | biological process | GO:0032501 | 6177 | 32 | 18204 | 50 |
FGFR3,ATP1A2,SLC1A3,AQP4,ZNRF3,PREX2,TRPS1,GJA1,GPM6A,GLUL,CPE,LRIG1,MEIS2,NFIA,TNIK,LSAMP,RFX4,CTNNA2,MSI2,RYR3,CDH20,SLC1A2,NTM,DTNA,ABLIM1,NEBL,SLC4A4,SOX5,BMPR1B,PTPRZ1,CTNND2,PARD3 |
1.886e-05 | -10.88 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 35 | 16828 | 49 |
LRIG1,NTM,GPM6A,GPC5,TRPS1,FBXL7,ABLIM1,ITPR2,ATP1A2,CDH20,TNIK,SOX5,PREX2,PARD3B,RYR3,LSAMP,DTNA,ZNRF3,SLC4A4,SPON1,NEBL,PARD3,ATP13A4,GLUL,SORBS1,SFXN5,MACF1,ZBTB20,NHSL1,PITPNC1,SLC1A2,CTNND2,RFX4,FGFR3,PTPRZ1 |
2.020e-05 | -10.81 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 9 | 16828 | 49 |
CTNND2,SOX5,LSAMP,RYR3,GPM6A,GPC5,NKAIN3,SFXN5,AHCYL2 |
2.057e-05 | -10.79 | cell junction | cellular component | GO:0030054 | 2224 | 17 | 19108 | 49 |
NFIA,PARD3,CTNNA2,GPM6A,FGFR3,TNIK,CTNND2,DTNA,SORBS1,PTPRZ1,GJA1,ATP1A2,SLC1A2,SLC1A3,SPARCL1,PARD3B,CDH20 |
2.257e-05 | -10.70 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 10 | 18094 | 48 |
RYR3,ATP13A4,ITPR2,GPM6A,GJA1,SFXN5,SLC1A2,SLC4A4,ATP1A2,SLC1A3 |
2.260e-05 | -10.70 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 18 | 16828 | 49 |
NEBL,MEIS2,GPM6A,GPC5,SPON1,FBXL7,SLC1A3,PARD3,NKAIN3,CDH20,ITPR2,LSAMP,RYR3,PTPRZ1,PREX2,CTNND2,SOX5,SLC1A2 |
2.260e-05 | -10.70 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 18 | 16828 | 49 |
CTNND2,SOX5,SLC1A2,PREX2,PTPRZ1,RYR3,LSAMP,ITPR2,NKAIN3,CDH20,PARD3,FBXL7,SLC1A3,SPON1,GPC5,GPM6A,MEIS2,NEBL |
2.773e-05 | -10.49 | developmental process | biological process | GO:0032502 | 5716 | 30 | 18204 | 50 |
GLUL,TRPS1,GJA1,GPM6A,SPARCL1,NHSL1,PREX2,ZNRF3,SLC1A3,ATP1A2,FGFR3,CTNNA2,TNIK,LSAMP,RFX4,NFIA,LRIG1,MEIS2,CPE,CDH20,MSI2,PARD3,CTNND2,NEBL,SOX5,PTPRZ1,BMPR1B,ABLIM1,NTM,SLC1A2 |
2.893e-05 | -10.45 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 20 | 16828 | 49 |
SLC4A4,GPC5,ATP13A4,NPAS3,NFIA,NHSL1,PITPNC1,MACF1,SORBS1,SFXN5,ATP1A2,RYR3,DTNA,PARD3B,RFX4,FGFR3,PTPRZ1,PREX2,SLC1A2,CTNND2 |
2.973e-05 | -10.42 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 49 |
MEIS2,SLC4A4,ZNRF3,ATP13A4,SFXN5,SORBS1,PITPNC1,NHSL1,RFX4,GPC5,GPM6A,LRIG1,MSI2,SLC1A3,FBXL7,CPE,TRPS1,CDH20,AHCYL2,ITPR2,LIFR,PREX2,SPARCL1,DTNA,RYR3,PARD3B,SPON1,NEBL,PARD3,ZBTB20,MACF1,FGFR3,PTPRZ1,BMPR1B,CTNND2,SLC1A2,NTM,PON2,ABLIM1,NPAS3,NKAIN3,AQP4,ATP1A2,NFIA,SOX5,TNIK,LSAMP |
3.970e-05 | -10.13 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 23 | 16828 | 49 |
PARD3,MEIS2,SPON1,SLC4A4,ZNRF3,PTPRZ1,BMPR1B,CTNND2,PITPNC1,MACF1,SLC1A3,CPE,FBXL7,NPAS3,GPC5,MSI2,PREX2,TNIK,DTNA,RYR3,LSAMP,PARD3B,LIFR |
3.970e-05 | -10.13 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 23 | 16828 | 49 |
LIFR,RYR3,LSAMP,DTNA,PARD3B,PREX2,TNIK,MSI2,GPC5,NPAS3,SLC1A3,FBXL7,CPE,PITPNC1,MACF1,BMPR1B,PTPRZ1,CTNND2,MEIS2,ZNRF3,SLC4A4,SPON1,PARD3 |
3.982e-05 | -10.13 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 31 | 16828 | 49 |
PARD3,NEBL,MEIS2,ZNRF3,SPON1,PTPRZ1,FGFR3,SLC1A2,GJA1,CTNND2,NHSL1,MACF1,SORBS1,TRPS1,NPAS3,FBXL7,SLC1A3,PON2,GPC5,GPM6A,LSAMP,RYR3,PARD3B,PREX2,SPARCL1,SOX5,NFIA,CDH20,AQP4,NKAIN3,ITPR2 |
4.105e-05 | -10.10 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 33 | 16828 | 49 |
ATP1A2,ITPR2,LIFR,AQP4,SOX5,SPARCL1,TNIK,PREX2,PARD3B,RYR3,GPM6A,GPC5,FBXL7,CPE,TRPS1,NPAS3,ABLIM1,SFXN5,SORBS1,MACF1,PITPNC1,ZBTB20,CTNND2,BMPR1B,FGFR3,PTPRZ1,SPON1,SLC4A4,MEIS2,NEBL,PARD3,ATP13A4,GLUL |
4.376e-05 | -10.04 | cell-cell junction | cellular component | GO:0005911 | 513 | 8 | 19108 | 49 |
PARD3,GJA1,ATP1A2,PARD3B,CTNND2,CDH20,SORBS1,CTNNA2 |
4.540e-05 | -10.00 | neurogenesis | biological process | GO:0022008 | 1334 | 13 | 18204 | 50 |
GPM6A,GJA1,SLC1A3,PREX2,PTPRZ1,SOX5,BMPR1B,TNIK,CTNND2,CTNNA2,PARD3,NFIA,NTM |
4.882e-05 | -9.93 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 8 | 18204 | 50 |
PARD3,CTNNA2,CTNND2,TNIK,BMPR1B,PTPRZ1,GPM6A,PREX2 |
5.246e-05 | -9.86 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 8 | 18204 | 50 |
PREX2,CTNNA2,PARD3,TNIK,BMPR1B,GPM6A,PTPRZ1,CTNND2 |
5.502e-05 | -9.81 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 10 | 18204 | 50 |
GPM6A,GJA1,SLC4A4,RYR3,SFXN5,SLC1A2,ATP1A2,ATP13A4,SLC1A3,ITPR2 |
5.590e-05 | -9.79 | transporter activity | molecular function | GO:0005215 | 1211 | 12 | 18094 | 48 |
PITPNC1,GJA1,SFXN5,ATP13A4,SLC4A4,SLC1A3,ATP1A2,SLC1A2,GPM6A,AQP4,RYR3,ITPR2 |
5.634e-05 | -9.78 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 8 | 18204 | 50 |
PARD3,CTNNA2,CTNND2,TNIK,GPM6A,PTPRZ1,BMPR1B,PREX2 |
5.762e-05 | -9.76 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 10 | 16828 | 49 |
PREX2,SLC1A2,FBXL7,PARD3,SOX5,LSAMP,RYR3,NKAIN3,ATP1A2,GPC5 |
6.287e-05 | -9.67 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 8 | 16828 | 49 |
CTNND2,ATP13A4,LSAMP,RYR3,GPM6A,GPC5,MEIS2,SFXN5 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
6.922e-05 | -9.58 | plasma membrane region | cellular component | GO:0098590 | 1278 | 12 | 19108 | 49 |
GPM6A,TNIK,MACF1,PARD3B,SORBS1,ATP1A2,GJA1,AQP4,SLC1A2,PARD3,SLC1A3,SLC4A4 |
7.145e-05 | -9.55 | nodular | COSMIC cancer mutations | nodular | 1515 | 14 | 16828 | 49 |
ATP1A2,CDH20,MACF1,CTNND2,SPARCL1,PREX2,FGFR3,PTPRZ1,SLC4A4,NEBL,NPAS3,CPE,ABLIM1,ATP13A4 |
7.355e-05 | -9.52 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
7.355e-05 | -9.52 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
7.513e-05 | -9.50 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2 |
7.567e-05 | -9.49 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 49 |
SPON1,GPC5,MEIS2,NEBL,SLC1A3,PARD3,FBXL7,ITPR2,NKAIN3,SOX5,CTNND2,PREX2,RYR3,LSAMP |
7.567e-05 | -9.49 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 49 |
ITPR2,NKAIN3,SOX5,CTNND2,PREX2,RYR3,LSAMP,SPON1,GPC5,MEIS2,NEBL,PARD3,SLC1A3,FBXL7 |
7.798e-05 | -9.46 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 30 | 16828 | 49 |
SOX5,PARD3B,LSAMP,RYR3,DTNA,ITPR2,LIFR,ATP1A2,CDH20,AHCYL2,NKAIN3,NPAS3,TRPS1,FBXL7,SLC1A3,LRIG1,NTM,GPM6A,GPC5,CTNND2,PTPRZ1,SORBS1,MACF1,PARD3,ATP13A4,SLC4A4,ZNRF3,SPON1,MEIS2,NEBL |
7.798e-05 | -9.46 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 30 | 16828 | 49 |
SORBS1,MACF1,CTNND2,PTPRZ1,ZNRF3,SLC4A4,SPON1,MEIS2,NEBL,PARD3,ATP13A4,ITPR2,LIFR,ATP1A2,AHCYL2,CDH20,NKAIN3,SOX5,PARD3B,RYR3,DTNA,LSAMP,NTM,LRIG1,GPC5,GPM6A,NPAS3,TRPS1,SLC1A3,FBXL7 |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
NTM,LSAMP,GPM6A |
9.059e-05 | -9.31 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 50 |
SLC1A3,ATP1A2,SLC4A4,SLC1A2 |
9.059e-05 | -9.31 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 50 |
SLC1A3,ATP1A2,SLC1A2,SLC4A4 |
9.194e-05 | -9.29 | cell junction organization | biological process | GO:0034330 | 532 | 8 | 18204 | 50 |
CTNND2,GPM6A,SORBS1,GJA1,CDH20,PARD3,SPARCL1,NFIA |
9.559e-05 | -9.26 | neuron development | biological process | GO:0048666 | 859 | 10 | 18204 | 50 |
NTM,SLC1A3,PREX2,CTNNA2,PARD3,BMPR1B,PTPRZ1,GPM6A,TNIK,CTNND2 |
9.700e-05 | -9.24 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 5 | 19454 | 50 |
FGFR3,AHCYL2,PARD3,GJA1,CTNNA2 |
1.012e-04 | -9.20 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 25 | 16828 | 49 |
NFIA,LIFR,ITPR2,CDH20,PARD3B,RYR3,TNIK,SOX5,PREX2,LRIG1,NTM,GPM6A,TRPS1,FBXL7,MACF1,ZBTB20,NHSL1,SORBS1,CTNND2,RFX4,PTPRZ1,FGFR3,SLC4A4,ATP13A4,PARD3 |
1.064e-04 | -9.15 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 2 | 18521 | 50 |
ITPR2,RYR3 |
1.064e-04 | -9.15 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.064e-04 | -9.15 | RIH_dom | interpro domains | IPR000699 | 6 | 2 | 18521 | 50 |
RYR3,ITPR2 |
1.080e-04 | -9.13 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 24 | 16828 | 49 |
FBXL7,TRPS1,NPAS3,GPM6A,TNIK,PREX2,PARD3B,RYR3,ATP1A2,AQP4,NFIA,PARD3,SLC4A4,ZNRF3,NEBL,CTNND2,GJA1,SLC1A2,PTPRZ1,FGFR3,RFX4,MACF1,NHSL1,PITPNC1 |
1.101e-04 | -9.11 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.101e-04 | -9.11 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.152e-04 | -9.07 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 2 | 17795 | 50 |
RYR3,ITPR2 |
1.152e-04 | -9.07 | RIH_assoc | pfam domains | PF08454 | 6 | 2 | 17795 | 50 |
RYR3,ITPR2 |
1.152e-04 | -9.07 | RYDR_ITPR | pfam domains | PF01365 | 6 | 2 | 17795 | 50 |
ITPR2,RYR3 |
1.158e-04 | -9.06 | glial cell projection | cellular component | GO:0097386 | 37 | 3 | 19108 | 49 |
GLUL,AQP4,SLC1A2 |
1.167e-04 | -9.06 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 4 | 19454 | 50 |
GJA1,SORBS1,PARD3,FGFR3 |
1.217e-04 | -9.01 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 11 | 18094 | 48 |
GJA1,SFXN5,ATP13A4,SLC4A4,ATP1A2,SLC1A3,SLC1A2,GPM6A,AQP4,RYR3,ITPR2 |
1.219e-04 | -9.01 | tibia | COSMIC cancer mutations | tibia | 836 | 10 | 16828 | 49 |
NKAIN3,GPM6A,MACF1,ABLIM1,FGFR3,PREX2,CTNND2,CPE,TNIK,LSAMP |
1.345e-04 | -8.91 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 2 | 14470 | 44 |
ITPR2,RYR3 |
1.349e-04 | -8.91 | neuron differentiation | biological process | GO:0030182 | 1081 | 11 | 18204 | 50 |
NFIA,NTM,CTNND2,PTPRZ1,BMPR1B,TNIK,PARD3,CTNNA2,PREX2,SLC1A3,GPM6A |
1.374e-04 | -8.89 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 6 | 19454 | 50 |
TNIK,PARD3,ABLIM1,AHCYL2,DTNA,MACF1 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.534e-04 | -8.78 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 7 | 18094 | 48 |
SLC4A4,ATP1A2,SLC1A3,SLC1A2,GPM6A,RYR3,ITPR2 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A2,SLC1A3 |
1.625e-04 | -8.72 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 34 | 16828 | 49 |
NTM,LRIG1,FBXL7,NPAS3,TRPS1,ATP1A2,LIFR,ITPR2,AQP4,CDH20,NFIA,SOX5,PREX2,PARD3B,LSAMP,RYR3,SPON1,SLC4A4,ZNRF3,MEIS2,NEBL,PARD3,ATP13A4,GLUL,SFXN5,MACF1,PITPNC1,NHSL1,ZBTB20,CTNND2,SLC1A2,FGFR3,PTPRZ1,RFX4 |
1.625e-04 | -8.72 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 34 | 16828 | 49 |
MACF1,ZBTB20,NHSL1,PITPNC1,SFXN5,SLC1A2,CTNND2,RFX4,FGFR3,PTPRZ1,NEBL,SLC4A4,ZNRF3,SPON1,MEIS2,ATP13A4,GLUL,PARD3,NFIA,LIFR,ITPR2,ATP1A2,CDH20,AQP4,PARD3B,LSAMP,RYR3,SOX5,PREX2,LRIG1,NTM,TRPS1,NPAS3,FBXL7 |
1.627e-04 | -8.72 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 5 | 19454 | 50 |
RYR3,GJA1,PARD3,ATP1A2,DTNA |
1.628e-04 | -8.72 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 49 |
GPC5,GPM6A,AHCYL2,NKAIN3,SFXN5,NEBL,SOX5,PARD3B |
1.662e-04 | -8.70 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 50 |
RYR3,SLC1A3,SLC1A2 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
CTNNA2,CTNND2,CDH20,GJA1 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
LSAMP,NKAIN3,CTNND2,GPM6A |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A2,SLC1A3 |
1.949e-04 | -8.54 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 7 | 18204 | 50 |
SLC1A3,PREX2,CTNNA2,PARD3,BMPR1B,PTPRZ1,CTNND2 |
2.037e-04 | -8.50 | cell adhesion | biological process | GO:0007155 | 942 | 10 | 18204 | 50 |
CTNND2,SPON1,SORBS1,LSAMP,PARD3B,PARD3,CDH20,CTNNA2,SPARCL1,NTM |
2.071e-04 | -8.48 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 11 | 18204 | 50 |
BMPR1B,SOX5,SORBS1,GJA1,RYR3,ATP1A2,SLC1A2,FGFR3,ITPR2,NFIA,SLC1A3 |
2.276e-04 | -8.39 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 48 |
SLC1A2,SLC1A3,ATP1A2,SLC4A4,ITPR2,ATP13A4,RYR3,GPM6A |
2.282e-04 | -8.39 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 6 | 16828 | 49 |
SOX5,GPM6A,GPC5,NKAIN3,SFXN5,AHCYL2 |
2.300e-04 | -8.38 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 45 | 16828 | 49 |
MACF1,ZBTB20,CTNND2,SLC1A2,GJA1,FGFR3,BMPR1B,PTPRZ1,NEBL,SPON1,GLUL,PARD3,NFIA,ATP1A2,LSAMP,SOX5,TNIK,PON2,NTM,NPAS3,ABLIM1,NHSL1,PITPNC1,SFXN5,SORBS1,RFX4,SLC4A4,ZNRF3,MEIS2,ATP13A4,ITPR2,LIFR,CDH20,PARD3B,DTNA,RYR3,SPARCL1,PREX2,GPC5,GPM6A,LRIG1,FBXL7,SLC1A3,CPE,TRPS1 |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.328e-04 | -8.37 | cervix | COSMIC cancer mutations | cervix | 11793 | 45 | 16828 | 49 |
TRPS1,SLC1A3,CPE,FBXL7,LRIG1,GPM6A,GPC5,DTNA,RYR3,PARD3B,PREX2,SPARCL1,CDH20,LIFR,ITPR2,ATP13A4,MEIS2,ZNRF3,SLC4A4,RFX4,PITPNC1,NHSL1,SORBS1,SFXN5,ABLIM1,NPAS3,PON2,NTM,LSAMP,TNIK,SOX5,NFIA,ATP1A2,GLUL,PARD3,NEBL,SPON1,FGFR3,BMPR1B,PTPRZ1,GJA1,SLC1A2,CTNND2,ZBTB20,MACF1 |
2.370e-04 | -8.35 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 9 | 19454 | 50 |
AHCYL2,DTNA,PARD3B,SLC1A3,MACF1,ABLIM1,GJA1,TNIK,PARD3 |
2.454e-04 | -8.31 | monoatomic ion transport | biological process | GO:0006811 | 964 | 10 | 18204 | 50 |
SLC4A4,GJA1,GPM6A,SFXN5,RYR3,ATP1A2,SLC1A2,ITPR2,SLC1A3,ATP13A4 |
2.464e-04 | -8.31 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 4 | 10285 | 30 |
SLC4A4,SLC1A2,AHCYL2,SLC1A3 |
2.531e-04 | -8.28 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 12 | 16828 | 49 |
NEBL,ATP13A4,ABLIM1,NPAS3,CPE,MACF1,CDH20,ATP1A2,PREX2,PTPRZ1,SPARCL1,CTNND2 |
2.551e-04 | -8.27 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 50 |
GJA1,SLC1A2,SLC1A3 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.645e-04 | -8.24 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 44 |
SLC1A3,SLC1A2 |
2.833e-04 | -8.17 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 35 | 16828 | 49 |
NHSL1,MACF1,SFXN5,BMPR1B,FGFR3,PTPRZ1,RFX4,CTNND2,SLC1A2,NEBL,MEIS2,SPON1,SLC4A4,ATP13A4,PARD3,NKAIN3,CDH20,AHCYL2,ATP1A2,ITPR2,LIFR,LSAMP,RYR3,PREX2,SOX5,TNIK,PON2,GPM6A,GPC5,LRIG1,ABLIM1,FBXL7,SLC1A3,CPE,TRPS1 |
2.855e-04 | -8.16 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 15 | 16828 | 49 |
GPM6A,ZNRF3,SLC4A4,NEBL,NPAS3,ITPR2,AHCYL2,MACF1,ZBTB20,SOX5,TNIK,FGFR3,BMPR1B,PARD3B,RYR3 |
2.887e-04 | -8.15 | larynx | COSMIC cancer mutations | larynx | 1948 | 15 | 16828 | 49 |
TNIK,SOX5,BMPR1B,FGFR3,PARD3B,RYR3,ITPR2,AHCYL2,MACF1,ZBTB20,NPAS3,ZNRF3,SLC4A4,GPM6A,NEBL |
2.894e-04 | -8.15 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 23 | 16828 | 49 |
RYR3,PARD3B,RFX4,PTPRZ1,PREX2,FGFR3,SLC1A2,GJA1,TNIK,CTNND2,NFIA,PITPNC1,MACF1,AQP4,ATP1A2,TRPS1,NPAS3,FBXL7,PARD3,NEBL,ZNRF3,SLC4A4,GPM6A |
2.903e-04 | -8.14 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 17 | 16828 | 49 |
PREX2,FGFR3,SPARCL1,RYR3,PARD3B,SORBS1,CDH20,NHSL1,NFIA,MACF1,SLC1A3,PARD3,TRPS1,NPAS3,SPON1,ZNRF3,PON2 |
2.903e-04 | -8.14 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 17 | 16828 | 49 |
PON2,ZNRF3,SPON1,TRPS1,NPAS3,SLC1A3,PARD3,NHSL1,NFIA,MACF1,CDH20,SORBS1,RYR3,PARD3B,FGFR3,PREX2,SPARCL1 |
2.905e-04 | -8.14 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 23 | 16828 | 49 |
NPAS3,TRPS1,FBXL7,GPM6A,PREX2,TNIK,RYR3,PARD3B,AQP4,ATP1A2,NFIA,PARD3,ZNRF3,SLC4A4,NEBL,RFX4,FGFR3,PTPRZ1,GJA1,SLC1A2,CTNND2,PITPNC1,MACF1 |
2.945e-04 | -8.13 | CXADR (CXADR Ig-like cell adhesion molecule) | protein interactions | 1525 | 357 | 6 | 19454 | 50 |
TNIK,NEBL,GJA1,SORBS1,PARD3,MACF1 |
2.958e-04 | -8.13 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 4 | 7161 | 21 |
SLC1A2,ITPR2,SLC1A3,GLUL |
2.958e-04 | -8.13 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 4 | 7161 | 21 |
SLC1A3,GLUL,SLC1A2,ITPR2 |
3.162e-04 | -8.06 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 4 | 19454 | 50 |
PARD3,DTNA,ABLIM1,MACF1 |
3.170e-04 | -8.06 | MIR_motif | interpro domains | IPR016093 | 10 | 2 | 18521 | 50 |
ITPR2,RYR3 |
3.170e-04 | -8.06 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 2 | 18521 | 50 |
ITPR2,RYR3 |
3.190e-04 | -8.05 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 21 |
SLC1A2,SLC1A3 |
3.220e-04 | -8.04 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 12 | 18204 | 50 |
NFIA,MEIS2,SLC1A2,SORBS1,BMPR1B,SOX5,ITPR2,SLC1A3,ATP1A2,FGFR3,RYR3,GJA1 |
3.272e-04 | -8.02 | striated muscle contraction | biological process | GO:0006941 | 120 | 4 | 18204 | 50 |
RYR3,DTNA,GJA1,ATP1A2 |
3.281e-04 | -8.02 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 2 | 18204 | 50 |
PARD3,PARD3B |
3.281e-04 | -8.02 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
3.346e-04 | -8.00 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 4 | 16828 | 49 |
RYR3,SLC1A2,SOX5,PREX2 |
3.432e-04 | -7.98 | MIR | pfam domains | PF02815 | 10 | 2 | 17795 | 50 |
ITPR2,RYR3 |
3.648e-04 | -7.92 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 30 |
SLC4A4,AHCYL2 |
3.702e-04 | -7.90 | EZR (ezrin) | protein interactions | 7430 | 526 | 7 | 19454 | 50 |
NEBL,MACF1,DTNA,AHCYL2,SORBS1,TNIK,ABLIM1 |
4.003e-04 | -7.82 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.003e-04 | -7.82 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
4.146e-04 | -7.79 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 50 |
BMPR1B,SOX5,TRPS1 |
4.185e-04 | -7.78 | anchoring junction | cellular component | GO:0070161 | 902 | 9 | 19108 | 49 |
CTNNA2,FGFR3,CDH20,SORBS1,PARD3B,CTNND2,GJA1,ATP1A2,PARD3 |
4.352e-04 | -7.74 | mouth | COSMIC cancer mutations | mouth | 9004 | 38 | 16828 | 49 |
CDH20,ITPR2,LIFR,ATP1A2,PREX2,TNIK,SOX5,DTNA,RYR3,LSAMP,PARD3B,NTM,LRIG1,GPM6A,GPC5,ABLIM1,NPAS3,TRPS1,SLC1A3,FBXL7,SORBS1,SFXN5,ZBTB20,NHSL1,PITPNC1,MACF1,RFX4,FGFR3,PTPRZ1,SLC1A2,CTNND2,SLC4A4,ZNRF3,SPON1,NEBL,PARD3,GLUL,ATP13A4 |
4.404e-04 | -7.73 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 50 |
FGFR3,LSAMP,LRIG1,NTM |
4.673e-04 | -7.67 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 15 | 16828 | 49 |
NEBL,MSI2,ZNRF3,GPM6A,GPC5,TRPS1,PARD3,ABLIM1,MACF1,ITPR2,AQP4,LSAMP,PTPRZ1,FGFR3,PREX2 |
4.698e-04 | -7.66 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 50 |
SLC1A2,GJA1,SLC1A3,SFXN5 |
4.778e-04 | -7.65 | sarcolemma | cellular component | GO:0042383 | 142 | 4 | 19108 | 49 |
AQP4,ATP1A2,RYR3,DTNA |
4.895e-04 | -7.62 | trunk | COSMIC cancer mutations | trunk | 3554 | 21 | 16828 | 49 |
LSAMP,RYR3,PREX2,PTPRZ1,FGFR3,CTNND2,SPARCL1,SOX5,MACF1,CDH20,LIFR,ATP1A2,ATP13A4,ABLIM1,NPAS3,TRPS1,PARD3,SLC1A3,CPE,NEBL,MEIS2 |
5.060e-04 | -7.59 | cell body | cellular component | GO:0044297 | 556 | 7 | 19108 | 49 |
GPM6A,CTNND2,GLUL,ATP1A2,SLC1A2,BMPR1B,SLC1A3 |
5.115e-04 | -7.58 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 50 |
NTM,LSAMP,FGFR3,LRIG1 |
5.139e-04 | -7.57 | visual behavior | biological process | GO:0007632 | 57 | 3 | 18204 | 50 |
MEIS2,ATP1A2,SLC1A2 |
5.199e-04 | -7.56 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 9 | 19454 | 50 |
NHSL1,PARD3,SORBS1,GJA1,CTNND2,PARD3B,PTPRZ1,DTNA,CTNNA2 |
5.223e-04 | -7.56 | transmembrane transport | biological process | GO:0055085 | 1264 | 11 | 18204 | 50 |
ATP1A2,SLC1A2,ITPR2,AQP4,SLC1A3,ATP13A4,SLC4A4,GJA1,GPM6A,SFXN5,RYR3 |
5.266e-04 | -7.55 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 8 | 18094 | 48 |
ITPR2,RYR3,AQP4,GPM6A,SLC1A2,ATP1A2,SLC1A3,SLC4A4 |
5.403e-04 | -7.52 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 8 | 10285 | 30 |
RYR3,ATP1A2,AQP4,AHCYL2,SLC1A3,SLC4A4,SLC1A2,ATP13A4 |
5.442e-04 | -7.52 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 21 |
ATP13A4,ATP1A2 |
5.522e-04 | -7.50 | neuron projection development | biological process | GO:0031175 | 693 | 8 | 18204 | 50 |
PREX2,PARD3,CTNNA2,CTNND2,PTPRZ1,BMPR1B,GPM6A,TNIK |
5.593e-04 | -7.49 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 30 |
ITPR2,RYR3,ATP1A2 |
5.629e-04 | -7.48 | MIR | prosite domains | PS50919 | 10 | 2 | 12186 | 44 |
RYR3,ITPR2 |
5.976e-04 | -7.42 | export across plasma membrane | biological process | GO:0140115 | 60 | 3 | 18204 | 50 |
GJA1,SLC4A4,ATP1A2 |
6.089e-04 | -7.40 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 40 | 16828 | 49 |
NEBL,MEIS2,ZNRF3,SLC4A4,SPON1,ATP13A4,PARD3,PITPNC1,MACF1,SORBS1,RFX4,BMPR1B,FGFR3,PTPRZ1,GJA1,CTNND2,MSI2,NTM,LRIG1,GPM6A,GPC5,ABLIM1,NPAS3,TRPS1,FBXL7,CPE,NFIA,AHCYL2,CDH20,NKAIN3,ITPR2,LIFR,ATP1A2,DTNA,RYR3,PARD3B,PREX2,TNIK,SOX5,SPARCL1 |
6.144e-04 | -7.39 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 33 | 16828 | 49 |
ATP13A4,PARD3,NEBL,SPON1,MEIS2,CTNND2,SLC1A2,BMPR1B,PTPRZ1,RFX4,MACF1,NHSL1,SFXN5,CPE,FBXL7,SLC1A3,ABLIM1,PON2,GPC5,GPM6A,LRIG1,PARD3B,RYR3,LSAMP,SPARCL1,SOX5,TNIK,PREX2,ITPR2,LIFR,NKAIN3,CDH20,AHCYL2 |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.176e-04 | -7.39 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 40 | 16828 | 49 |
PARD3,ATP13A4,MEIS2,SPON1,ZNRF3,SLC4A4,NEBL,BMPR1B,FGFR3,PTPRZ1,RFX4,CTNND2,GJA1,SORBS1,PITPNC1,MACF1,ABLIM1,CPE,FBXL7,TRPS1,NPAS3,GPM6A,GPC5,NTM,LRIG1,MSI2,PREX2,SPARCL1,SOX5,TNIK,RYR3,DTNA,PARD3B,NKAIN3,CDH20,AHCYL2,ATP1A2,LIFR,ITPR2,NFIA |
6.239e-04 | -7.38 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
SLC4A4,ATP13A4,NFIA,PITPNC1,NHSL1,ATP1A2,SFXN5,CTNND2,SLC1A2,FGFR3,PREX2,RFX4 |
6.239e-04 | -7.38 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
ATP13A4,SLC4A4,SLC1A2,CTNND2,RFX4,PREX2,FGFR3,ATP1A2,SFXN5,NFIA,PITPNC1,NHSL1 |
6.388e-04 | -7.36 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 8 | 19454 | 50 |
MACF1,NEBL,CTNNA2,ABLIM1,CTNND2,SORBS1,NHSL1,PARD3 |
6.556e-04 | -7.33 | Ig_3 | pfam domains | PF13927 | 141 | 4 | 17795 | 50 |
LRIG1,NTM,FGFR3,LSAMP |
6.570e-04 | -7.33 | MIR | smart domains | SM00472 | 10 | 2 | 9717 | 38 |
RYR3,ITPR2 |
6.588e-04 | -7.33 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 50 |
ATP1A2,SLC4A4 |
6.642e-04 | -7.32 | ACTB (actin beta) | protein interactions | 60 | 958 | 9 | 19454 | 50 |
ABLIM1,SFXN5,SORBS1,NHSL1,DTNA,AHCYL2,MACF1,NEBL,MEIS2 |
6.654e-04 | -7.32 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 2 | 19454 | 50 |
PARD3,TNIK |
6.850e-04 | -7.29 | scalp | COSMIC cancer mutations | scalp | 2110 | 15 | 16828 | 49 |
SOX5,FGFR3,PTPRZ1,PREX2,LSAMP,ATP1A2,SORBS1,MACF1,NFIA,TRPS1,ATP13A4,SLC4A4,NTM,GPC5,NEBL |
6.989e-04 | -7.27 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 5 | 18094 | 48 |
SLC1A3,SFXN5,GJA1,SLC4A4,SLC1A2 |
7.220e-04 | -7.23 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 50 |
CTNNA2,PREX2,CTNND2 |
7.592e-04 | -7.18 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 2 | 19454 | 50 |
CPE,MACF1 |
7.721e-04 | -7.17 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 5 | 18094 | 48 |
SLC1A3,ATP1A2,SLC4A4,ATP13A4,SLC1A2 |
7.916e-04 | -7.14 | face | COSMIC cancer mutations | face | 2139 | 15 | 16828 | 49 |
ITPR2,AQP4,MACF1,PREX2,PTPRZ1,FGFR3,LSAMP,GPM6A,GPC5,ZNRF3,NEBL,MSI2,PARD3,TRPS1,ABLIM1 |
8.077e-04 | -7.12 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 48 |
SLC4A4,SLC1A3,ATP1A2,SLC1A2 |
8.086e-04 | -7.12 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 50 |
ZBTB20,LSAMP |
8.309e-04 | -7.09 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 5 | 19454 | 50 |
GJA1,SORBS1,PARD3,DTNA,PARD3B |
8.340e-04 | -7.09 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 11 | 16828 | 49 |
MACF1,RYR3,TNIK,CTNND2,FGFR3,NEBL,NTM,GPM6A,ATP13A4,TRPS1,ABLIM1 |
8.340e-04 | -7.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 11 | 16828 | 49 |
TNIK,CTNND2,FGFR3,RYR3,MACF1,TRPS1,ABLIM1,ATP13A4,NTM,GPM6A,NEBL |
8.632e-04 | -7.05 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 48 |
RYR3,ITPR2,GPM6A,SLC1A2,SLC4A4,SLC1A3,ATP1A2 |
8.657e-04 | -7.05 | asymmetric cell division | biological process | GO:0008356 | 16 | 2 | 18204 | 50 |
PARD3,SOX5 |
9.003e-04 | -7.01 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 7 | 19454 | 50 |
FGFR3,AHCYL2,DTNA,ABLIM1,NHSL1,PARD3,TNIK |
9.072e-04 | -7.01 | prostate | COSMIC cancer mutations | prostate | 13883 | 48 | 16828 | 49 |
LSAMP,TNIK,SOX5,NFIA,AQP4,NKAIN3,ATP1A2,ABLIM1,NPAS3,PON2,NTM,PTPRZ1,FGFR3,BMPR1B,SLC1A2,GJA1,CTNND2,ZBTB20,MACF1,PARD3,NEBL,SPON1,DTNA,RYR3,PARD3B,PREX2,SPARCL1,CDH20,AHCYL2,ITPR2,LIFR,TRPS1,SLC1A3,FBXL7,CPE,MSI2,LRIG1,GPM6A,GPC5,RFX4,PITPNC1,NHSL1,SORBS1,SFXN5,ATP13A4,MEIS2,ZNRF3,SLC4A4 |
9.332e-04 | -6.98 | bone | COSMIC cancer mutations | bone | 8157 | 35 | 16828 | 49 |
CTNND2,FGFR3,PTPRZ1,MACF1,ZBTB20,SORBS1,SFXN5,ATP13A4,GLUL,PARD3,NEBL,SLC4A4,SPON1,PARD3B,LSAMP,DTNA,RYR3,TNIK,SOX5,SPARCL1,PREX2,LIFR,ITPR2,ATP1A2,AHCYL2,NKAIN3,NPAS3,TRPS1,SLC1A3,CPE,ABLIM1,PON2,LRIG1,GPM6A,GPC5 |
9.648e-04 | -6.94 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 2 | 19454 | 50 |
FGFR3,PARD3 |
9.763e-04 | -6.93 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 5 | 16828 | 49 |
PREX2,FGFR3,SLC1A2,SOX5,RYR3 |
9.794e-04 | -6.93 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
9.873e-04 | -6.92 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 7 | 18204 | 50 |
AQP4,SLC1A3,ATP13A4,RYR3,ATP1A2,ZBTB20,SLC4A4 |
9.965e-04 | -6.91 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 10 | 18204 | 50 |
ABLIM1,PREX2,CTNNA2,PARD3,BMPR1B,RFX4,GPM6A,PTPRZ1,TNIK,CTNND2 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
GPM6A,LSAMP,NTM |
1.026e-03 | -6.88 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 2 | 18094 | 48 |
RYR3,ITPR2 |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.030e-03 | -6.88 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 6 | 19454 | 50 |
PARD3,SORBS1,SOX5,ABLIM1,MACF1,DTNA |
1.048e-03 | -6.86 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 5 | 18204 | 50 |
TNIK,CPE,MACF1,CTNND2,ZNRF3 |
1.049e-03 | -6.86 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 13 | 19454 | 50 |
ABLIM1,BMPR1B,PARD3,TRPS1,PARD3B,AHCYL2,MSI2,NFIA,PON2,ZBTB20,MACF1,FGFR3,DTNA |
1.059e-03 | -6.85 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 50 |
TRPS1,BMPR1B,SOX5 |
1.063e-03 | -6.85 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
1.071e-03 | -6.84 | astrocyte projection | cellular component | GO:0097449 | 19 | 2 | 19108 | 49 |
SLC1A2,AQP4 |
1.082e-03 | -6.83 | cell junction assembly | biological process | GO:0034329 | 285 | 5 | 18204 | 50 |
GPM6A,SORBS1,GJA1,PARD3,CDH20 |
1.093e-03 | -6.82 | Bile secretion | KEGG pathways | hsa04976 | 71 | 3 | 7161 | 21 |
ATP1A2,AQP4,SLC4A4 |
1.093e-03 | -6.82 | Bile secretion | KEGG pathways | ko04976 | 71 | 3 | 7161 | 21 |
SLC4A4,ATP1A2,AQP4 |
1.109e-03 | -6.80 | glutamate dependent acid resistance | BIOCYC pathways | HUMAN_PWY0-1305 | 1 | 1 | 902 | 1 |
GLUL |
1.109e-03 | -6.80 | L-glutamine biosynthesis I | BIOCYC pathways | META_GLNSYN-PWY | 1 | 1 | 902 | 1 |
GLUL |
1.109e-03 | -6.80 | glutamine biosynthesis | BIOCYC pathways | HUMAN_GLNSYN-PWY | 1 | 1 | 902 | 1 |
GLUL |
1.134e-03 | -6.78 | spleen | COSMIC cancer mutations | spleen | 408 | 6 | 16828 | 49 |
SORBS1,MEIS2,NTM,PARD3B,PTPRZ1,TNIK |
1.138e-03 | -6.78 | Adherens junction | KEGG pathways | hsa04520 | 72 | 3 | 7161 | 21 |
SORBS1,PARD3,CTNNA2 |
1.138e-03 | -6.78 | Adherens junction | KEGG pathways | ko04520 | 72 | 3 | 7161 | 21 |
PARD3,SORBS1,CTNNA2 |
1.150e-03 | -6.77 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
1.165e-03 | -6.76 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 49 | 16828 | 49 |
SLC4A4,ZNRF3,MEIS2,ATP13A4,PITPNC1,NHSL1,SFXN5,SORBS1,RFX4,MSI2,GPC5,GPM6A,LRIG1,SLC1A3,CPE,FBXL7,TRPS1,LIFR,ITPR2,CDH20,AHCYL2,PARD3B,RYR3,DTNA,SPARCL1,PREX2,NEBL,SPON1,GLUL,PARD3,MACF1,ZBTB20,CTNND2,GJA1,SLC1A2,PTPRZ1,BMPR1B,FGFR3,PON2,NTM,NPAS3,ABLIM1,NFIA,ATP1A2,AQP4,NKAIN3,LSAMP,SOX5,TNIK |
1.226e-03 | -6.70 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
1.227e-03 | -6.70 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
1.271e-03 | -6.67 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 20 | 16828 | 49 |
PON2,NEBL,SLC4A4,LRIG1,SPON1,GPC5,GPM6A,ABLIM1,PARD3,ZBTB20,NHSL1,MACF1,ATP1A2,RYR3,PREX2,PTPRZ1,TNIK,SOX5,SPARCL1,CTNND2 |
1.281e-03 | -6.66 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 20 | 16828 | 49 |
ATP1A2,ZBTB20,NHSL1,MACF1,PREX2,PTPRZ1,TNIK,SOX5,SPARCL1,CTNND2,RYR3,SLC4A4,LRIG1,SPON1,GPC5,GPM6A,PON2,NEBL,ABLIM1,PARD3 |
1.283e-03 | -6.66 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 50 |
GJA1,SLC1A2,SLC1A3 |
1.283e-03 | -6.66 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 3 | 18204 | 50 |
ZBTB20,SLC4A4,SORBS1 |
1.290e-03 | -6.65 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 50 |
NFIA,FGFR3,BMPR1B,SOX5 |
1.314e-03 | -6.63 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 8 | 16828 | 49 |
NEBL,ITPR2,DTNA,SLC1A3,SOX5,PARD3,CTNND2,TRPS1 |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
MACF1,SORBS1 |
1.318e-03 | -6.63 | HTR2A (5-hydroxytryptamine receptor 2A) | protein interactions | 3356 | 21 | 2 | 19454 | 50 |
GLUL,PON2 |
1.321e-03 | -6.63 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 9 | 18204 | 50 |
CTNNA2,GJA1,SOX5,BMPR1B,ABLIM1,LRIG1,MEIS2,FGFR3,CPE |
1.357e-03 | -6.60 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 14 | 19108 | 49 |
GPM6A,CTNNA2,GLUL,ABLIM1,DTNA,CTNND2,AQP4,PARD3,MACF1,AHCYL2,SLC1A2,ATP1A2,SLC1A3,BMPR1B |
1.359e-03 | -6.60 | cell projection organization | biological process | GO:0030030 | 1200 | 10 | 18204 | 50 |
ABLIM1,PREX2,PARD3,CTNNA2,CTNND2,TNIK,PTPRZ1,RFX4,GPM6A,BMPR1B |
1.361e-03 | -6.60 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.361e-03 | -6.60 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 50 |
BMPR1B,SOX5 |
1.397e-03 | -6.57 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 3 | 19108 | 49 |
ABLIM1,NEBL,SORBS1 |
1.397e-03 | -6.57 | stress fiber | cellular component | GO:0001725 | 86 | 3 | 19108 | 49 |
SORBS1,ABLIM1,NEBL |
1.398e-03 | -6.57 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 32 | 16828 | 49 |
ABLIM1,CPE,FBXL7,SLC1A3,GPC5,GPM6A,LRIG1,PON2,PREX2,SOX5,RYR3,LSAMP,NKAIN3,CDH20,AHCYL2,ATP1A2,ITPR2,LIFR,PARD3,ATP13A4,MEIS2,SPON1,SLC4A4,NEBL,BMPR1B,FGFR3,RFX4,CTNND2,SLC1A2,SFXN5,NHSL1,MACF1 |
1.439e-03 | -6.54 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 22 | 16828 | 49 |
ATP13A4,TRPS1,PARD3,CPE,LRIG1,ZNRF3,GPC5,RYR3,DTNA,LSAMP,FGFR3,PTPRZ1,TNIK,SOX5,CTNND2,SPARCL1,NFIA,MACF1,AQP4,ITPR2,LIFR,ATP1A2 |
1.484e-03 | -6.51 | ROR2 (receptor tyrosine kinase like orphan receptor 2) | protein interactions | 4920 | 327 | 5 | 19454 | 50 |
DTNA,TNIK,GJA1,SORBS1,PARD3 |
1.502e-03 | -6.50 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
1.502e-03 | -6.50 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.502e-03 | -6.50 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.502e-03 | -6.50 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 50 |
SOX5,BMPR1B |
1.548e-03 | -6.47 | SFN (stratifin) | protein interactions | 2810 | 671 | 7 | 19454 | 50 |
SORBS1,PARD3,TNIK,ABLIM1,NFIA,MACF1,PARD3B |
1.582e-03 | -6.45 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 50 |
MSI2,MEIS2 |
1.582e-03 | -6.45 | ZDHHC8 (zinc finger DHHC-type palmitoyltransferase 8) | protein interactions | 29801 | 23 | 2 | 19454 | 50 |
PARD3,GJA1 |
1.620e-03 | -6.43 | OCLN (occludin) | protein interactions | 100506658 | 495 | 6 | 19454 | 50 |
GJA1,TNIK,PARD3,DTNA,ABLIM1,MACF1 |
1.644e-03 | -6.41 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 50 |
FGFR3,BMPR1B,SOX5 |
1.649e-03 | -6.41 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 50 |
ATP1A2,SLC1A3 |
1.649e-03 | -6.41 | cell communication by electrical coupling | biological process | GO:0010644 | 22 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
1.664e-03 | -6.40 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 50 |
RYR3,ATP13A4,SLC1A3,ITPR2,GPM6A,SLC4A4,ATP1A2 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.695e-03 | -6.38 | actomyosin | cellular component | GO:0042641 | 92 | 3 | 19108 | 49 |
SORBS1,ABLIM1,NEBL |
1.708e-03 | -6.37 | RLN1 (relaxin 1) | protein interactions | 6013 | 92 | 3 | 19454 | 50 |
PON2,LRIG1,CPE |
1.723e-03 | -6.36 | LNP1 (leukemia NUP98 fusion partner 1) | protein interactions | 348801 | 24 | 2 | 19454 | 50 |
AHCYL2,GLUL |
1.726e-03 | -6.36 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 38 |
ATP1A2,ATP13A4 |
1.751e-03 | -6.35 | neuron projection | cellular component | GO:0043005 | 1331 | 10 | 19108 | 49 |
DTNA,AHCYL2,CTNND2,CTNNA2,GPM6A,SLC1A3,PARD3,BMPR1B,SLC1A2,ATP1A2 |
1.792e-03 | -6.32 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 17 | 16828 | 49 |
PARD3,TRPS1,SLC4A4,LRIG1,ZNRF3,RYR3,SPARCL1,CTNND2,TNIK,PTPRZ1,PREX2,FGFR3,MACF1,NHSL1,PITPNC1,ITPR2,NKAIN3 |
1.792e-03 | -6.32 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 17 | 16828 | 49 |
TRPS1,PARD3,SLC4A4,ZNRF3,LRIG1,RYR3,TNIK,CTNND2,SPARCL1,PREX2,PTPRZ1,FGFR3,MACF1,PITPNC1,NHSL1,ITPR2,NKAIN3 |
1.832e-03 | -6.30 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
1.832e-03 | -6.30 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
1.848e-03 | -6.29 | cell surface | cellular component | GO:0009986 | 896 | 8 | 19108 | 49 |
SLC4A4,SLC1A3,GPC5,SLC1A2,AQP4,LIFR,ATP1A2,FGFR3 |
1.854e-03 | -6.29 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 4 | 19454 | 50 |
DTNA,PARD3B,ABLIM1,GJA1 |
1.888e-03 | -6.27 | UTRN (utrophin) | protein interactions | 7402 | 205 | 4 | 19454 | 50 |
DTNA,FGFR3,GJA1,PARD3 |
1.909e-03 | -6.26 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
PREX2,FGFR3,PTPRZ1,CTNND2,DTNA,PARD3B,CDH20,SORBS1,LIFR,MACF1,ABLIM1,CPE |
1.909e-03 | -6.26 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 12 | 16828 | 49 |
LIFR,SORBS1,CDH20,MACF1,CTNND2,PREX2,PTPRZ1,FGFR3,PARD3B,DTNA,CPE,ABLIM1 |
1.913e-03 | -6.26 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 50 |
TNIK |
1.913e-03 | -6.26 | human chr10p11.22-p11.21 | chromosome location | human chr10p11.22-p11.21 | 1 | 1 | 26134 | 50 |
PARD3 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.915e-03 | -6.26 | actin filament bundle | cellular component | GO:0032432 | 96 | 3 | 19108 | 49 |
SORBS1,ABLIM1,NEBL |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 21 |
ATP1A2,SLC4A4 |
1.997e-03 | -6.22 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 21 |
SLC4A4,ATP1A2 |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.130e-03 | -6.15 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
CDH20,DTNA,CTNNA2 |
2.161e-03 | -6.14 | cell projection | cellular component | GO:0042995 | 2398 | 14 | 19108 | 49 |
AQP4,PARD3,CTNNA2,GPM6A,GLUL,CTNND2,ABLIM1,DTNA,SLC1A2,ATP1A2,SLC1A3,BMPR1B,AHCYL2,MACF1 |
2.167e-03 | -6.13 | Salivary secretion | KEGG pathways | ko04970 | 90 | 3 | 7161 | 21 |
RYR3,ATP1A2,ITPR2 |
2.167e-03 | -6.13 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 3 | 7161 | 21 |
ITPR2,ATP1A2,RYR3 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
ABLIM1,DTNA |
2.181e-03 | -6.13 | HPCAL4 (hippocalcin like 4) | protein interactions | 51440 | 27 | 2 | 19454 | 50 |
GPM6A,AQP4 |
2.181e-03 | -6.13 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
2.185e-03 | -6.13 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 7 | 19454 | 50 |
MSI2,SLC1A3,MACF1,DTNA,PARD3,TNIK,ABLIM1 |
2.198e-03 | -6.12 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 10 | 16828 | 49 |
LSAMP,TNIK,PARD3,SOX5,CTNND2,NKAIN3,AQP4,ITPR2,SPON1,GPC5 |
2.217e-03 | -6.11 | L-glutamate and L-glutamine biosynthesis | BIOCYC pathways | META_PWY-5505 | 2 | 1 | 902 | 1 |
GLUL |
2.226e-03 | -6.11 | membrane | cellular component | GO:0016020 | 9220 | 34 | 19108 | 49 |
ATP1A2,GJA1,PON2,GPC5,ITPR2,MACF1,CPE,AQP4,LIFR,LRIG1,PARD3,ATP13A4,TNIK,LSAMP,FGFR3,CTNNA2,GLUL,SORBS1,SLC1A2,PTPRZ1,SFXN5,SLC1A3,SLC4A4,ZNRF3,BMPR1B,NKAIN3,CDH20,PARD3B,PREX2,NTM,GPM6A,RYR3,DTNA,CTNND2 |
2.291e-03 | -6.08 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 7 | 19454 | 50 |
PARD3,TNIK,GJA1,MACF1,SLC1A3,DTNA,AHCYL2 |
2.304e-03 | -6.07 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.317e-03 | -6.07 | protein binding | molecular function | GO:0005515 | 13983 | 45 | 18094 | 48 |
CDH20,GJA1,PITPNC1,LRIG1,SFXN5,ITPR2,GPM6A,MACF1,CTNNA2,TNIK,CTNND2,NTM,RYR3,PARD3B,GLUL,ABLIM1,SPON1,LIFR,BMPR1B,ATP1A2,DTNA,AHCYL2,SORBS1,PTPRZ1,PON2,NPAS3,SPARCL1,AQP4,ZNRF3,GPC5,SLC1A3,LSAMP,PARD3,RFX4,CPE,NFIA,FGFR3,NEBL,FBXL7,MSI2,TRPS1,MEIS2,SOX5,SLC1A2,SLC4A4 |
2.341e-03 | -6.06 | actin filament binding | molecular function | GO:0051015 | 211 | 4 | 18094 | 48 |
CTNNA2,MACF1,ABLIM1,NEBL |
2.362e-03 | -6.05 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 48 | 16828 | 49 |
GPC5,GPM6A,LRIG1,SLC1A3,FBXL7,CPE,TRPS1,AHCYL2,CDH20,ITPR2,LIFR,RYR3,DTNA,PARD3B,PREX2,SPARCL1,MEIS2,SLC4A4,ZNRF3,ATP13A4,NHSL1,PITPNC1,SFXN5,SORBS1,RFX4,PON2,NTM,ABLIM1,NPAS3,NFIA,AQP4,NKAIN3,ATP1A2,LSAMP,SOX5,TNIK,NEBL,SPON1,GLUL,PARD3,ZBTB20,MACF1,BMPR1B,PTPRZ1,FGFR3,CTNND2,SLC1A2,GJA1 |
2.377e-03 | -6.04 | skeletal system development | biological process | GO:0001501 | 500 | 6 | 18204 | 50 |
SOX5,BMPR1B,GJA1,TRPS1,FGFR3,NFIA |
2.412e-03 | -6.03 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 5 | 16828 | 49 |
PARD3B,NTM,PTPRZ1,MEIS2,SORBS1 |
2.424e-03 | -6.02 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 3 | 19454 | 50 |
ABLIM1,SORBS1,SPARCL1 |
2.496e-03 | -5.99 | system process | biological process | GO:0003008 | 2015 | 13 | 18204 | 50 |
SLC1A3,DTNA,AQP4,ABLIM1,SLC1A2,ATP1A2,LRIG1,MEIS2,CTNNA2,RYR3,GJA1,SLC4A4,PTPRZ1 |
2.498e-03 | -5.99 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 6 | 18204 | 50 |
RYR3,GJA1,SORBS1,ITPR2,SLC1A3,SLC1A2 |
2.514e-03 | -5.99 | INSC (INSC spindle orientation adaptor protein) | protein interactions | 387755 | 29 | 2 | 19454 | 50 |
PARD3,PARD3B |
2.530e-03 | -5.98 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 3 | 7161 | 21 |
ITPR2,SLC4A4,ATP1A2 |
2.530e-03 | -5.98 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 3 | 7161 | 21 |
SLC4A4,ITPR2,ATP1A2 |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.593e-03 | -5.95 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
2.614e-03 | -5.95 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 50 |
SLC1A2,SLC1A3,RYR3 |
2.615e-03 | -5.95 | cellular homeostasis | biological process | GO:0019725 | 689 | 7 | 18204 | 50 |
ATP13A4,SLC1A3,AQP4,ATP1A2,RYR3,SLC4A4,ZBTB20 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.673e-03 | -5.92 | ligand-gated calcium channel activity | molecular function | GO:0099604 | 29 | 2 | 18094 | 48 |
RYR3,ITPR2 |
2.681e-03 | -5.92 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 5 | 16828 | 49 |
PARD3B,NTM,SORBS1,PTPRZ1,MEIS2 |
2.698e-03 | -5.92 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 3 | 19454 | 50 |
AHCYL2,NFIA,TRPS1 |
2.700e-03 | -5.91 | Gln_synth_N_conserv_site | interpro domains | IPR027302 | 1 | 1 | 18521 | 50 |
GLUL |
2.700e-03 | -5.91 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 50 |
ZNRF3 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Alpha_helix_dom_sf | interpro domains | IPR035091 | 1 | 1 | 18521 | 50 |
GJA1 |
2.700e-03 | -5.91 | Nebulette_SH3 | interpro domains | IPR035631 | 1 | 1 | 18521 | 50 |
NEBL |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | LIFR_N | interpro domains | IPR040901 | 1 | 1 | 18521 | 50 |
LIFR |
2.700e-03 | -5.91 | Gln_synth_gly_rich_site | interpro domains | IPR027303 | 1 | 1 | 18521 | 50 |
GLUL |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.700e-03 | -5.91 | Connexin43 | interpro domains | IPR002261 | 1 | 1 | 18521 | 50 |
GJA1 |
2.700e-03 | -5.91 | Connexin43_C | interpro domains | IPR013124 | 1 | 1 | 18521 | 50 |
GJA1 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
CTNND2,SLC1A2,GJA1,FGFR3,BMPR1B,PTPRZ1,MACF1,ZBTB20,PARD3,GLUL,SPON1,NEBL,SOX5,TNIK,LSAMP,ATP1A2,AQP4,NKAIN3,NFIA,NPAS3,ABLIM1,NTM,PON2,RFX4,SFXN5,SORBS1,PITPNC1,NHSL1,ATP13A4,ZNRF3,SLC4A4,MEIS2,SPARCL1,PREX2,PARD3B,RYR3,DTNA,LIFR,ITPR2,AHCYL2,CDH20,FBXL7,SLC1A3,CPE,TRPS1,GPC5,GPM6A,LRIG1 |
2.747e-03 | -5.90 | atrial ventricular junction remodeling | biological process | GO:0003294 | 1 | 1 | 18204 | 50 |
GJA1 |
2.747e-03 | -5.90 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.747e-03 | -5.90 | milk ejection reflex | biological process | GO:0060156 | 1 | 1 | 18204 | 50 |
GJA1 |
2.747e-03 | -5.90 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 50 |
ATP1A2 |
2.749e-03 | -5.90 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 4 | 10285 | 30 |
RYR3,ATP1A2,ITPR2,SORBS1 |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
SPARCL1,PREX2,PARD3B,RYR3,DTNA,LIFR,ITPR2,CDH20,AHCYL2,TRPS1,SLC1A3,FBXL7,CPE,LRIG1,GPM6A,GPC5,RFX4,SORBS1,SFXN5,NHSL1,PITPNC1,ATP13A4,SLC4A4,ZNRF3,MEIS2,TNIK,SOX5,LSAMP,ATP1A2,AQP4,NKAIN3,NFIA,NPAS3,ABLIM1,NTM,PON2,GJA1,SLC1A2,CTNND2,FGFR3,PTPRZ1,BMPR1B,MACF1,ZBTB20,PARD3,GLUL,SPON1,NEBL |
2.810e-03 | -5.87 | Gln-synt_N | pfam domains | PF03951 | 1 | 1 | 17795 | 50 |
GLUL |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.810e-03 | -5.87 | Connexin43 | pfam domains | PF03508 | 1 | 1 | 17795 | 50 |
GJA1 |
2.810e-03 | -5.87 | LIFR_N | pfam domains | PF18207 | 1 | 1 | 17795 | 50 |
LIFR |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CTNNA2,CDH20 |
2.863e-03 | -5.86 | DST (dystonin) | protein interactions | 667 | 230 | 4 | 19454 | 50 |
PARD3,GJA1,TNIK,ATP1A2 |
2.917e-03 | -5.84 | Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | REACTOME pathways | R-HSA-190840 | 1 | 1 | 10285 | 30 |
GJA1 |
2.917e-03 | -5.84 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 30 |
FGFR3 |
2.978e-03 | -5.82 | RAB35 (RAB35, member RAS oncogene family) | protein interactions | 11021 | 559 | 6 | 19454 | 50 |
AHCYL2,DTNA,SLC1A3,MACF1,GJA1,PARD3 |
2.991e-03 | -5.81 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
2.993e-03 | -5.81 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 8 | 19454 | 50 |
PARD3,NHSL1,SORBS1,PITPNC1,ABLIM1,PARD3B,MACF1,FGFR3 |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.041e-03 | -5.80 | Connexin43 | gene3d domains | 1.20.5.1130 | 1 | 1 | 14470 | 44 |
GJA1 |
3.051e-03 | -5.79 | intracellularly ligand-gated monoatomic ion channel activity | molecular function | GO:0005217 | 31 | 2 | 18094 | 48 |
ITPR2,RYR3 |
3.062e-03 | -5.79 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
3.093e-03 | -5.78 | MARK3 (microtubule affinity regulating kinase 3) | protein interactions | 4140 | 235 | 4 | 19454 | 50 |
MACF1,DTNA,PARD3,GJA1 |
3.222e-03 | -5.74 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 3 | 19454 | 50 |
PARD3,SOX5,BMPR1B |
3.289e-03 | -5.72 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 22 | 16828 | 49 |
PARD3,GLUL,MEIS2,ZNRF3,SPON1,RFX4,FGFR3,PTPRZ1,CTNND2,NHSL1,MACF1,ABLIM1,TRPS1,SLC1A3,GPM6A,PON2,PREX2,SOX5,RYR3,DTNA,LIFR,ATP1A2 |
3.289e-03 | -5.72 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 22 | 16828 | 49 |
GPM6A,SPON1,ZNRF3,MEIS2,PON2,PARD3,SLC1A3,TRPS1,ABLIM1,GLUL,ATP1A2,LIFR,MACF1,NHSL1,SOX5,CTNND2,PTPRZ1,FGFR3,PREX2,RFX4,DTNA,RYR3 |
3.302e-03 | -5.71 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 3 | 19454 | 50 |
GLUL,SPARCL1,MACF1 |
3.326e-03 | -5.71 | GABA shunt | BIOCYC pathways | HUMAN_GLUDEG-I-PWY | 3 | 1 | 902 | 1 |
GLUL |
3.336e-03 | -5.70 | GJA1 (gap junction protein alpha 1) | protein interactions | 2697 | 572 | 6 | 19454 | 50 |
TNIK,ITPR2,GJA1,PARD3,DTNA,MACF1 |
3.383e-03 | -5.69 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 21 | 16828 | 49 |
MACF1,AHCYL2,CDH20,ITPR2,ATP1A2,PARD3B,RFX4,FGFR3,PREX2,SLC1A2,CTNND2,PON2,NEBL,MEIS2,SLC4A4,LRIG1,GPC5,ATP13A4,ABLIM1,TRPS1,PARD3 |
3.415e-03 | -5.68 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 50 |
ATP1A2,ATP13A4 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
FGFR3,PREX2 |
3.479e-03 | -5.66 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
3.479e-03 | -5.66 | microtubule organizing center localization | biological process | GO:0061842 | 32 | 2 | 18204 | 50 |
PARD3B,PARD3 |
3.479e-03 | -5.66 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
3.479e-03 | -5.66 | centrosome localization | biological process | GO:0051642 | 32 | 2 | 18204 | 50 |
PARD3,PARD3B |
3.479e-03 | -5.66 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 50 |
SOX5,BMPR1B |
3.482e-03 | -5.66 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 6 | 18094 | 48 |
PTPRZ1,CPE,CTNNA2,MACF1,CTNND2,CDH20 |
3.611e-03 | -5.62 | GLNA_ATP | prosite domains | PS00181 | 1 | 1 | 12186 | 44 |
GLUL |
3.611e-03 | -5.62 | GLNA_1 | prosite domains | PS00180 | 1 | 1 | 12186 | 44 |
GLUL |
3.637e-03 | -5.62 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 50 |
ATP13A4,ATP1A2 |
3.649e-03 | -5.61 | TPRA1 (transmembrane protein adipocyte associated 1) | protein interactions | 131601 | 35 | 2 | 19454 | 50 |
BMPR1B,ITPR2 |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
3.688e-03 | -5.60 | calcium channel activity | molecular function | GO:0005262 | 117 | 3 | 18094 | 48 |
ITPR2,RYR3,GPM6A |
3.692e-03 | -5.60 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 50 |
CTNND2,CTNNA2,PREX2 |
3.697e-03 | -5.60 | response to auditory stimulus | biological process | GO:0010996 | 33 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
3.741e-03 | -5.59 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 50 |
BMPR1B,SOX5,FGFR3,NFIA |
3.827e-03 | -5.57 | eye development | biological process | GO:0001654 | 381 | 5 | 18204 | 50 |
NFIA,MEIS2,GJA1,BMPR1B,GPM6A |
3.836e-03 | -5.56 | RAC1 (Rac family small GTPase 1) | protein interactions | 5879 | 1005 | 8 | 19454 | 50 |
MACF1,SLC1A3,DTNA,AHCYL2,PREX2,PON2,PARD3,GJA1 |
3.857e-03 | -5.56 | ZNRF1 (zinc and ring finger 1) | protein interactions | 84937 | 36 | 2 | 19454 | 50 |
ATP1A2,GLUL |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
3.908e-03 | -5.54 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 8 | 16828 | 49 |
LRIG1,ITPR2,ATP1A2,ABLIM1,PTPRZ1,FGFR3,NPAS3,SPARCL1 |
3.911e-03 | -5.54 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 38 |
MACF1 |
3.912e-03 | -5.54 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 50 |
FGFR3,LSAMP,LRIG1,NTM |
3.936e-03 | -5.54 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 21 | 16828 | 49 |
SLC1A3,PARD3,TRPS1,NPAS3,PON2,SPON1,ZNRF3,RYR3,PARD3B,PTPRZ1,FGFR3,PREX2,SPARCL1,CTNND2,GJA1,NHSL1,NFIA,MACF1,AQP4,CDH20,SORBS1 |
3.969e-03 | -5.53 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 4 | 19454 | 50 |
TNIK,GJA1,SORBS1,NHSL1 |
4.001e-03 | -5.52 | visual system development | biological process | GO:0150063 | 385 | 5 | 18204 | 50 |
BMPR1B,GPM6A,GJA1,MEIS2,NFIA |
4.005e-03 | -5.52 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 13 | 16828 | 49 |
ATP1A2,LIFR,SORBS1,CTNND2,SPARCL1,BMPR1B,PREX2,FGFR3,NEBL,CPE,PARD3,ABLIM1,ATP13A4 |
4.005e-03 | -5.52 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 13 | 16828 | 49 |
PREX2,BMPR1B,FGFR3,SPARCL1,CTNND2,SORBS1,LIFR,ATP1A2,ATP13A4,ABLIM1,CPE,PARD3,NEBL |
4.018e-03 | -5.52 | AQUAPORIN4 | prints domains | PR02016 | 1 | 1 | 5227 | 21 |
AQP4 |
4.018e-03 | -5.52 | CONNEXINA1 | prints domains | PR01132 | 1 | 1 | 5227 | 21 |
GJA1 |
4.071e-03 | -5.50 | ROBO2 (roundabout guidance receptor 2) | protein interactions | 6092 | 37 | 2 | 19454 | 50 |
GJA1,CPE |
4.096e-03 | -5.50 | muscle contraction | biological process | GO:0006936 | 238 | 4 | 18204 | 50 |
DTNA,RYR3,ATP1A2,GJA1 |
4.152e-03 | -5.48 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 6 | 19108 | 49 |
GJA1,CTNNA2,ATP1A2,BMPR1B,SORBS1,CDH20 |
4.238e-03 | -5.46 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 8 | 16828 | 49 |
ATP1A2,LRIG1,ITPR2,ABLIM1,FGFR3,PTPRZ1,SPARCL1,NPAS3 |
4.244e-03 | -5.46 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 50 |
ATP1A2,ATP13A4 |
4.244e-03 | -5.46 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.244e-03 | -5.46 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.271e-03 | -5.46 | sensory system development | biological process | GO:0048880 | 391 | 5 | 18204 | 50 |
GJA1,BMPR1B,GPM6A,MEIS2,NFIA |
4.289e-03 | -5.45 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 9 | 16828 | 49 |
ATP13A4,PREX2,FGFR3,CTNND2,MACF1,SORBS1,NTM,SLC4A4,LIFR |
4.310e-03 | -5.45 | membrane protein complex | cellular component | GO:0098796 | 1261 | 9 | 19108 | 49 |
SLC1A2,ATP1A2,GJA1,SLC1A3,BMPR1B,CTNNA2,RYR3,CDH20,SORBS1 |
4.373e-03 | -5.43 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 4 | 19454 | 50 |
PARD3,GJA1,PARD3B,DTNA |
4.413e-03 | -5.42 | arm | COSMIC cancer mutations | arm | 1331 | 10 | 16828 | 49 |
ATP1A2,SLC4A4,NTM,SORBS1,MACF1,ZBTB20,TRPS1,NPAS3,FGFR3,PARD3B |
4.448e-03 | -5.42 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 3 | 19454 | 50 |
ITPR2,ABLIM1,ZBTB20 |
4.478e-03 | -5.41 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
4.545e-03 | -5.39 | DVL1 (dishevelled segment polarity protein 1) | protein interactions | 1855 | 130 | 3 | 19454 | 50 |
ZNRF3,GJA1,PARD3 |
4.603e-03 | -5.38 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 50 |
SLC1A2,SLC4A4,GJA1,SLC1A3,SFXN5 |
4.610e-03 | -5.38 | tight junction | cellular component | GO:0070160 | 131 | 3 | 19108 | 49 |
GJA1,PARD3,PARD3B |
4.616e-03 | -5.38 | kidney-carcinoma-papillary_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
CTNND2,RFX4,FGFR3,PTPRZ1,BMPR1B,MACF1,ZBTB20,PITPNC1,PARD3,ATP13A4,GLUL,ZNRF3,SLC4A4,SPON1,TNIK,SOX5,PREX2,RYR3,LIFR,ITPR2,ATP1A2,NFIA,CPE,ABLIM1,LRIG1,NTM,GPC5,PON2 |
4.616e-03 | -5.38 | papillary_renal_cell_carcinoma | COSMIC cancer mutations | papillary_renal_cell_carcinoma | 6364 | 28 | 16828 | 49 |
ZNRF3,SLC4A4,SPON1,ATP13A4,GLUL,PARD3,MACF1,ZBTB20,PITPNC1,CTNND2,RFX4,FGFR3,PTPRZ1,BMPR1B,PON2,NTM,LRIG1,GPC5,CPE,ABLIM1,NFIA,LIFR,ITPR2,ATP1A2,RYR3,TNIK,SOX5,PREX2 |
4.631e-03 | -5.38 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
4.631e-03 | -5.38 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
4.631e-03 | -5.38 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
4.632e-03 | -5.37 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 44 | 16828 | 49 |
RYR3,PARD3B,PREX2,SPARCL1,AHCYL2,CDH20,ITPR2,LIFR,TRPS1,CPE,FBXL7,SLC1A3,LRIG1,GPC5,GPM6A,RFX4,NHSL1,PITPNC1,SORBS1,SFXN5,ATP13A4,MEIS2,LSAMP,TNIK,SOX5,NFIA,AQP4,NKAIN3,ATP1A2,ABLIM1,NPAS3,PON2,NTM,BMPR1B,FGFR3,PTPRZ1,SLC1A2,GJA1,CTNND2,ZBTB20,MACF1,PARD3,NEBL,SPON1 |
4.691e-03 | -5.36 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 50 |
ITPR2,ATP13A4,RYR3,SLC1A3,ATP1A2,GPM6A,SLC4A4 |
4.744e-03 | -5.35 | DZIP1 (DAZ interacting zinc finger protein 1) | protein interactions | 22873 | 40 | 2 | 19454 | 50 |
PARD3,GJA1 |
4.873e-03 | -5.32 | PDZ | pfam domains | PF00595 | 122 | 3 | 17795 | 50 |
PARD3B,PREX2,PARD3 |
4.880e-03 | -5.32 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
4.928e-03 | -5.31 | cellular response to nitrogen compound | biological process | GO:1901699 | 580 | 6 | 18204 | 50 |
GJA1,SLC1A2,SORBS1,SLC1A3,RYR3,ITPR2 |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
CPE,NTM,GPM6A |
4.969e-03 | -5.30 | sensory organ development | biological process | GO:0007423 | 581 | 6 | 18204 | 50 |
GJA1,BMPR1B,GPM6A,LRIG1,MEIS2,NFIA |
4.977e-03 | -5.30 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 21 | 16828 | 49 |
NFIA,NHSL1,MACF1,CDH20,SORBS1,AQP4,RYR3,PARD3B,FGFR3,PTPRZ1,PREX2,GJA1,SPARCL1,CTNND2,PON2,ZNRF3,SPON1,NPAS3,TRPS1,SLC1A3,PARD3 |
4.980e-03 | -5.30 | TAFA2 (TAFA chemokine like family member 2) | protein interactions | 338811 | 41 | 2 | 19454 | 50 |
CPE,LIFR |
5.049e-03 | -5.29 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 50 |
PARD3,ABLIM1,DTNA |
5.049e-03 | -5.29 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 3 | 19454 | 50 |
TRPS1,ITPR2,ABLIM1 |
5.118e-03 | -5.28 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 3 | 18204 | 50 |
PARD3,CDH20,GJA1 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
DTNA,MACF1,RYR3,SPARCL1 |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | THSD1 (thrombospondin type 1 domain containing 1) | protein interactions | 55901 | 2 | 1 | 19454 | 50 |
GJA1 |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | DEFB126 (defensin beta 126) | protein interactions | 81623 | 2 | 1 | 19454 | 50 |
GJA1 |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 50 |
SLC1A3,ATP1A2 |
5.154e-03 | -5.27 | spindle | COSMIC cancer mutations | spindle | 386 | 5 | 16828 | 49 |
FGFR3,PREX2,CPE,CTNND2,MACF1 |
5.198e-03 | -5.26 | RDX (radixin) | protein interactions | 5962 | 272 | 4 | 19454 | 50 |
MACF1,FGFR3,ABLIM1,NEBL |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
DTNA,FGFR3,CDH20 |
5.299e-03 | -5.24 | leukemia inhibitory factor receptor activity | molecular function | GO:0004923 | 2 | 1 | 18094 | 48 |
LIFR |
5.299e-03 | -5.24 | glutamine synthetase activity | molecular function | GO:0004356 | 2 | 1 | 18094 | 48 |
GLUL |
5.299e-03 | -5.24 | ammonia ligase activity | molecular function | GO:0016211 | 2 | 1 | 18094 | 48 |
GLUL |
5.302e-03 | -5.24 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 6 | 16828 | 49 |
LIFR,SLC4A4,TRPS1,CTNND2,FBXL7,RYR3 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 44 |
ATP1A2,ATP13A4 |
5.331e-03 | -5.23 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
5.366e-03 | -5.23 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
5.379e-03 | -5.23 | central nervous system development | biological process | GO:0007417 | 995 | 8 | 18204 | 50 |
SLC1A2,ATP1A2,MEIS2,PTPRZ1,RFX4,BMPR1B,MSI2,CTNNA2 |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | LIFR_D2 | interpro domains | IPR040817 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | Spondin_N_sf | interpro domains | IPR038678 | 2 | 1 | 18521 | 50 |
SPON1 |
5.392e-03 | -5.22 | Paraoxonase2 | interpro domains | IPR008364 | 2 | 1 | 18521 | 50 |
PON2 |
5.392e-03 | -5.22 | Gln_synth_cat_dom | interpro domains | IPR008146 | 2 | 1 | 18521 | 50 |
GLUL |
5.392e-03 | -5.22 | LIF-R-like_Ig-like | interpro domains | IPR048497 | 2 | 1 | 18521 | 50 |
LIFR |
5.392e-03 | -5.22 | Spondin_N | interpro domains | IPR009465 | 2 | 1 | 18521 | 50 |
SPON1 |
5.392e-03 | -5.22 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 50 |
ZNRF3 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Gln_synt_N | interpro domains | IPR008147 | 2 | 1 | 18521 | 50 |
GLUL |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Gln_synt_N_sf | interpro domains | IPR036651 | 2 | 1 | 18521 | 50 |
GLUL |
5.394e-03 | -5.22 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 6 | 16828 | 49 |
RYR3,SLC4A4,TRPS1,LIFR,CTNND2,FBXL7 |
5.440e-03 | -5.21 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 49 |
ITPR2,RYR3 |
5.486e-03 | -5.21 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 50 |
FGFR3 |
5.486e-03 | -5.21 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 50 |
ZNRF3 |
5.486e-03 | -5.21 | glutamine biosynthetic process | biological process | GO:0006542 | 2 | 1 | 18204 | 50 |
GLUL |
5.505e-03 | -5.20 | acral_lentiginous | COSMIC cancer mutations | acral_lentiginous | 745 | 7 | 16828 | 49 |
ATP13A4,MACF1,PREX2,FGFR3,CDH20,PARD3,GJA1 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
5.585e-03 | -5.19 | CEP89 (centrosomal protein 89) | protein interactions | 84902 | 140 | 3 | 19454 | 50 |
GJA1,PARD3,ABLIM1 |
5.611e-03 | -5.18 | TJP2 (tight junction protein 2) | protein interactions | 9414 | 278 | 4 | 19454 | 50 |
GJA1,NEBL,PARD3,SORBS1 |
5.612e-03 | -5.18 | LIF-R_Ig-like | pfam domains | PF21177 | 2 | 1 | 17795 | 50 |
LIFR |
5.612e-03 | -5.18 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 50 |
ZNRF3 |
5.612e-03 | -5.18 | Spond_N | pfam domains | PF06468 | 2 | 1 | 17795 | 50 |
SPON1 |
5.612e-03 | -5.18 | Gln-synt_C | pfam domains | PF00120 | 2 | 1 | 17795 | 50 |
GLUL |
5.612e-03 | -5.18 | Reeler | pfam domains | PF02014 | 2 | 1 | 17795 | 50 |
SPON1 |
5.612e-03 | -5.18 | LIFR_D2 | pfam domains | PF17971 | 2 | 1 | 17795 | 50 |
LIFR |
5.612e-03 | -5.18 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 3 | 18094 | 48 |
GPM6A,RYR3,ITPR2 |
5.692e-03 | -5.17 | actin binding | molecular function | GO:0003779 | 434 | 5 | 18094 | 48 |
SORBS1,ABLIM1,NEBL,MACF1,CTNNA2 |
5.696e-03 | -5.17 | MAB21L2 (mab-21 like 2) | protein interactions | 10586 | 141 | 3 | 19454 | 50 |
LIFR,MEIS2,CTNNA2 |
5.817e-03 | -5.15 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 3 | 18204 | 50 |
ITPR2,RYR3,ATP1A2 |
5.826e-03 | -5.15 | Transport of connexons to the plasma membrane | REACTOME pathways | R-HSA-190872 | 2 | 1 | 10285 | 30 |
GJA1 |
5.922e-03 | -5.13 | SLC6A15 (solute carrier family 6 member 15) | protein interactions | 55117 | 143 | 3 | 19454 | 50 |
PARD3,SFXN5,GJA1 |
5.939e-03 | -5.13 | establishment of cell polarity | biological process | GO:0030010 | 134 | 3 | 18204 | 50 |
PARD3,PARD3B,GJA1 |
5.968e-03 | -5.12 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 4 | 16828 | 49 |
MACF1,ZNRF3,TNIK,FGFR3 |
6.037e-03 | -5.11 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 50 |
MACF1,ABLIM1,ZBTB20 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.073e-03 | -5.10 | Glutamine synthetase, N-terminal domain | gene3d domains | 3.10.20.70 | 2 | 1 | 14470 | 44 |
GLUL |
6.073e-03 | -5.10 | F-spondin domain | gene3d domains | 2.60.40.2130 | 2 | 1 | 14470 | 44 |
SPON1 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.087e-03 | -5.10 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 4 | 18094 | 48 |
PITPNC1,PARD3B,PARD3,ITPR2 |
6.161e-03 | -5.09 | cell development | biological process | GO:0048468 | 2236 | 13 | 18204 | 50 |
PREX2,SLC1A3,MSI2,GPM6A,GJA1,NTM,CTNND2,BMPR1B,PTPRZ1,TNIK,NEBL,PARD3,CTNNA2 |
6.237e-03 | -5.08 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 50 |
SLC1A3,ATP13A4,RYR3,SLC4A4,ATP1A2 |
6.257e-03 | -5.07 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 5 | 18094 | 48 |
SLC1A2,ATP13A4,ATP1A2,SLC1A3,SLC4A4 |
6.348e-03 | -5.06 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 4 | 19454 | 50 |
NEBL,NHSL1,PARD3,SORBS1 |
6.435e-03 | -5.05 | cytoskeleton organization | biological process | GO:0007010 | 1251 | 9 | 18204 | 50 |
MACF1,GJA1,NEBL,TNIK,SORBS1,PARD3,PARD3B,CTNNA2,ABLIM1 |
6.441e-03 | -5.05 | membrane raft | cellular component | GO:0045121 | 290 | 4 | 19108 | 49 |
GJA1,ATP1A2,SLC1A2,SORBS1 |
6.441e-03 | -5.04 | regulation of generation of precursor metabolites and energy | biological process | GO:0043467 | 138 | 3 | 18204 | 50 |
SORBS1,ZBTB20,SLC4A4 |
6.498e-03 | -5.04 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
PTPRZ1,GPM6A |
6.500e-03 | -5.04 | LRIG3 (leucine rich repeats and immunoglobulin like domains 3) | protein interactions | 121227 | 47 | 2 | 19454 | 50 |
GJA1,LRIG1 |
6.597e-03 | -5.02 | membrane microdomain | cellular component | GO:0098857 | 292 | 4 | 19108 | 49 |
SORBS1,ATP1A2,GJA1,SLC1A2 |
6.599e-03 | -5.02 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 9 | 19454 | 50 |
SOX5,MACF1,MEIS2,ITPR2,MSI2,NFIA,GJA1,TRPS1,LSAMP |
6.634e-03 | -5.02 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 50 |
SOX5,TNIK,NFIA |
6.634e-03 | -5.02 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 50 |
SLC4A4,SLC1A2,ATP1A2,SLC1A3 |
6.646e-03 | -5.01 | skin-trunk-malignant_melanoma | COSMIC cancer mutations | skin-trunk-malignant_melanoma | 2647 | 15 | 16828 | 49 |
CDH20,ATP1A2,LIFR,PTPRZ1,PREX2,SOX5,CTNND2,LSAMP,RYR3,MEIS2,NEBL,PARD3,SLC1A3,TRPS1,ATP13A4 |
6.676e-03 | -5.01 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 50 |
GPM6A,SLC4A4,ATP1A2,RYR3,SLC1A3,ITPR2 |
6.702e-03 | -5.01 | neurotransmitter transport | biological process | GO:0006836 | 140 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,ATP1A2 |
6.709e-03 | -5.00 | apical junction complex | cellular component | GO:0043296 | 150 | 3 | 19108 | 49 |
SORBS1,PARD3,PARD3B |
6.728e-03 | -5.00 | behavior | biological process | GO:0007610 | 619 | 6 | 18204 | 50 |
PREX2,SLC1A3,MEIS2,ATP1A2,PTPRZ1,SLC1A2 |
6.788e-03 | -4.99 | cell communication involved in cardiac conduction | biological process | GO:0086065 | 45 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
6.798e-03 | -4.99 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 50 |
ATP1A2,SLC4A4,SLC1A3,RYR3,ATP13A4 |
6.881e-03 | -4.98 | TNIK (TRAF2 and NCK interacting kinase) | protein interactions | 23043 | 151 | 3 | 19454 | 50 |
TNIK,GJA1,MACF1 |
6.932e-03 | -4.97 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 15 | 16828 | 49 |
NPAS3,ZNRF3,SPON1,PON2,PTPRZ1,FGFR3,PREX2,SPARCL1,CTNND2,RYR3,PARD3B,SORBS1,AQP4,NFIA,MACF1 |
6.932e-03 | -4.97 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 15 | 16828 | 49 |
MACF1,NFIA,PON2,SPON1,ZNRF3,AQP4,SORBS1,PARD3B,RYR3,CTNND2,SPARCL1,NPAS3,PTPRZ1,PREX2,FGFR3 |
6.939e-03 | -4.97 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 8 | 16828 | 49 |
CTNND2,PARD3,SOX5,LSAMP,NKAIN3,GPC5,SPON1,ITPR2 |
6.969e-03 | -4.97 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 50 |
SORBS1,ZBTB20,SLC4A4 |
6.969e-03 | -4.97 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 50 |
SLC1A3,SLC1A2,SLC4A4 |
7.064e-03 | -4.95 | TJP1 (tight junction protein 1) | protein interactions | 7082 | 297 | 4 | 19454 | 50 |
GJA1,NEBL,PARD3,DTNA |
7.084e-03 | -4.95 | regulation of myelination | biological process | GO:0031641 | 46 | 2 | 18204 | 50 |
PTPRZ1,PARD3 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
7.135e-03 | -4.94 | SOX6 (SRY-box transcription factor 6) | protein interactions | 55553 | 153 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
7.175e-03 | -4.94 | PDZ | interpro domains | IPR001478 | 146 | 3 | 18521 | 50 |
PREX2,PARD3B,PARD3 |
7.209e-03 | -4.93 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | SPONDIN | prosite domains | PS51020 | 2 | 1 | 12186 | 44 |
SPON1 |
7.209e-03 | -4.93 | GS_CATALYTIC | prosite domains | PS51987 | 2 | 1 | 12186 | 44 |
GLUL |
7.209e-03 | -4.93 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 44 |
SPARCL1 |
7.209e-03 | -4.93 | GS_BETA_GRASP | prosite domains | PS51986 | 2 | 1 | 12186 | 44 |
GLUL |
7.266e-03 | -4.92 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 6 | 16828 | 49 |
TRPS1,GJA1,CTNND2,PREX2,SPON1,MACF1 |
7.312e-03 | -4.92 | metal ion transport | biological process | GO:0030001 | 630 | 6 | 18204 | 50 |
GPM6A,SLC4A4,ATP1A2,RYR3,SLC1A3,ITPR2 |
7.368e-03 | -4.91 | Signaling pathways regulating pluripotency of stem cells | KEGG pathways | ko04550 | 139 | 3 | 7161 | 21 |
FGFR3,BMPR1B,LIFR |
7.368e-03 | -4.91 | Signaling pathways regulating pluripotency of stem cells | KEGG pathways | hsa04550 | 139 | 3 | 7161 | 21 |
LIFR,FGFR3,BMPR1B |
7.404e-03 | -4.91 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 49 |
RYR3,LIFR,SOX5,CDH20 |
7.426e-03 | -4.90 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 44 |
ATP1A2,ATP13A4 |
7.521e-03 | -4.89 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 50 |
SLC1A2,ATP1A2,PREX2 |
7.581e-03 | -4.88 | intercalated disc | cellular component | GO:0014704 | 51 | 2 | 19108 | 49 |
GJA1,ATP1A2 |
7.587e-03 | -4.88 | PDZ_sf | interpro domains | IPR036034 | 149 | 3 | 18521 | 50 |
PREX2,PARD3B,PARD3 |
7.592e-03 | -4.88 | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-small_intestine-lymphoid_neoplasm-enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.592e-03 | -4.88 | enteropathy_type_T_cell_lymphoma | COSMIC cancer mutations | enteropathy_type_T_cell_lymphoma | 45 | 2 | 16828 | 49 |
ZNRF3,MACF1 |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
NHSL1,MACF1 |
7.617e-03 | -4.88 | FAM171B (family with sequence similarity 171 member B) | protein interactions | 165215 | 51 | 2 | 19454 | 50 |
PARD3,GJA1 |
7.617e-03 | -4.88 | LINGO1 (leucine rich repeat and Ig domain containing 1) | protein interactions | 84894 | 51 | 2 | 19454 | 50 |
NTM,PON2 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.647e-03 | -4.87 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-hairy_cell_leukaemia | 1440 | 10 | 16828 | 49 |
RFX4,PREX2,FGFR3,PTPRZ1,CTNND2,RYR3,CDH20,LIFR,MACF1,NEBL |
7.647e-03 | -4.87 | hairy_cell_leukaemia | COSMIC cancer mutations | hairy_cell_leukaemia | 1440 | 10 | 16828 | 49 |
LIFR,CDH20,NEBL,MACF1,CTNND2,FGFR3,PTPRZ1,PREX2,RFX4,RYR3 |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | DEFB124 (defensin beta 124) | protein interactions | 245937 | 3 | 1 | 19454 | 50 |
GJA1 |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | PIGL (phosphatidylinositol glycan anchor biosynthesis class L) | protein interactions | 9487 | 3 | 1 | 19454 | 50 |
MEIS2 |
7.700e-03 | -4.87 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 49 |
FGFR3,PARD3,GPC5 |
7.702e-03 | -4.87 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 50 |
CTNNA2,NEBL,RFX4,BMPR1B,SOX5,NFIA,ABLIM1,CPE,SLC1A2,LRIG1,MEIS2,GJA1,GPM6A,FGFR3,ATP1A2 |
7.806e-03 | -4.85 | Gln-synt_C | smart domains | SM01230 | 2 | 1 | 9717 | 38 |
GLUL |
7.938e-03 | -4.84 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 48 |
AHCYL2 |
7.938e-03 | -4.84 | acid-ammonia (or amide) ligase activity | molecular function | GO:0016880 | 3 | 1 | 18094 | 48 |
GLUL |
7.938e-03 | -4.84 | acyl-L-homoserine-lactone lactonohydrolase activity | molecular function | GO:0102007 | 3 | 1 | 18094 | 48 |
PON2 |
7.938e-03 | -4.84 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 48 |
AHCYL2 |
7.938e-03 | -4.84 | inositol 1,4,5-trisphosphate-gated calcium channel activity | molecular function | GO:0005220 | 3 | 1 | 18094 | 48 |
ITPR2 |
7.938e-03 | -4.84 | lactonohydrolase activity | molecular function | GO:0046573 | 3 | 1 | 18094 | 48 |
PON2 |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.938e-03 | -4.84 | oncostatin-M receptor activity | molecular function | GO:0004924 | 3 | 1 | 18094 | 48 |
LIFR |
7.964e-03 | -4.83 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 30 |
RYR3,ATP1A2,ITPR2 |
8.007e-03 | -4.83 | visual learning | biological process | GO:0008542 | 49 | 2 | 18204 | 50 |
ATP1A2,MEIS2 |
8.020e-03 | -4.83 | PARAOXONASE2 | prints domains | PR01787 | 2 | 1 | 5227 | 21 |
PON2 |
8.021e-03 | -4.83 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 8 | 19454 | 50 |
NHSL1,PARD3,SORBS1,GJA1,PITPNC1,ABLIM1,PARD3B,MACF1 |
8.065e-03 | -4.82 | PTPN14 (protein tyrosine phosphatase non-receptor type 14) | protein interactions | 5784 | 160 | 3 | 19454 | 50 |
GJA1,CTNNA2,PARD3 |
8.065e-03 | -4.82 | SOX5 (SRY-box transcription factor 5) | protein interactions | 6660 | 160 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
8.078e-03 | -4.82 | Arylesterase | interpro domains | IPR002640 | 3 | 1 | 18521 | 50 |
PON2 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Connexin_C | interpro domains | IPR034634 | 3 | 1 | 18521 | 50 |
GJA1 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | InsP3_rcpt | interpro domains | IPR000493 | 3 | 1 | 18521 | 50 |
ITPR2 |
8.078e-03 | -4.82 | Reeler_sf | interpro domains | IPR042307 | 3 | 1 | 18521 | 50 |
SPON1 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.078e-03 | -4.82 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 50 |
AHCYL2 |
8.078e-03 | -4.82 | Reeler_dom | interpro domains | IPR002861 | 3 | 1 | 18521 | 50 |
SPON1 |
8.100e-03 | -4.82 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 50 |
MACF1,DTNA,PARD3,SORBS1 |
8.124e-03 | -4.81 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 49 |
BMPR1B,CTNND2,SLC1A3,GPM6A,ATP1A2 |
8.183e-03 | -4.81 | Spinal Cord Injury | WikiPathways | WP2431 | 119 | 3 | 5310 | 19 |
AQP4,GJA1,PTPRZ1 |
8.206e-03 | -4.80 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 50 |
ZBTB20,AHCYL2 |
8.218e-03 | -4.80 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.218e-03 | -4.80 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 50 |
CTNNA2 |
8.218e-03 | -4.80 | cardiac muscle thin filament assembly | biological process | GO:0071691 | 3 | 1 | 18204 | 50 |
NEBL |
8.218e-03 | -4.80 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 50 |
ATP1A2 |
8.218e-03 | -4.80 | cell communication by chemical coupling | biological process | GO:0010643 | 3 | 1 | 18204 | 50 |
GJA1 |
8.218e-03 | -4.80 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 50 |
SLC1A2 |
8.343e-03 | -4.79 | KLRC1 (killer cell lectin like receptor C1) | protein interactions | 3821 | 162 | 3 | 19454 | 50 |
LRIG1,PON2,SFXN5 |
8.406e-03 | -4.78 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 50 |
SORBS1 |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 50 |
MACF1 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.406e-03 | -4.78 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 50 |
AHCYL2 |
8.406e-03 | -4.78 | Arylesterase | pfam domains | PF01731 | 3 | 1 | 17795 | 50 |
PON2 |
8.446e-03 | -4.77 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 21 |
ATP13A4,ATP1A2 |
8.507e-03 | -4.77 | TAFA4 (TAFA chemokine like family member 4) | protein interactions | 151647 | 54 | 2 | 19454 | 50 |
LIFR,ITPR2 |
8.603e-03 | -4.76 | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | 48 | 2 | 16828 | 49 |
PARD3,RYR3 |
8.627e-03 | -4.75 | SCYL1 (SCY1 like pseudokinase 1) | protein interactions | 57410 | 164 | 3 | 19454 | 50 |
MACF1,GJA1,MEIS2 |
8.693e-03 | -4.75 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 50 |
SLC1A2,ATP1A2,SLC1A3,RYR3,ITPR2 |
8.702e-03 | -4.74 | calcium-mediated signaling | biological process | GO:0019722 | 154 | 3 | 18204 | 50 |
ATP1A2,RYR3,ITPR2 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.712e-03 | -4.74 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 48 |
ATP1A2,ATP13A4 |
8.726e-03 | -4.74 | c-src mediated regulation of Cx43 function and closure of gap junctions | REACTOME pathways | R-HSA-191647 | 3 | 1 | 10285 | 30 |
GJA1 |
8.726e-03 | -4.74 | Oligomerization of connexins into connexons | REACTOME pathways | R-HSA-190704 | 3 | 1 | 10285 | 30 |
GJA1 |
8.726e-03 | -4.74 | Transport of connexins along the secretory pathway | REACTOME pathways | R-HSA-190827 | 3 | 1 | 10285 | 30 |
GJA1 |
8.726e-03 | -4.74 | Regulation of gap junction activity | REACTOME pathways | R-HSA-191650 | 3 | 1 | 10285 | 30 |
GJA1 |
8.748e-03 | -4.74 | ZYX (zyxin) | protein interactions | 7791 | 316 | 4 | 19454 | 50 |
NEBL,SORBS1,MACF1,ABLIM1 |
8.771e-03 | -4.74 | EGR2 (early growth response 2) | protein interactions | 1959 | 165 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
8.814e-03 | -4.73 | AMPH (amphiphysin) | protein interactions | 273 | 55 | 2 | 19454 | 50 |
GLUL,GPM6A |
8.873e-03 | -4.72 | muscle system process | biological process | GO:0003012 | 297 | 4 | 18204 | 50 |
DTNA,RYR3,ATP1A2,GJA1 |
8.873e-03 | -4.72 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 50 |
GJA1,SLC1A2,SFXN5,SLC1A3 |
8.917e-03 | -4.72 | SCLT1 (sodium channel and clathrin linker 1) | protein interactions | 132320 | 166 | 3 | 19454 | 50 |
ABLIM1,ATP1A2,NEBL |
8.976e-03 | -4.71 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 50 |
GJA1,SLC1A2,SLC1A3,SFXN5 |
8.982e-03 | -4.71 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
8.982e-03 | -4.71 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 50 |
ZBTB20,SLC4A4 |
9.013e-03 | -4.71 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 50 |
GPM6A,BMPR1B,NFIA |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.095e-03 | -4.70 | Reeler domain | gene3d domains | 2.60.40.4060 | 3 | 1 | 14470 | 44 |
SPON1 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.095e-03 | -4.70 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 44 |
AHCYL2 |
9.185e-03 | -4.69 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 4 | 10285 | 30 |
SLC1A3,AHCYL2,SLC4A4,SLC1A2 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
RYR3,MACF1,SPARCL1,DTNA |
9.212e-03 | -4.69 | POU2F1 (POU class 2 homeobox 1) | protein interactions | 5451 | 168 | 3 | 19454 | 50 |
LIFR,SOX5,GPC5 |
9.318e-03 | -4.68 | EGFR (epidermal growth factor receptor) | protein interactions | 1956 | 3105 | 15 | 19454 | 50 |
PON2,SORBS1,GLUL,CTNND2,DTNA,LIFR,CTNNA2,SPARCL1,ABLIM1,TRPS1,PARD3,LRIG1,GJA1,TNIK,AHCYL2 |
9.318e-03 | -4.68 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
9.428e-03 | -4.66 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 10 | 16828 | 49 |
SORBS1,GPC5,MACF1,PTPRZ1,PREX2,FGFR3,NPAS3,DTNA,RYR3,PARD3B |
9.492e-03 | -4.66 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 50 |
SLC4A4,SLC1A2,SLC1A3 |
9.564e-03 | -4.65 | side of membrane | cellular component | GO:0098552 | 715 | 6 | 19108 | 49 |
GPC5,DTNA,LIFR,NTM,AQP4,LSAMP |
9.597e-03 | -4.65 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
9.665e-03 | -4.64 | PPFIBP1 (PPFIA binding protein 1) | protein interactions | 8496 | 171 | 3 | 19454 | 50 |
PARD3,MEIS2,GJA1 |
9.665e-03 | -4.64 | TLX1 (T cell leukemia homeobox 1) | protein interactions | 3195 | 171 | 3 | 19454 | 50 |
TRPS1,NFIA,MEIS2 |
9.762e-03 | -4.63 | Hippo signaling pathway | KEGG pathways | hsa04390 | 154 | 3 | 7161 | 21 |
BMPR1B,PARD3,CTNNA2 |
9.762e-03 | -4.63 | Hippo signaling pathway | KEGG pathways | ko04390 | 154 | 3 | 7161 | 21 |
CTNNA2,BMPR1B,PARD3 |
9.763e-03 | -4.63 | CACHD1 (cache domain containing 1) | protein interactions | 57685 | 58 | 2 | 19454 | 50 |
GJA1,PON2 |
9.763e-03 | -4.63 | HOXB6 (homeobox B6) | protein interactions | 3216 | 58 | 2 | 19454 | 50 |
AHCYL2,GLUL |
9.858e-03 | -4.62 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 6 | 16828 | 49 |
NFIA,NEBL,PREX2,PTPRZ1,SORBS1,NTM |
1.001e-02 | -4.60 | establishment or maintenance of epithelial cell apical/basal polarity | biological process | GO:0045197 | 55 | 2 | 18204 | 50 |
PARD3B,PARD3 |
1.001e-02 | -4.60 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
1.009e-02 | -4.60 | MARVELD2 (MARVEL domain containing 2) | protein interactions | 153562 | 59 | 2 | 19454 | 50 |
GJA1,PARD3 |
1.017e-02 | -4.59 | RHOA (ras homolog family member A) | protein interactions | 387 | 1186 | 8 | 19454 | 50 |
MACF1,PARD3B,PREX2,PON2,PARD3,ITPR2,CTNNA2,GJA1 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
DTNA,CDH20,CTNNA2 |
1.022e-02 | -4.58 | internode region of axon | cellular component | GO:0033269 | 4 | 1 | 19108 | 49 |
PARD3 |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.025e-02 | -4.58 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 26 | 16828 | 49 |
ABLIM1,SLC1A3,TRPS1,GPC5,GPM6A,LRIG1,PON2,PREX2,SPARCL1,DTNA,PARD3B,CDH20,ATP1A2,ITPR2,NFIA,PARD3,ATP13A4,SLC4A4,NEBL,FGFR3,PTPRZ1,RFX4,SFXN5,SORBS1,ZBTB20,MACF1 |
1.029e-02 | -4.58 | LHX3 (LIM homeobox 3) | protein interactions | 8022 | 175 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.030e-02 | -4.58 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 26 | 16828 | 49 |
TRPS1,SLC1A3,ABLIM1,LRIG1,GPC5,GPM6A,PON2,SPARCL1,PREX2,PARD3B,DTNA,ITPR2,ATP1A2,CDH20,NFIA,PARD3,ATP13A4,SLC4A4,NEBL,RFX4,FGFR3,PTPRZ1,SORBS1,SFXN5,MACF1,ZBTB20 |
1.034e-02 | -4.57 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 7 | 19454 | 50 |
ZBTB20,SLC1A3,NFIA,ATP13A4,TRPS1,PON2,CTNND2 |
1.034e-02 | -4.57 | channel activity | molecular function | GO:0015267 | 502 | 5 | 18094 | 48 |
GJA1,GPM6A,AQP4,RYR3,ITPR2 |
1.036e-02 | -4.57 | cardiac muscle cell action potential | biological process | GO:0086001 | 56 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
1.036e-02 | -4.57 | release of sequestered calcium ion into cytosol | biological process | GO:0051209 | 56 | 2 | 18204 | 50 |
ITPR2,RYR3 |
1.041e-02 | -4.56 | - | gene3d domains | 2.30.42.10 | 149 | 3 | 14470 | 44 |
PREX2,PARD3,PARD3B |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DTNA,FGFR3 |
1.042e-02 | -4.56 | LRIG2 (leucine rich repeats and immunoglobulin like domains 2) | protein interactions | 9860 | 60 | 2 | 19454 | 50 |
PON2,LRIG1 |
1.042e-02 | -4.56 | passive transmembrane transporter activity | molecular function | GO:0022803 | 503 | 5 | 18094 | 48 |
AQP4,GPM6A,GJA1,ITPR2,RYR3 |
1.043e-02 | -4.56 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 5 | 19108 | 49 |
ABLIM1,MACF1,NEBL,SORBS1,CTNNA2 |
1.049e-02 | -4.56 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 50 |
SLC1A3,ATP1A2,SLC1A2 |
1.050e-02 | -4.56 | response to light stimulus | biological process | GO:0009416 | 312 | 4 | 18204 | 50 |
SLC1A3,SLC1A2,MEIS2,ATP1A2 |
1.057e-02 | -4.55 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.057e-02 | -4.55 | ciliary neurotrophic factor receptor activity | molecular function | GO:0004897 | 4 | 1 | 18094 | 48 |
LIFR |
1.057e-02 | -4.55 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 48 |
SFXN5 |
1.071e-02 | -4.54 | sulfur compound transmembrane transporter activity | molecular function | GO:1901682 | 59 | 2 | 18094 | 48 |
GJA1,SLC1A2 |
1.072e-02 | -4.54 | negative regulation of sequestering of calcium ion | biological process | GO:0051283 | 57 | 2 | 18204 | 50 |
ITPR2,RYR3 |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | PKNOX/Meis_N | interpro domains | IPR032453 | 4 | 1 | 18521 | 50 |
MEIS2 |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | Nebulin_repeat | interpro domains | IPR000900 | 4 | 1 | 18521 | 50 |
NEBL |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.079e-02 | -4.53 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 44 |
AHCYL2 |
1.079e-02 | -4.53 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 44 |
AHCYL2 |
1.079e-02 | -4.53 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 44 |
SORBS1 |
1.079e-02 | -4.53 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 44 |
GPM6A |
1.079e-02 | -4.53 | REELIN | prosite domains | PS51019 | 3 | 1 | 12186 | 44 |
SPON1 |
1.079e-02 | -4.53 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 44 |
CTNNA2 |
1.085e-02 | -4.52 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 39 | 16828 | 49 |
PON2,LRIG1,GPM6A,GPC5,TRPS1,NPAS3,SLC1A3,CPE,FBXL7,ABLIM1,ITPR2,ATP1A2,AHCYL2,CDH20,NKAIN3,AQP4,LSAMP,DTNA,RYR3,TNIK,SOX5,SPARCL1,PREX2,NEBL,SPON1,MEIS2,ATP13A4,GLUL,PARD3,MACF1,ZBTB20,NHSL1,SORBS1,SFXN5,SLC1A2,CTNND2,RFX4,PTPRZ1,FGFR3 |
1.094e-02 | -4.52 | positive regulation of striated muscle tissue development | biological process | GO:0045844 | 4 | 1 | 18204 | 50 |
GJA1 |
1.094e-02 | -4.52 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | oncostatin-M-mediated signaling pathway | biological process | GO:0038165 | 4 | 1 | 18204 | 50 |
LIFR |
1.094e-02 | -4.52 | positive regulation of muscle organ development | biological process | GO:0048636 | 4 | 1 | 18204 | 50 |
GJA1 |
1.094e-02 | -4.52 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 50 |
SOX5 |
1.094e-02 | -4.52 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 50 |
BMPR1B |
1.094e-02 | -4.52 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 50 |
CPE |
1.094e-02 | -4.52 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 50 |
ATP1A2 |
1.094e-02 | -4.52 | positive regulation of cardiac muscle myoblast proliferation | biological process | GO:0110024 | 4 | 1 | 18204 | 50 |
MEIS2 |
1.094e-02 | -4.52 | leukemia inhibitory factor signaling pathway | biological process | GO:0048861 | 4 | 1 | 18204 | 50 |
LIFR |
1.094e-02 | -4.52 | positive regulation of mesodermal cell differentiation | biological process | GO:1905772 | 4 | 1 | 18204 | 50 |
GJA1 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
PREX2,SPARCL1,DTNA,RYR3,PARD3B,AHCYL2,CDH20,ITPR2,LIFR,TRPS1,CPE,SLC1A3,FBXL7,LRIG1,GPM6A,GPC5,MSI2,RFX4,SORBS1,SFXN5,PITPNC1,NHSL1,ATP13A4,MEIS2,ZNRF3,SLC4A4,TNIK,SOX5,LSAMP,AQP4,NKAIN3,ATP1A2,NFIA,ABLIM1,NPAS3,NTM,PON2,PTPRZ1,FGFR3,BMPR1B,SLC1A2,GJA1,CTNND2,ZBTB20,MACF1,PARD3,GLUL,SPON1,NEBL |
1.118e-02 | -4.49 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 4 | 16828 | 49 |
GPC5,TRPS1,RYR3,MACF1 |
1.119e-02 | -4.49 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.119e-02 | -4.49 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | Nebulin | pfam domains | PF00880 | 4 | 1 | 17795 | 50 |
NEBL |
1.119e-02 | -4.49 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 50 |
ABLIM1 |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | Meis_PKNOX_N | pfam domains | PF16493 | 4 | 1 | 17795 | 50 |
MEIS2 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.138e-02 | -4.48 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 49 | 16828 | 49 |
SPON1,NEBL,PARD3,GLUL,MACF1,ZBTB20,GJA1,SLC1A2,CTNND2,PTPRZ1,BMPR1B,FGFR3,NTM,PON2,NPAS3,ABLIM1,ATP1A2,NKAIN3,AQP4,NFIA,TNIK,SOX5,LSAMP,SLC4A4,ZNRF3,MEIS2,ATP13A4,SORBS1,SFXN5,PITPNC1,NHSL1,RFX4,LRIG1,GPM6A,GPC5,MSI2,TRPS1,CPE,SLC1A3,FBXL7,ITPR2,LIFR,CDH20,AHCYL2,SPARCL1,PREX2,PARD3B,DTNA,RYR3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.144e-02 | -4.47 | NAXD (NAD(P)HX dehydratase) | protein interactions | 55739 | 63 | 2 | 19454 | 50 |
NEBL,PON2 |
1.145e-02 | -4.47 | establishment or maintenance of apical/basal cell polarity | biological process | GO:0035088 | 59 | 2 | 18204 | 50 |
PARD3,PARD3B |
1.145e-02 | -4.47 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 50 |
FGFR3,BMPR1B |
1.145e-02 | -4.47 | establishment or maintenance of bipolar cell polarity | biological process | GO:0061245 | 59 | 2 | 18204 | 50 |
PARD3B,PARD3 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | synapse | cellular component | GO:0045202 | 1473 | 9 | 19108 | 49 |
TNIK,SLC1A2,SPARCL1,PTPRZ1,GPM6A,ATP1A2,SLC1A3,CTNND2,DTNA |
1.166e-02 | -4.45 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 2 |
FGFR3 |
1.167e-02 | -4.45 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-peripheral_T_cell_lymphoma_unspecified | 162 | 3 | 16828 | 49 |
ITPR2,RYR3,MACF1 |
1.169e-02 | -4.45 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 38 |
AHCYL2 |
1.169e-02 | -4.45 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 38 |
SORBS1 |
1.169e-02 | -4.45 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 38 |
AHCYL2 |
1.169e-02 | -4.45 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 38 |
GPM6A |
1.171e-02 | -4.45 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 40 | 16828 | 49 |
TNIK,SPARCL1,SOX5,PREX2,PARD3B,LSAMP,RYR3,DTNA,LIFR,ITPR2,ATP1A2,AHCYL2,CDH20,NKAIN3,NFIA,NPAS3,CPE,FBXL7,SLC1A3,ABLIM1,LRIG1,NTM,GPC5,PON2,MSI2,SLC1A2,CTNND2,RFX4,PTPRZ1,BMPR1B,FGFR3,SFXN5,MACF1,NHSL1,PARD3,ATP13A4,SLC4A4,SPON1,MEIS2,NEBL |
1.178e-02 | -4.44 | TMEM87A (transmembrane protein 87A) | protein interactions | 25963 | 184 | 3 | 19454 | 50 |
FGFR3,CPE,GJA1 |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.182e-02 | -4.44 | protein homotetramerization | biological process | GO:0051289 | 60 | 2 | 18204 | 50 |
RYR3,AQP4 |
1.182e-02 | -4.44 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
CDH20,CTNND2,MACF1,CTNNA2 |
1.184e-02 | -4.44 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 27 | 16828 | 49 |
LIFR,CDH20,PARD3B,RYR3,SOX5,PREX2,NTM,GPC5,GPM6A,TRPS1,NPAS3,SLC1A3,FBXL7,ABLIM1,MACF1,ZBTB20,PITPNC1,NHSL1,SORBS1,SFXN5,SLC1A2,CTNND2,RFX4,FGFR3,SLC4A4,SPON1,PARD3 |
1.192e-02 | -4.43 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 50 |
SLC4A4,ZBTB20,RYR3,ATP1A2,SLC1A3,ATP13A4,AQP4 |
1.199e-02 | -4.42 | response to organonitrogen compound | biological process | GO:0010243 | 915 | 7 | 18204 | 50 |
RYR3,SORBS1,GJA1,TNIK,ITPR2,SLC1A3,SLC1A2 |
1.201e-02 | -4.42 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 21 |
GPM6A |
1.201e-02 | -4.42 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 21 |
RYR3 |
1.201e-02 | -4.42 | INSP3RECEPTR | prints domains | PR00779 | 3 | 1 | 5227 | 21 |
ITPR2 |
1.201e-02 | -4.42 | PARAOXONASE | prints domains | PR01785 | 3 | 1 | 5227 | 21 |
PON2 |
1.205e-02 | -4.42 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 20 | 19454 | 50 |
GLUL,PITPNC1,CTNND2,NTM,PON2,CTNNA2,DTNA,SLC1A3,PTPRZ1,MACF1,TNIK,LSAMP,PARD3,LRIG1,SLC4A4,ATP1A2,ITPR2,MSI2,AHCYL2,GPM6A |
1.209e-02 | -4.42 | kidney | COSMIC cancer mutations | kidney | 15380 | 49 | 16828 | 49 |
CDH20,AHCYL2,ITPR2,LIFR,PREX2,SPARCL1,DTNA,RYR3,PARD3B,GPC5,GPM6A,LRIG1,MSI2,CPE,SLC1A3,FBXL7,TRPS1,SFXN5,SORBS1,PITPNC1,NHSL1,RFX4,MEIS2,SLC4A4,ZNRF3,ATP13A4,NKAIN3,AQP4,ATP1A2,NFIA,SOX5,TNIK,LSAMP,NTM,PON2,ABLIM1,NPAS3,ZBTB20,MACF1,BMPR1B,FGFR3,PTPRZ1,CTNND2,GJA1,SLC1A2,SPON1,NEBL,PARD3,GLUL |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.216e-02 | -4.41 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 5 | 16828 | 49 |
RYR3,MACF1,TRPS1,GPM6A,GPC5 |
1.219e-02 | -4.41 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 9 | 16828 | 49 |
ATP1A2,NTM,SLC4A4,SORBS1,MACF1,ZBTB20,TRPS1,NPAS3,PARD3B |
1.223e-02 | -4.40 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 50 |
ATP13A4,RYR3,SLC1A3,SLC4A4,ATP1A2 |
1.229e-02 | -4.40 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 2 | 10285 | 30 |
ATP1A2,ATP13A4 |
1.229e-02 | -4.40 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 39 | 16828 | 49 |
GLUL,ATP13A4,PARD3,NEBL,MEIS2,SLC4A4,ZNRF3,PTPRZ1,FGFR3,BMPR1B,GJA1,SLC1A2,CTNND2,ZBTB20,NHSL1,MACF1,SORBS1,SFXN5,TRPS1,NPAS3,FBXL7,CPE,SLC1A3,MSI2,NTM,LRIG1,GPC5,RYR3,LSAMP,DTNA,PARD3B,PREX2,TNIK,SOX5,CDH20,AHCYL2,ITPR2,LIFR,ATP1A2 |
1.248e-02 | -4.38 | HNF1B (HNF1 homeobox B) | protein interactions | 6928 | 188 | 3 | 19454 | 50 |
SOX5,NFIA,TRPS1 |
1.249e-02 | -4.38 | back | COSMIC cancer mutations | back | 310 | 4 | 16828 | 49 |
FGFR3,PREX2,ATP1A2,TNIK |
1.250e-02 | -4.38 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 2 | 19454 | 50 |
GJA1,SFXN5 |
1.252e-02 | -4.38 | circulatory system process | biological process | GO:0003013 | 508 | 5 | 18204 | 50 |
SLC4A4,GJA1,SLC1A2,ATP1A2,SLC1A3 |
1.259e-02 | -4.38 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.259e-02 | -4.38 | sulfur compound transport | biological process | GO:0072348 | 62 | 2 | 18204 | 50 |
GJA1,SLC1A2 |
1.262e-02 | -4.37 | Ig-like_fold | interpro domains | IPR013783 | 721 | 6 | 18521 | 50 |
LRIG1,LIFR,FGFR3,LSAMP,PTPRZ1,NTM |
1.266e-02 | -4.37 | peripheral_T_cell_lymphoma_unspecified | COSMIC cancer mutations | peripheral_T_cell_lymphoma_unspecified | 167 | 3 | 16828 | 49 |
RYR3,MACF1,ITPR2 |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 50 |
RFX4 |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 50 |
AHCYL2 |
1.287e-02 | -4.35 | EFR3B (EFR3 homolog B) | protein interactions | 22979 | 67 | 2 | 19454 | 50 |
PARD3,GJA1 |
1.291e-02 | -4.35 | VIRMA (vir like m6A methyltransferase associated) | protein interactions | 25962 | 2914 | 14 | 19454 | 50 |
ZBTB20,MACF1,ZNRF3,LIFR,GLUL,NHSL1,SORBS1,PON2,PARD3B,ITPR2,ABLIM1,TNIK,PARD3,TRPS1 |
1.302e-02 | -4.34 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 48 | 16828 | 49 |
PREX2,SPARCL1,RYR3,PARD3B,CDH20,AHCYL2,LIFR,ITPR2,FBXL7,CPE,SLC1A3,TRPS1,GPM6A,GPC5,LRIG1,MSI2,RFX4,SFXN5,SORBS1,NHSL1,PITPNC1,ATP13A4,MEIS2,SLC4A4,ZNRF3,SOX5,TNIK,LSAMP,NKAIN3,AQP4,ATP1A2,NFIA,ABLIM1,NPAS3,NTM,PON2,FGFR3,BMPR1B,PTPRZ1,CTNND2,SLC1A2,GJA1,ZBTB20,MACF1,PARD3,GLUL,SPON1,NEBL |
1.308e-02 | -4.34 | synapse organization | biological process | GO:0050808 | 333 | 4 | 18204 | 50 |
CTNND2,GPM6A,SPARCL1,NFIA |
1.314e-02 | -4.33 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 50 |
ITPR2,RYR3,SLC1A3,ATP1A2,GPM6A,SLC4A4 |
1.317e-02 | -4.33 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 3 | 18094 | 48 |
SLC1A2,SFXN5,SLC1A3 |
1.318e-02 | -4.33 | main axon | cellular component | GO:0044304 | 68 | 2 | 19108 | 49 |
PARD3,SLC1A2 |
1.320e-02 | -4.33 | gap junction channel activity involved in cardiac conduction electrical coupling | molecular function | GO:0086075 | 5 | 1 | 18094 | 48 |
GJA1 |
1.320e-02 | -4.33 | glutathione transmembrane transporter activity | molecular function | GO:0034634 | 5 | 1 | 18094 | 48 |
GJA1 |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.322e-02 | -4.33 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 50 |
RYR3,ATP13A4,SLC1A3,SLC4A4,ATP1A2 |
1.324e-02 | -4.32 | MARK1 (microtubule affinity regulating kinase 1) | protein interactions | 4139 | 68 | 2 | 19454 | 50 |
GJA1,DTNA |
1.324e-02 | -4.32 | PLCH1 (phospholipase C eta 1) | protein interactions | 23007 | 68 | 2 | 19454 | 50 |
PARD3,GJA1 |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.335e-02 | -4.32 | camera-type eye development | biological process | GO:0043010 | 335 | 4 | 18204 | 50 |
NFIA,GJA1,BMPR1B,GPM6A |
1.336e-02 | -4.32 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 3 | 18094 | 48 |
SFXN5,SLC1A3,SLC1A2 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.343e-02 | -4.31 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 50 |
SFXN5 |
1.346e-02 | -4.31 | cell-cell junction organization | biological process | GO:0045216 | 181 | 3 | 18204 | 50 |
GJA1,PARD3,CDH20 |
1.352e-02 | -4.30 | NS-malignant_melanoma | COSMIC cancer mutations | NS-malignant_melanoma | 3420 | 17 | 16828 | 49 |
ATP13A4,PARD3,NEBL,SPON1,GPC5,LRIG1,MEIS2,CTNND2,FGFR3,PREX2,PTPRZ1,RFX4,MACF1,PITPNC1,ATP1A2,LIFR,ITPR2 |
1.355e-02 | -4.30 | SH3_9 | pfam domains | PF14604 | 63 | 2 | 17795 | 50 |
NEBL,SORBS1 |
1.359e-02 | -4.30 | Axon guidance | KEGG pathways | ko04360 | 174 | 3 | 7161 | 21 |
BMPR1B,PARD3,ABLIM1 |
1.359e-02 | -4.30 | Axon guidance | KEGG pathways | hsa04360 | 174 | 3 | 7161 | 21 |
ABLIM1,PARD3,BMPR1B |
1.363e-02 | -4.30 | temporoparietal | COSMIC cancer mutations | temporoparietal | 61 | 2 | 16828 | 49 |
RYR3,PARD3 |
1.366e-02 | -4.29 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 50 |
ATP1A2 |
1.366e-02 | -4.29 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 50 |
BMPR1B |
1.366e-02 | -4.29 | ciliary neurotrophic factor-mediated signaling pathway | biological process | GO:0070120 | 5 | 1 | 18204 | 50 |
LIFR |
1.366e-02 | -4.29 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 50 |
SFXN5 |
1.366e-02 | -4.29 | otolith morphogenesis | biological process | GO:0032474 | 5 | 1 | 18204 | 50 |
LRIG1 |
1.368e-02 | -4.29 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 38 |
LRIG1,LSAMP,FGFR3,NTM |
1.377e-02 | -4.29 | regulation of protein processing | biological process | GO:0070613 | 65 | 2 | 18204 | 50 |
SPON1,RFX4 |
1.386e-02 | -4.28 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 3 | 18204 | 50 |
SORBS1,SLC4A4,ZBTB20 |
1.389e-02 | -4.28 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 4 | 18204 | 50 |
ZNRF3,GPC5,MACF1,CTNND2 |
1.392e-02 | -4.27 | extracellular matrix | cellular component | GO:0031012 | 559 | 5 | 19108 | 49 |
SPON1,SPARCL1,PTPRZ1,LRIG1,GPC5 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.397e-02 | -4.27 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 50 |
SFXN5 |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.397e-02 | -4.27 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 50 |
SPARCL1 |
1.399e-02 | -4.27 | PCDH20 (protocadherin 20) | protein interactions | 64881 | 70 | 2 | 19454 | 50 |
CTNNA2,PON2 |
1.400e-02 | -4.27 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 49 |
NEBL,GPM6A,GPC5,PARD3,NPAS3,ZBTB20,MACF1,CDH20,LIFR,RYR3,FGFR3,BMPR1B,PTPRZ1,CTNND2,SOX5 |
1.402e-02 | -4.27 | external encapsulating structure | cellular component | GO:0030312 | 560 | 5 | 19108 | 49 |
GPC5,LRIG1,PTPRZ1,SPARCL1,SPON1 |
1.408e-02 | -4.26 | cell population proliferation | biological process | GO:0008283 | 726 | 6 | 18204 | 50 |
GLUL,ZNRF3,NFIA,FGFR3,GJA1,SOX5 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
SLC4A4,ZNRF3,MEIS2,ATP13A4,SORBS1,SFXN5,NHSL1,PITPNC1,RFX4,LRIG1,GPC5,GPM6A,TRPS1,SLC1A3,FBXL7,CPE,LIFR,ITPR2,AHCYL2,CDH20,SPARCL1,PREX2,PARD3B,DTNA,RYR3,SPON1,NEBL,PARD3,GLUL,MACF1,ZBTB20,GJA1,SLC1A2,CTNND2,BMPR1B,PTPRZ1,FGFR3,NTM,PON2,NPAS3,ABLIM1,ATP1A2,AQP4,NKAIN3,NFIA,TNIK,SOX5,LSAMP |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
GLUL,PARD3,NEBL,SPON1,GJA1,SLC1A2,CTNND2,PTPRZ1,FGFR3,BMPR1B,MACF1,ZBTB20,NPAS3,ABLIM1,PON2,NTM,LSAMP,TNIK,SOX5,NFIA,ATP1A2,AQP4,NKAIN3,ATP13A4,SLC4A4,ZNRF3,MEIS2,RFX4,NHSL1,PITPNC1,SORBS1,SFXN5,TRPS1,CPE,FBXL7,SLC1A3,LRIG1,GPM6A,GPC5,PARD3B,RYR3,DTNA,SPARCL1,PREX2,LIFR,ITPR2,AHCYL2,CDH20 |
1.418e-02 | -4.26 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
1.425e-02 | -4.25 | DNAJC5 (DnaJ heat shock protein family (Hsp40) member C5) | protein interactions | 80331 | 365 | 4 | 19454 | 50 |
DTNA,MACF1,GJA1,PARD3 |
1.427e-02 | -4.25 | response to growth factor | biological process | GO:0070848 | 525 | 5 | 18204 | 50 |
NFIA,FGFR3,SOX5,BMPR1B,MEIS2 |
1.433e-02 | -4.25 | NFIX (nuclear factor I X) | protein interactions | 4784 | 198 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
1.433e-02 | -4.25 | CAMK2D (calcium/calmodulin dependent protein kinase II delta) | protein interactions | 817 | 198 | 3 | 19454 | 50 |
PON2,ITPR2,FGFR3 |
1.437e-02 | -4.24 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 44 |
NFIA |
1.437e-02 | -4.24 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 44 |
NFIA |
1.437e-02 | -4.24 | NEBULIN | prosite domains | PS51216 | 4 | 1 | 12186 | 44 |
NEBL |
1.437e-02 | -4.24 | AKR7L (aldo-keto reductase family 7 like (gene/pseudogene)) | protein interactions | 246181 | 71 | 2 | 19454 | 50 |
PARD3,MACF1 |
1.437e-02 | -4.24 | TSPAN17 (tetraspanin 17) | protein interactions | 26262 | 71 | 2 | 19454 | 50 |
GJA1,GPM6A |
1.437e-02 | -4.24 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 50 |
GPM6A,TNIK |
1.446e-02 | -4.24 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 19 |
SLC1A3,ATP1A2 |
1.447e-02 | -4.24 | limb development | biological process | GO:0060173 | 186 | 3 | 18204 | 50 |
NFIA,ZNRF3,GJA1 |
1.447e-02 | -4.24 | appendage development | biological process | GO:0048736 | 186 | 3 | 18204 | 50 |
GJA1,ZNRF3,NFIA |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.23 | cell differentiation | biological process | GO:0030154 | 3645 | 17 | 18204 | 50 |
FGFR3,NHSL1,PREX2,SLC1A3,MSI2,GJA1,GPM6A,NTM,NFIA,CTNND2,NEBL,TNIK,SOX5,PTPRZ1,BMPR1B,PARD3,CTNNA2 |
1.451e-02 | -4.23 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 4 | 19454 | 50 |
AHCYL2,ABLIM1,TNIK,PARD3 |
1.460e-02 | -4.23 | cellular developmental process | biological process | GO:0048869 | 3648 | 17 | 18204 | 50 |
FGFR3,NHSL1,PREX2,SLC1A3,MSI2,GJA1,GPM6A,NTM,NFIA,CTNND2,TNIK,NEBL,SOX5,PTPRZ1,BMPR1B,PARD3,CTNNA2 |
1.475e-02 | -4.22 | PDZ | prosite domains | PS50106 | 143 | 3 | 12186 | 44 |
PREX2,PARD3B,PARD3 |
1.476e-02 | -4.22 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 50 |
ABLIM1,PARD3 |
1.476e-02 | -4.22 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 50 |
TNIK,GPM6A |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.484e-02 | -4.21 | scaffold protein binding | molecular function | GO:0097110 | 70 | 2 | 18094 | 48 |
GJA1,ITPR2 |
1.508e-02 | -4.19 | upper_back | COSMIC cancer mutations | upper_back | 328 | 4 | 16828 | 49 |
MACF1,PARD3B,FGFR3,GPC5 |
1.512e-02 | -4.19 | FEV (FEV transcription factor, ETS family member) | protein interactions | 54738 | 202 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
1.520e-02 | -4.19 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 10 | 16828 | 49 |
LSAMP,ATP13A4,FGFR3,PTPRZ1,SOX5,TRPS1,MACF1,GPC5,ATP1A2,SLC4A4 |
1.529e-02 | -4.18 | PAR polarity complex | cellular component | GO:0120157 | 6 | 1 | 19108 | 49 |
PARD3 |
1.532e-02 | -4.18 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | CYP39A1 (cytochrome P450 family 39 subfamily A member 1) | protein interactions | 51302 | 6 | 1 | 19454 | 50 |
GLUL |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 50 |
SOX5 |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | TAT (tyrosine aminotransferase) | protein interactions | 6898 | 6 | 1 | 19454 | 50 |
GLUL |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | LIF (LIF interleukin 6 family cytokine) | protein interactions | 3976 | 6 | 1 | 19454 | 50 |
LIFR |
1.532e-02 | -4.18 | SAA4 (serum amyloid A4, constitutive) | protein interactions | 6291 | 6 | 1 | 19454 | 50 |
GJA1 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 50 |
ZNRF3 |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.543e-02 | -4.17 | regulation of protein maturation | biological process | GO:1903317 | 69 | 2 | 18204 | 50 |
RFX4,SPON1 |
1.547e-02 | -4.17 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 49 |
ATP1A2,GJA1 |
1.549e-02 | -4.17 | skin-ear-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-ear-carcinoma-squamous_cell_carcinoma | 506 | 5 | 16828 | 49 |
FGFR3,SPARCL1,LIFR,NPAS3,ZBTB20 |
1.552e-02 | -4.17 | NFIC (nuclear factor I C) | protein interactions | 4782 | 204 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
1.554e-02 | -4.16 | CACNA2D1 (calcium voltage-gated channel auxiliary subunit alpha2delta 1) | protein interactions | 781 | 74 | 2 | 19454 | 50 |
GPM6A,PON2 |
1.555e-02 | -4.16 | NEBU | smart domains | SM00227 | 4 | 1 | 9717 | 38 |
NEBL |
1.564e-02 | -4.16 | Calcium Regulation in the Cardiac Cell | WikiPathways | WP536 | 151 | 3 | 5310 | 19 |
RYR3,GJA1,ITPR2 |
1.576e-02 | -4.15 | Znf_LIM | interpro domains | IPR001781 | 71 | 2 | 18521 | 50 |
NEBL,ABLIM1 |
1.581e-02 | -4.15 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 48 |
ATP1A2 |
1.581e-02 | -4.15 | gap junction hemi-channel activity | molecular function | GO:0055077 | 6 | 1 | 18094 | 48 |
GJA1 |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.581e-02 | -4.15 | ciliary neurotrophic factor receptor binding | molecular function | GO:0005127 | 6 | 1 | 18094 | 48 |
LIFR |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | arylesterase activity | molecular function | GO:0004064 | 6 | 1 | 18094 | 48 |
PON2 |
1.585e-02 | -4.14 | cardiac conduction | biological process | GO:0061337 | 70 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
1.594e-02 | -4.14 | UNC5B (unc-5 netrin receptor B) | protein interactions | 219699 | 75 | 2 | 19454 | 50 |
GJA1,PARD3 |
1.594e-02 | -4.14 | CLRN2 (clarin 2) | protein interactions | 645104 | 75 | 2 | 19454 | 50 |
GJA1,LRIG1 |
1.598e-02 | -4.14 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 21 |
CTNNA2 |
1.609e-02 | -4.13 | TSP1_spondin_dom | interpro domains | IPR044004 | 6 | 1 | 18521 | 50 |
SPON1 |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 50 |
ATP1A2 |
1.610e-02 | -4.13 | LIM | pfam domains | PF00412 | 69 | 2 | 17795 | 50 |
ABLIM1,NEBL |
1.613e-02 | -4.13 | SNX6 (sorting nexin 6) | protein interactions | 58533 | 207 | 3 | 19454 | 50 |
BMPR1B,GJA1,TNIK |
1.613e-02 | -4.13 | MAGEA9 (MAGE family member A9) | protein interactions | 4108 | 207 | 3 | 19454 | 50 |
NHSL1,ITPR2,MEIS2 |
1.618e-02 | -4.12 | protein homooligomerization | biological process | GO:0051260 | 194 | 3 | 18204 | 50 |
RYR3,AQP4,SLC1A2 |
1.627e-02 | -4.12 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 49 |
RYR3,ITPR2 |
1.629e-02 | -4.12 | MKRN2 (makorin ring finger protein 2) | protein interactions | 23609 | 380 | 4 | 19454 | 50 |
PARD3,FGFR3,BMPR1B,MACF1 |
1.635e-02 | -4.11 | KIAA1549 (KIAA1549) | protein interactions | 57670 | 76 | 2 | 19454 | 50 |
PARD3,GJA1 |
1.637e-02 | -4.11 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 50 |
SOX5 |
1.637e-02 | -4.11 | neuroblast migration | biological process | GO:0097402 | 6 | 1 | 18204 | 50 |
GJA1 |
1.637e-02 | -4.11 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 50 |
SLC1A3 |
1.637e-02 | -4.11 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 50 |
BMPR1B |
1.637e-02 | -4.11 | intracellular water homeostasis | biological process | GO:0009992 | 6 | 1 | 18204 | 50 |
AQP4 |
1.640e-02 | -4.11 | bone development | biological process | GO:0060348 | 195 | 3 | 18204 | 50 |
FGFR3,GJA1,BMPR1B |
1.672e-02 | -4.09 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
1.674e-02 | -4.09 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | TSP1_spondin | pfam domains | PF19028 | 6 | 1 | 17795 | 50 |
SPON1 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.675e-02 | -4.09 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 50 |
NHSL1,SORBS1,SLC1A3 |
1.675e-02 | -4.09 | GOLGA4 (golgin A4) | protein interactions | 2803 | 210 | 3 | 19454 | 50 |
MACF1,TNIK,GJA1 |
1.676e-02 | -4.09 | ADGRL2 (adhesion G protein-coupled receptor L2) | protein interactions | 23266 | 77 | 2 | 19454 | 50 |
GJA1,PARD3 |
1.677e-02 | -4.09 | cellular response to organic substance | biological process | GO:0071310 | 1716 | 10 | 18204 | 50 |
SLC1A2,ATP1A2,SLC1A3,AQP4,ITPR2,ZBTB20,GJA1,LIFR,SORBS1,RYR3 |
1.696e-02 | -4.08 | CDK6 (cyclin dependent kinase 6) | protein interactions | 1021 | 211 | 3 | 19454 | 50 |
SORBS1,FGFR3,SOX5 |
1.701e-02 | -4.07 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 9 | 16828 | 49 |
FGFR3,CPE,CTNND2,RYR3,ATP13A4,PARD3B,ITPR2,ATP1A2,MACF1 |
1.705e-02 | -4.07 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.716e-02 | -4.07 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 50 |
SLC1A2,CPE |
1.716e-02 | -4.07 | MARCKS (myristoylated alanine rich protein kinase C substrate) | protein interactions | 4082 | 588 | 5 | 19454 | 50 |
AHCYL2,DTNA,ABLIM1,SLC1A3,MACF1 |
1.717e-02 | -4.06 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 2 | 19454 | 50 |
MSI2,SOX5 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.738e-02 | -4.05 | signaling | biological process | GO:0023052 | 4968 | 21 | 18204 | 50 |
RYR3,GJA1,ZNRF3,PREX2,SPARCL1,ITPR2,SLC1A3,ATP1A2,FGFR3,PARD3,MACF1,CTNND2,BMPR1B,SORBS1,LIFR,TNIK,PITPNC1,DTNA,NFIA,SLC1A2,CPE |
1.746e-02 | -4.05 | Lactose Degradation | SMPDB pathways | SMP0000457 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.746e-02 | -4.05 | Lactose Intolerance | SMPDB pathways | SMP0000458 | 12 | 1 | 1369 | 2 |
ATP1A2 |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.759e-02 | -4.04 | CANT1 (calcium activated nucleotidase 1) | protein interactions | 124583 | 79 | 2 | 19454 | 50 |
GJA1,LRIG1 |
1.765e-02 | -4.04 | Myometrial Relaxation and Contraction Pathways | WikiPathways | WP289 | 158 | 3 | 5310 | 19 |
RYR3,ITPR2,GJA1 |
1.768e-02 | -4.04 | ovary-carcinoma | COSMIC cancer mutations | ovary-carcinoma | 933 | 7 | 16828 | 49 |
PREX2,BMPR1B,FGFR3,TNIK,MACF1,ATP1A2,ITPR2 |
1.776e-02 | -4.03 | M (membrane glycoprotein) | protein interactions | 43740571 | 1057 | 7 | 19454 | 50 |
MACF1,PARD3B,GJA1,PON2,PARD3,ATP1A2,ABLIM1 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 50 |
ZBTB20 |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 50 |
AHCYL2 |
1.790e-02 | -4.02 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 50 |
CTNNA2,PARD3,BMPR1B,PTPRZ1 |
1.801e-02 | -4.02 | GPRIN1 (G protein regulated inducer of neurite outgrowth 1) | protein interactions | 114787 | 80 | 2 | 19454 | 50 |
FGFR3,GJA1 |
1.804e-02 | -4.01 | ATP2B1 (ATPase plasma membrane Ca2+ transporting 1) | protein interactions | 490 | 216 | 3 | 19454 | 50 |
FGFR3,GJA1,PARD3 |
1.806e-02 | -4.01 | amino acid biosynthetic process | biological process | GO:0008652 | 75 | 2 | 18204 | 50 |
GLUL,SLC1A3 |
1.808e-02 | -4.01 | PDZ | smart domains | SM00228 | 143 | 3 | 9717 | 38 |
PREX2,PARD3B,PARD3 |
1.811e-02 | -4.01 | Glutamine synthetase/guanido kinase, catalytic domain | gene3d domains | 3.30.590.10 | 6 | 1 | 14470 | 44 |
GLUL |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.843e-02 | -3.99 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | LBD domain binding | molecular function | GO:0050693 | 7 | 1 | 18094 | 48 |
SPON1 |
1.843e-02 | -3.99 | tripeptide transmembrane transporter activity | molecular function | GO:0042937 | 7 | 1 | 18094 | 48 |
GJA1 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.843e-02 | -3.99 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 48 |
ATP1A2 |
1.843e-02 | -3.99 | FAM135A (family with sequence similarity 135 member A) | protein interactions | 57579 | 81 | 2 | 19454 | 50 |
GLUL,GJA1 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.843e-02 | -3.99 | ARNT2 (aryl hydrocarbon receptor nuclear translocator 2) | protein interactions | 9915 | 81 | 2 | 19454 | 50 |
MEIS2,NPAS3 |
1.847e-02 | -3.99 | regulation of multicellular organismal development | biological process | GO:2000026 | 1484 | 9 | 18204 | 50 |
GLUL,PARD3,MACF1,GJA1,TRPS1,SOX5,PTPRZ1,BMPR1B,MEIS2 |
1.851e-02 | -3.99 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | KEGG pathways | hsa05412 | 72 | 2 | 7161 | 21 |
GJA1,CTNNA2 |
1.851e-02 | -3.99 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | KEGG pathways | ko05412 | 72 | 2 | 7161 | 21 |
CTNNA2,GJA1 |
1.872e-02 | -3.98 | calcium ion transmembrane transport | biological process | GO:0070588 | 205 | 3 | 18204 | 50 |
RYR3,ITPR2,GPM6A |
1.872e-02 | -3.98 | establishment or maintenance of cell polarity | biological process | GO:0007163 | 205 | 3 | 18204 | 50 |
GJA1,PARD3,PARD3B |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | Aquaporin_transptr | interpro domains | IPR034294 | 7 | 1 | 18521 | 50 |
AQP4 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Hematopoietin_rcpt_Gp130_CS | interpro domains | IPR003529 | 7 | 1 | 18521 | 50 |
LIFR |
1.882e-02 | -3.97 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 50 |
ATP13A4,ATP1A2 |
1.884e-02 | -3.97 | extracellular region | cellular component | GO:0005576 | 4350 | 18 | 19108 | 49 |
PTPRZ1,ATP1A2,SLC4A4,PON2,GPC5,NEBL,SPARCL1,AQP4,CPE,LIFR,LRIG1,SPON1,TNIK,LSAMP,NTM,GPM6A,FGFR3,GLUL |
1.886e-02 | -3.97 | Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways | WikiPathways | WP706 | 162 | 3 | 5310 | 19 |
GJA1,SLC1A3,AQP4 |
1.889e-02 | -3.97 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 49 |
NTM,PON2,ABLIM1,NPAS3,AQP4,NKAIN3,ATP1A2,NFIA,TNIK,SOX5,LSAMP,SPON1,NEBL,PARD3,ZBTB20,MACF1,PTPRZ1,BMPR1B,FGFR3,SLC1A2,CTNND2,LRIG1,GPM6A,GPC5,MSI2,TRPS1,CPE,FBXL7,SLC1A3,CDH20,AHCYL2,ITPR2,LIFR,PREX2,SPARCL1,DTNA,RYR3,PARD3B,MEIS2,SLC4A4,ZNRF3,ATP13A4,SORBS1,SFXN5,NHSL1,PITPNC1,RFX4 |
1.891e-02 | -3.97 | Trehalose Degradation | SMPDB pathways | SMP0000467 | 13 | 1 | 1369 | 2 |
ATP1A2 |
1.897e-02 | -3.96 | human chr12p11.23 | chromosome location | human chr12p11.23 | 10 | 1 | 26134 | 50 |
ITPR2 |
1.898e-02 | -3.96 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 50 |
BMPR1B,NFIA |
1.902e-02 | -3.96 | testis | COSMIC cancer mutations | testis | 733 | 6 | 16828 | 49 |
FGFR3,BMPR1B,PREX2,TNIK,TRPS1,MACF1 |
1.907e-02 | -3.96 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 50 |
AHCYL2 |
1.907e-02 | -3.96 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 50 |
RYR3 |
1.907e-02 | -3.96 | regulation of cardiac muscle myoblast proliferation | biological process | GO:0110022 | 7 | 1 | 18204 | 50 |
MEIS2 |
1.907e-02 | -3.96 | glutathione transmembrane transport | biological process | GO:0034775 | 7 | 1 | 18204 | 50 |
GJA1 |
1.907e-02 | -3.96 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 50 |
NFIA |
1.907e-02 | -3.96 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 50 |
PTPRZ1 |
1.907e-02 | -3.96 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 50 |
CTNNA2 |
1.907e-02 | -3.96 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 50 |
ZNRF3 |
1.909e-02 | -3.96 | cell communication | biological process | GO:0007154 | 5010 | 21 | 18204 | 50 |
RYR3,GJA1,SLC1A3,PREX2,ZNRF3,SPARCL1,ITPR2,FGFR3,ATP1A2,PARD3,BMPR1B,SORBS1,LIFR,TNIK,MACF1,CTNND2,NFIA,DTNA,PITPNC1,SLC1A2,CPE |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.921e-02 | -3.95 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 49 |
SORBS1,ATP1A2 |
1.930e-02 | -3.95 | TM2D3 (TM2 domain containing 3) | protein interactions | 80213 | 83 | 2 | 19454 | 50 |
FGFR3,PON2 |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.939e-02 | -3.94 | YWHAQ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta) | protein interactions | 10971 | 1076 | 7 | 19454 | 50 |
ABLIM1,GJA1,PARD3,NHSL1,SORBS1,PARD3B,MACF1 |
1.943e-02 | -3.94 | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | stomach-carcinoma-mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
MACF1,ITPR2,GPC5,ATP13A4,SLC1A2,PARD3,PREX2 |
1.943e-02 | -3.94 | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | COSMIC cancer mutations | mixed_intestinal_and_diffuse_adenocarcinoma-unclassifiable | 951 | 7 | 16828 | 49 |
PREX2,SLC1A2,PARD3,ATP13A4,ITPR2,GPC5,MACF1 |
1.944e-02 | -3.94 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 50 |
SORBS1,SLC1A2 |
1.949e-02 | -3.94 | Thyroid hormone synthesis | KEGG pathways | ko04918 | 74 | 2 | 7161 | 21 |
ATP1A2,ITPR2 |
1.949e-02 | -3.94 | Thyroid hormone synthesis | KEGG pathways | hsa04918 | 74 | 2 | 7161 | 21 |
ATP1A2,ITPR2 |
1.951e-02 | -3.94 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 50 |
SPARCL1 |
1.951e-02 | -3.94 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 50 |
BMPR1B |
1.954e-02 | -3.94 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 48 |
FGFR3,BMPR1B |
1.962e-02 | -3.93 | UBE2A (ubiquitin conjugating enzyme E2 A) | protein interactions | 7319 | 223 | 3 | 19454 | 50 |
GJA1,CTNNA2,TNIK |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.974e-02 | -3.93 | ST8SIA4 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4) | protein interactions | 7903 | 84 | 2 | 19454 | 50 |
PON2,LRIG1 |
1.976e-02 | -3.92 | FBXO2 (F-box protein 2) | protein interactions | 26232 | 403 | 4 | 19454 | 50 |
LIFR,LRIG1,NTM,FGFR3 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
GPM6A,ABLIM1,MACF1 |
1.991e-02 | -3.92 | apical plasma membrane | cellular component | GO:0016324 | 405 | 4 | 19108 | 49 |
PARD3B,PARD3,TNIK,GJA1 |
1.993e-02 | -3.92 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 21 |
SLC4A4 |
1.993e-02 | -3.92 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 21 |
PITPNC1 |
1.999e-02 | -3.91 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 21 |
ATP1A2,ITPR2 |
1.999e-02 | -3.91 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 21 |
ITPR2,ATP1A2 |
2.002e-02 | -3.91 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 7 | 19454 | 50 |
ABLIM1,PITPNC1,SORBS1,NHSL1,PARD3,MACF1,PARD3B |
2.003e-02 | -3.91 | metal ion binding | molecular function | GO:0046872 | 4239 | 18 | 18094 | 48 |
CPE,ZBTB20,DTNA,ATP13A4,SPARCL1,TRPS1,SPON1,ABLIM1,ITPR2,GLUL,RYR3,PON2,ATP1A2,SLC1A3,ZNRF3,BMPR1B,MACF1,SLC1A2 |
2.008e-02 | -3.91 | KLF3 (KLF transcription factor 3) | protein interactions | 51274 | 225 | 3 | 19454 | 50 |
TRPS1,NFIA,SOX5 |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.025e-02 | -3.90 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 30 |
FGFR3 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.034e-02 | -3.90 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 49 |
SORBS1 |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | SCT (secretin) | protein interactions | 6343 | 8 | 1 | 19454 | 50 |
MEIS2 |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | DEFB104A (defensin beta 104A) | protein interactions | 140596 | 8 | 1 | 19454 | 50 |
GJA1 |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.055e-02 | -3.88 | MAP4K4 (mitogen-activated protein kinase kinase kinase kinase 4) | protein interactions | 9448 | 227 | 3 | 19454 | 50 |
GJA1,TNIK,PARD3 |
2.055e-02 | -3.88 | receptor complex | cellular component | GO:0043235 | 409 | 4 | 19108 | 49 |
ITPR2,BMPR1B,FGFR3,LIFR |
2.063e-02 | -3.88 | FAM171A1 (family with sequence similarity 171 member A1) | protein interactions | 221061 | 86 | 2 | 19454 | 50 |
PARD3,GJA1 |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
SORBS1,GPM6A |
2.072e-02 | -3.88 | Cysteine Rich Protein | gene3d domains | 2.10.110.10 | 73 | 2 | 14470 | 44 |
NEBL,ABLIM1 |
2.076e-02 | -3.87 | response to nitrogen compound | biological process | GO:1901698 | 1021 | 7 | 18204 | 50 |
SORBS1,TNIK,GJA1,RYR3,SLC1A2,SLC1A3,ITPR2 |
2.087e-02 | -3.87 | adult locomotory behavior | biological process | GO:0008344 | 81 | 2 | 18204 | 50 |
ATP1A2,PREX2 |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
MACF1,SPARCL1,RYR3 |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.103e-02 | -3.86 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 48 |
ATP1A2 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | gap junction channel activity involved in cell communication by electrical coupling | molecular function | GO:1903763 | 8 | 1 | 18094 | 48 |
GJA1 |
2.105e-02 | -3.86 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 49 |
SLC1A2,TNIK,SPARCL1,GPM6A |
2.106e-02 | -3.86 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 4 | 16828 | 49 |
MACF1,PREX2,CPE,CTNND2 |
2.106e-02 | -3.86 | Immunoglobulins | gene3d domains | 2.60.40.10 | 721 | 6 | 14470 | 44 |
NTM,LSAMP,PTPRZ1,LIFR,LRIG1,FGFR3 |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
SLC1A3,TRPS1 |
2.108e-02 | -3.86 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 50 |
NFIA,SOX5 |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.123e-02 | -3.85 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
ABLIM1,NPAS3,LSAMP,TNIK,SOX5,NFIA,AQP4,NKAIN3,ATP1A2,GLUL,PARD3,NEBL,SPON1,BMPR1B,FGFR3,PTPRZ1,GJA1,SLC1A2,CTNND2,ZBTB20,MACF1,TRPS1,FBXL7,CPE,SLC1A3,MSI2,LRIG1,GPM6A,GPC5,RYR3,DTNA,PARD3B,PREX2,SPARCL1,AHCYL2,CDH20,LIFR,ITPR2,ATP13A4,MEIS2,ZNRF3,SLC4A4,PITPNC1,NHSL1,SORBS1,SFXN5 |
2.123e-02 | -3.85 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
BMPR1B,FGFR3,PTPRZ1,SLC1A2,GJA1,CTNND2,ZBTB20,MACF1,PARD3,GLUL,SPON1,NEBL,TNIK,SOX5,LSAMP,AQP4,NKAIN3,ATP1A2,NFIA,ABLIM1,NPAS3,SORBS1,SFXN5,PITPNC1,NHSL1,ATP13A4,MEIS2,SLC4A4,ZNRF3,PREX2,SPARCL1,RYR3,DTNA,PARD3B,AHCYL2,CDH20,ITPR2,LIFR,TRPS1,CPE,SLC1A3,FBXL7,LRIG1,GPC5,GPM6A,MSI2 |
2.125e-02 | -3.85 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 44 |
ATP13A4,ATP1A2 |
2.125e-02 | -3.85 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 12 | 16828 | 49 |
ATP1A2,NFIA,BMPR1B,PTPRZ1,FGFR3,PREX2,SOX5,TNIK,DTNA,PARD3B,SLC4A4,TRPS1 |
2.126e-02 | -3.85 | femur | COSMIC cancer mutations | femur | 1197 | 8 | 16828 | 49 |
RYR3,GLUL,PTPRZ1,PON2,SPON1,GPC5,LRIG1,SLC4A4 |
2.130e-02 | -3.85 | leg | COSMIC cancer mutations | leg | 969 | 7 | 16828 | 49 |
NTM,SLC4A4,ZBTB20,NEBL,FGFR3,PTPRZ1,ATP13A4 |
2.135e-02 | -3.85 | regulation of bone mineralization | biological process | GO:0030500 | 82 | 2 | 18204 | 50 |
BMPR1B,GJA1 |
2.140e-02 | -3.84 | Gln_synth/guanido_kin_cat_dom | interpro domains | IPR014746 | 8 | 1 | 18521 | 50 |
GLUL |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 50 |
RFX4 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.147e-02 | -3.84 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 44 |
MACF1 |
2.147e-02 | -3.84 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 44 |
GPC5 |
2.151e-02 | -3.84 | SLC15A3 (solute carrier family 15 member 3) | protein interactions | 51296 | 231 | 3 | 19454 | 50 |
ITPR2,GJA1,PON2 |
2.153e-02 | -3.84 | TMEM128 (transmembrane protein 128) | protein interactions | 85013 | 88 | 2 | 19454 | 50 |
GJA1,SLC1A3 |
2.153e-02 | -3.84 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 50 |
TNIK,BMPR1B |
2.153e-02 | -3.84 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 50 |
NTM,LRIG1,LSAMP,FGFR3 |
2.177e-02 | -3.83 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 50 |
ATP1A2 |
2.177e-02 | -3.83 | gap junction assembly | biological process | GO:0016264 | 8 | 1 | 18204 | 50 |
GJA1 |
2.177e-02 | -3.83 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 50 |
CTNNA2 |
2.177e-02 | -3.83 | glutamate catabolic process | biological process | GO:0006538 | 8 | 1 | 18204 | 50 |
GLUL |
2.177e-02 | -3.83 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 50 |
SLC1A3 |
2.177e-02 | -3.83 | regulation of ventricular cardiac muscle cell membrane depolarization | biological process | GO:0060373 | 8 | 1 | 18204 | 50 |
GJA1 |
2.177e-02 | -3.83 | negative regulation of gonadotropin secretion | biological process | GO:0032277 | 8 | 1 | 18204 | 50 |
GJA1 |
2.177e-02 | -3.83 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 50 |
CPE |
2.177e-02 | -3.83 | negative regulation of trophoblast cell migration | biological process | GO:1901164 | 8 | 1 | 18204 | 50 |
GJA1 |
2.184e-02 | -3.82 | cardiac muscle contraction | biological process | GO:0060048 | 83 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
2.185e-02 | -3.82 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 9 | 16828 | 49 |
SLC4A4,GPC5,SORBS1,LSAMP,RYR3,TNIK,TRPS1,CTNND2,PARD3 |
2.195e-02 | -3.82 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 39 | 16828 | 49 |
MACF1,NHSL1,ZBTB20,SFXN5,SORBS1,CTNND2,GJA1,SLC1A2,FGFR3,BMPR1B,PTPRZ1,NEBL,SLC4A4,ZNRF3,MEIS2,ATP13A4,GLUL,PARD3,ATP1A2,ITPR2,LIFR,CDH20,AHCYL2,PARD3B,LSAMP,RYR3,DTNA,SOX5,TNIK,PREX2,MSI2,GPC5,LRIG1,NTM,FBXL7,SLC1A3,CPE,TRPS1,NPAS3 |
2.199e-02 | -3.82 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 50 |
DTNA,AHCYL2 |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.203e-02 | -3.82 | SH3_domain | interpro domains | IPR001452 | 222 | 3 | 18521 | 50 |
NEBL,SORBS1,MACF1 |
2.207e-02 | -3.81 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 19 |
SOX5,FGFR3 |
2.210e-02 | -3.81 | response to stimulus | biological process | GO:0050896 | 7803 | 29 | 18204 | 50 |
CTNNA2,PON2,ZBTB20,TNIK,PITPNC1,NFIA,MEIS2,CPE,GLUL,GPM6A,GJA1,ZNRF3,PREX2,SPARCL1,AQP4,SLC1A3,ATP1A2,FGFR3,PARD3,CTNND2,MACF1,SORBS1,BMPR1B,SOX5,LIFR,DTNA,SLC1A2,RYR3,ITPR2 |
2.212e-02 | -3.81 | RHOJ (ras homolog family member J) | protein interactions | 57381 | 628 | 5 | 19454 | 50 |
MACF1,SLC1A3,BMPR1B,GJA1,PARD3 |
2.224e-02 | -3.81 | glial cell differentiation | biological process | GO:0010001 | 219 | 3 | 18204 | 50 |
PTPRZ1,PARD3,NFIA |
2.224e-02 | -3.81 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 50 |
DTNA,SOX5,NFIA |
2.226e-02 | -3.80 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 50 |
ABLIM1 |
2.233e-02 | -3.80 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 50 |
SLC1A3,SLC1A2 |
2.233e-02 | -3.80 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 50 |
ATP1A2,NKAIN3 |
2.244e-02 | -3.80 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 3 | 10285 | 30 |
ATP13A4,ATP1A2,RYR3 |
2.246e-02 | -3.80 | STXBP2 (syntaxin binding protein 2) | protein interactions | 6813 | 90 | 2 | 19454 | 50 |
GLUL,GJA1 |
2.250e-02 | -3.79 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 3 | 18204 | 50 |
ATP1A2,MEIS2,SLC1A3 |
2.272e-02 | -3.78 | human chr11p15.2 | chromosome location | human chr11p15.2 | 12 | 1 | 26134 | 50 |
SPON1 |
2.274e-02 | -3.78 | CREB3 (cAMP responsive element binding protein 3) | protein interactions | 10488 | 236 | 3 | 19454 | 50 |
AQP4,GJA1,GLUL |
2.285e-02 | -3.78 | astrocyte end-foot | cellular component | GO:0097450 | 9 | 1 | 19108 | 49 |
AQP4 |
2.285e-02 | -3.78 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 49 |
SORBS1 |
2.285e-02 | -3.78 | platelet dense tubular network membrane | cellular component | GO:0031095 | 9 | 1 | 19108 | 49 |
ITPR2 |
2.285e-02 | -3.78 | fascia adherens | cellular component | GO:0005916 | 9 | 1 | 19108 | 49 |
GJA1 |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.292e-02 | -3.78 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 50 |
TNIK,SORBS1 |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
NTM,GPM6A |
2.292e-02 | -3.78 | TRIO (trio Rho guanine nucleotide exchange factor) | protein interactions | 7204 | 91 | 2 | 19454 | 50 |
GJA1,PARD3 |
2.299e-02 | -3.77 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 50 |
ITPR2,GPM6A,SOX5 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.311e-02 | -3.77 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 30 |
GPC5 |
2.312e-02 | -3.77 | STX4 (syntaxin 4) | protein interactions | 6810 | 423 | 4 | 19454 | 50 |
DTNA,PARD3,LIFR,GJA1 |
2.318e-02 | -3.76 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 3 | 16828 | 49 |
NTM,SLC4A4,ATP13A4 |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
GLUL,SPARCL1,MACF1 |
2.324e-02 | -3.76 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 38 |
MACF1 |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
FGFR3,PREX2 |
2.339e-02 | -3.76 | GPR12 (G protein-coupled receptor 12) | protein interactions | 2835 | 92 | 2 | 19454 | 50 |
GJA1,SFXN5 |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.339e-02 | -3.76 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 50 |
TNIK,FGFR3 |
2.339e-02 | -3.76 | ADGRG5 (adhesion G protein-coupled receptor G5) | protein interactions | 221188 | 92 | 2 | 19454 | 50 |
GPM6A,GJA1 |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.346e-02 | -3.75 | cellular response to oxygen-containing compound | biological process | GO:1901701 | 1047 | 7 | 18204 | 50 |
SORBS1,GJA1,ZBTB20,RYR3,SLC1A2,ITPR2,SLC1A3 |
2.346e-02 | -3.75 | response to oxygen-containing compound | biological process | GO:1901700 | 1546 | 9 | 18204 | 50 |
SLC1A2,ATP1A2,SLC1A3,ITPR2,GJA1,ZBTB20,SORBS1,RYR3,GLUL |
2.381e-02 | -3.74 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 4 | 19108 | 49 |
SPON1,PTPRZ1,SPARCL1,GPC5 |
2.384e-02 | -3.74 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 50 |
ATP1A2,MEIS2 |
2.385e-02 | -3.74 | intermediate filament cytoskeleton | cellular component | GO:0045111 | 241 | 3 | 19108 | 49 |
GJA1,DTNA,MACF1 |
2.387e-02 | -3.74 | MPDZ (multiple PDZ domain crumbs cell polarity complex component) | protein interactions | 8777 | 93 | 2 | 19454 | 50 |
FGFR3,PARD3 |
2.387e-02 | -3.74 | ODR4 (odr-4 GPCR localization factor homolog) | protein interactions | 54953 | 93 | 2 | 19454 | 50 |
LRIG1,GPM6A |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
ABLIM1,BMPR1B |
2.387e-02 | -3.74 | PTPRG (protein tyrosine phosphatase receptor type G) | protein interactions | 5793 | 93 | 2 | 19454 | 50 |
GJA1,PARD3 |
2.388e-02 | -3.73 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 21 |
BMPR1B |
2.401e-02 | -3.73 | ERBIN (erbb2 interacting protein) | protein interactions | 55914 | 241 | 3 | 19454 | 50 |
PARD3,GJA1,CTNND2 |
2.401e-02 | -3.73 | - | gene3d domains | 2.80.10.50 | 79 | 2 | 14470 | 44 |
ITPR2,RYR3 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 50 |
RFX4 |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.435e-02 | -3.72 | KIAA1217 (KIAA1217) | protein interactions | 56243 | 94 | 2 | 19454 | 50 |
GJA1,PARD3 |
2.435e-02 | -3.72 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 50 |
ABLIM1,TNIK |
2.435e-02 | -3.72 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 50 |
SOX5,NFIA |
2.435e-02 | -3.72 | TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1) | protein interactions | 85461 | 94 | 2 | 19454 | 50 |
GJA1,PARD3 |
2.435e-02 | -3.72 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 50 |
SOX5,NFIA |
2.440e-02 | -3.71 | cell-cell signaling | biological process | GO:0007267 | 822 | 6 | 18204 | 50 |
SLC1A3,DTNA,GJA1,CPE,FGFR3,SLC1A2 |
2.446e-02 | -3.71 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 50 |
CTNNA2 |
2.446e-02 | -3.71 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 50 |
RYR3 |
2.446e-02 | -3.71 | glutathione transport | biological process | GO:0034635 | 9 | 1 | 18204 | 50 |
GJA1 |
2.446e-02 | -3.71 | tripeptide transmembrane transport | biological process | GO:0035443 | 9 | 1 | 18204 | 50 |
GJA1 |
2.446e-02 | -3.71 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 50 |
ATP1A2 |
2.446e-02 | -3.71 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 50 |
ATP13A4 |
2.446e-02 | -3.71 | regulation of protein localization to nucleolus | biological process | GO:1904749 | 9 | 1 | 18204 | 50 |
GLUL |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.468e-02 | -3.70 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 50 |
FGFR3,BMPR1B,SOX5 |
2.474e-02 | -3.70 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 3 | 10285 | 30 |
GLUL,SLC1A2,SLC1A3 |
2.483e-02 | -3.70 | MPP7 (MAGUK p55 scaffold protein 7) | protein interactions | 143098 | 95 | 2 | 19454 | 50 |
MEIS2,GJA1 |
2.487e-02 | -3.69 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 50 |
SORBS1,ZBTB20 |
2.495e-02 | -3.69 | axon | cellular component | GO:0030424 | 650 | 5 | 19108 | 49 |
CTNNA2,GPM6A,SLC1A2,PARD3,DTNA |
2.501e-02 | -3.69 | HEMATOPO_REC_L_F2 | prosite domains | PS01353 | 7 | 1 | 12186 | 44 |
LIFR |
2.501e-02 | -3.69 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 44 |
BMPR1B |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 50 |
BMPR1B |
2.501e-02 | -3.69 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 50 |
RFX4 |
2.505e-02 | -3.69 | SCRIB (scribble planar cell polarity protein) | protein interactions | 23513 | 245 | 3 | 19454 | 50 |
GJA1,LRIG1,PARD3 |
2.521e-02 | -3.68 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 49 |
ITPR2,RYR3 |
2.523e-02 | -3.68 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-NK-T_cell_lymphoma | 217 | 3 | 16828 | 49 |
PON2,DTNA,RFX4 |
2.523e-02 | -3.68 | cation binding | molecular function | GO:0043169 | 4341 | 18 | 18094 | 48 |
MACF1,SLC1A2,ATP1A2,SLC1A3,ZNRF3,BMPR1B,ITPR2,ABLIM1,RYR3,GLUL,PON2,SPARCL1,TRPS1,SPON1,ZBTB20,DTNA,ATP13A4,CPE |
2.528e-02 | -3.68 | Diseases of glycosylation | REACTOME pathways | R-HSA-3781865 | 85 | 2 | 10285 | 30 |
GPC5,SPON1 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.539e-02 | -3.67 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | BANK1 (B cell scaffold protein with ankyrin repeats 1) | protein interactions | 55024 | 10 | 1 | 19454 | 50 |
ITPR2 |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | ALKAL2 (ALK and LTK ligand 2) | protein interactions | 285016 | 10 | 1 | 19454 | 50 |
PON2 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | TSHZ1 (teashirt zinc finger homeobox 1) | protein interactions | 10194 | 10 | 1 | 19454 | 50 |
MEIS2 |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
GLUL,SPARCL1 |
2.585e-02 | -3.66 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 50 |
SOX5,TNIK,NFIA |
2.585e-02 | -3.66 | MET (MET proto-oncogene, receptor tyrosine kinase) | protein interactions | 4233 | 248 | 3 | 19454 | 50 |
LRIG1,GJA1,ZNRF3 |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
FGFR3,PREX2,CPE,MACF1 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.592e-02 | -3.65 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 50 |
SLC4A4,ZBTB20 |
2.592e-02 | -3.65 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 50 |
BMPR1B,NFIA |
2.592e-02 | -3.65 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 50 |
BMPR1B,NFIA |
2.595e-02 | -3.65 | contractile muscle fiber | cellular component | GO:0043292 | 249 | 3 | 19108 | 49 |
GJA1,RYR3,NEBL |
2.596e-02 | -3.65 | Synthesis of 5-eicosatetraenoic acids | REACTOME pathways | R-HSA-2142688 | 9 | 1 | 10285 | 30 |
PON2 |
2.596e-02 | -3.65 | Formation of annular gap junctions | REACTOME pathways | R-HSA-196025 | 9 | 1 | 10285 | 30 |
GJA1 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
GPM6A,LSAMP |
2.637e-02 | -3.64 | intracellular signaling cassette | biological process | GO:0141124 | 837 | 6 | 18204 | 50 |
ATP1A2,FGFR3,ITPR2,PREX2,TNIK,RYR3 |
2.645e-02 | -3.63 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 50 |
RYR3,AQP4 |
2.646e-02 | -3.63 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 50 |
SFXN5 |
2.654e-02 | -3.63 | upper_arm | COSMIC cancer mutations | upper_arm | 582 | 5 | 16828 | 49 |
SLC4A4,ITPR2,FGFR3,PREX2,PARD3B |
2.666e-02 | -3.62 | TCF7L2 (transcription factor 7 like 2) | protein interactions | 6934 | 251 | 3 | 19454 | 50 |
NFIA,LIFR,CTNNA2 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | MIP_CS | interpro domains | IPR022357 | 10 | 1 | 18521 | 50 |
AQP4 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.680e-02 | -3.62 | DEFA1 (defensin alpha 1) | protein interactions | 1667 | 99 | 2 | 19454 | 50 |
LIFR,LRIG1 |
2.680e-02 | -3.62 | ZFHX3 (zinc finger homeobox 3) | protein interactions | 463 | 99 | 2 | 19454 | 50 |
SOX5,TRPS1 |
2.683e-02 | -3.62 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 48 |
ATP13A4,ATP1A2 |
2.693e-02 | -3.61 | CRX (cone-rod homeobox) | protein interactions | 1406 | 252 | 3 | 19454 | 50 |
SOX5,TRPS1,NFIA |
2.695e-02 | -3.61 | Gap junction | KEGG pathways | ko04540 | 88 | 2 | 7161 | 21 |
ITPR2,GJA1 |
2.695e-02 | -3.61 | Gap junction | KEGG pathways | hsa04540 | 88 | 2 | 7161 | 21 |
GJA1,ITPR2 |
2.705e-02 | -3.61 | LIM_DOMAIN_2 | prosite domains | PS50023 | 71 | 2 | 12186 | 44 |
NEBL,ABLIM1 |
2.705e-02 | -3.61 | LIM_DOMAIN_1 | prosite domains | PS00478 | 71 | 2 | 12186 | 44 |
NEBL,ABLIM1 |
2.706e-02 | -3.61 | peritoneum-appendix-other-pseudomyxoma_peritonei | COSMIC cancer mutations | peritoneum-appendix-other-pseudomyxoma_peritonei | 585 | 5 | 16828 | 49 |
TRPS1,FBXL7,FGFR3,MEIS2,MACF1 |
2.706e-02 | -3.61 | pseudomyxoma_peritonei | COSMIC cancer mutations | pseudomyxoma_peritonei | 585 | 5 | 16828 | 49 |
MACF1,MEIS2,FGFR3,FBXL7,TRPS1 |
2.706e-02 | -3.61 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 38 |
MACF1 |
2.706e-02 | -3.61 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 38 |
BMPR1B |
2.714e-02 | -3.61 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.714e-02 | -3.61 | regulation of mesodermal cell differentiation | biological process | GO:1905770 | 10 | 1 | 18204 | 50 |
GJA1 |
2.714e-02 | -3.61 | action potential propagation | biological process | GO:0098870 | 10 | 1 | 18204 | 50 |
ATP1A2 |
2.714e-02 | -3.61 | otolith development | biological process | GO:0048840 | 10 | 1 | 18204 | 50 |
LRIG1 |
2.714e-02 | -3.61 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 50 |
RYR3 |
2.714e-02 | -3.61 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 50 |
SOX5 |
2.714e-02 | -3.61 | regulation of atrial cardiac muscle cell membrane depolarization | biological process | GO:0060371 | 10 | 1 | 18204 | 50 |
GJA1 |
2.723e-02 | -3.60 | appendix | COSMIC cancer mutations | appendix | 586 | 5 | 16828 | 49 |
FBXL7,TRPS1,MEIS2,FGFR3,MACF1 |
2.731e-02 | -3.60 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 50 |
ATP1A2,GPM6A |
2.741e-02 | -3.60 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 5 | 16828 | 49 |
CTNND2,CPE,PREX2,FGFR3,MACF1 |
2.741e-02 | -3.60 | peritoneum | COSMIC cancer mutations | peritoneum | 587 | 5 | 16828 | 49 |
MEIS2,FGFR3,FBXL7,TRPS1,MACF1 |
2.769e-02 | -3.59 | NK-T_cell_lymphoma | COSMIC cancer mutations | NK-T_cell_lymphoma | 225 | 3 | 16828 | 49 |
RFX4,PON2,DTNA |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
NHSL1,TRPS1,NFIA |
2.781e-02 | -3.58 | STAMBP (STAM binding protein) | protein interactions | 10617 | 101 | 2 | 19454 | 50 |
BMPR1B,GJA1 |
2.781e-02 | -3.58 | PRKCG (protein kinase C gamma) | protein interactions | 5582 | 101 | 2 | 19454 | 50 |
GJA1,PARD3 |
2.781e-02 | -3.58 | CPNE8 (copine 8) | protein interactions | 144402 | 101 | 2 | 19454 | 50 |
PARD3,GJA1 |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.786e-02 | -3.58 | platelet dense tubular network | cellular component | GO:0031094 | 11 | 1 | 19108 | 49 |
ITPR2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.792e-02 | -3.58 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 23 | 18204 | 50 |
CTNND2,MACF1,SORBS1,PTPRZ1,BMPR1B,NEBL,PARD3,SLC1A2,ABLIM1,CDH20,RYR3,RFX4,TNIK,CTNNA2,PITPNC1,NFIA,GPM6A,GJA1,PARD3B,GLUL,PREX2,AQP4,SPARCL1 |
2.792e-02 | -3.58 | IRAG1 (inositol 1,4,5-triphosphate receptor associated 1) | protein interactions | 10335 | 11 | 1 | 19454 | 50 |
ITPR2 |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | GAL3ST1 (galactose-3-O-sulfotransferase 1) | protein interactions | 9514 | 11 | 1 | 19454 | 50 |
LRIG1 |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 50 |
ATP1A2 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.795e-02 | -3.58 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 50 |
BMPR1B,PTPRZ1,PARD3,CTNNA2 |
2.807e-02 | -3.57 | calcium ion transmembrane import into cytosol | biological process | GO:0097553 | 95 | 2 | 18204 | 50 |
RYR3,ITPR2 |
2.809e-02 | -3.57 | enzyme-linked receptor protein signaling pathway | biological process | GO:0007167 | 626 | 5 | 18204 | 50 |
FGFR3,LIFR,SORBS1,BMPR1B,NFIA |
2.829e-02 | -3.57 | Phase I biotransformations, non P450 | WikiPathways | WP136 | 8 | 1 | 5310 | 19 |
PON2 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | human chr10p12.31 | chromosome location | human chr10p12.31 | 15 | 1 | 26134 | 50 |
NEBL |
2.832e-02 | -3.56 | TMPRSS13 (transmembrane serine protease 13) | protein interactions | 84000 | 102 | 2 | 19454 | 50 |
SPON1,CPE |
2.838e-02 | -3.56 | response to radiation | biological process | GO:0009314 | 422 | 4 | 18204 | 50 |
SLC1A3,MEIS2,ATP1A2,SLC1A2 |
2.853e-02 | -3.56 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 44 |
ABLIM1 |
2.853e-02 | -3.56 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 44 |
TRPS1 |
2.872e-02 | -3.55 | cellular component biogenesis | biological process | GO:0044085 | 2716 | 13 | 18204 | 50 |
SLC1A2,ABLIM1,SORBS1,RFX4,NEBL,TNIK,PARD3,AQP4,GPM6A,GJA1,RYR3,CDH20,GLUL |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.880e-02 | -3.55 | Gap junction degradation | REACTOME pathways | R-HSA-190873 | 10 | 1 | 10285 | 30 |
GJA1 |
2.880e-02 | -3.55 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 30 |
FGFR3 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.880e-02 | -3.55 | oligopeptide transmembrane transporter activity | molecular function | GO:0035673 | 11 | 1 | 18094 | 48 |
GJA1 |
2.881e-02 | -3.55 | growth | biological process | GO:0040007 | 424 | 4 | 18204 | 50 |
FGFR3,GJA1,SLC1A2,BMPR1B |
2.881e-02 | -3.55 | developmental growth | biological process | GO:0048589 | 424 | 4 | 18204 | 50 |
GJA1,FGFR3,SLC1A2,BMPR1B |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
GPM6A,BMPR1B |
2.884e-02 | -3.55 | PLEKHA1 (pleckstrin homology domain containing A1) | protein interactions | 59338 | 103 | 2 | 19454 | 50 |
PARD3,GJA1 |
2.884e-02 | -3.55 | ZDHHC5 (zinc finger DHHC-type palmitoyltransferase 5) | protein interactions | 25921 | 103 | 2 | 19454 | 50 |
PARD3,GJA1 |
2.884e-02 | -3.55 | C1orf94 (chromosome 1 open reading frame 94) | protein interactions | 84970 | 103 | 2 | 19454 | 50 |
MEIS2,GLUL |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.894e-02 | -3.54 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 50 |
NTM,LSAMP,FGFR3,LRIG1 |
2.896e-02 | -3.54 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 21 |
AHCYL2 |
2.896e-02 | -3.54 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 21 |
AHCYL2 |
2.917e-02 | -3.53 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 50 |
SLC1A2,SLC1A3 |
2.917e-02 | -3.53 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 50 |
SLC1A3,LRIG1 |
2.920e-02 | -3.53 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 4 | 19454 | 50 |
DTNA,MACF1,CTNND2,PARD3 |
2.927e-02 | -3.53 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 30 |
NTM,LSAMP |
2.946e-02 | -3.52 | DIRAS3 (DIRAS family GTPase 3) | protein interactions | 9077 | 261 | 3 | 19454 | 50 |
PARD3,DTNA,MACF1 |
2.954e-02 | -3.52 | Arrhythmogenic Right Ventricular Cardiomyopathy | WikiPathways | WP2118 | 76 | 2 | 5310 | 19 |
CTNNA2,GJA1 |
2.981e-02 | -3.51 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 50 |
ATP13A4 |
2.981e-02 | -3.51 | glutamate secretion | biological process | GO:0014047 | 11 | 1 | 18204 | 50 |
GJA1 |
2.981e-02 | -3.51 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 50 |
RYR3 |
2.981e-02 | -3.51 | tripeptide transport | biological process | GO:0042939 | 11 | 1 | 18204 | 50 |
GJA1 |
2.981e-02 | -3.51 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.981e-02 | -3.51 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 50 |
BMPR1B |
2.981e-02 | -3.51 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 50 |
ATP1A2 |
2.988e-02 | -3.51 | BEND3 (BEN domain containing 3) | protein interactions | 57673 | 105 | 2 | 19454 | 50 |
TRPS1,TNIK |
2.988e-02 | -3.51 | ABCA2 (ATP binding cassette subfamily A member 2) | protein interactions | 20 | 105 | 2 | 19454 | 50 |
PON2,FGFR3 |
2.988e-02 | -3.51 | ANP32E (acidic nuclear phosphoprotein 32 family member E) | protein interactions | 81611 | 105 | 2 | 19454 | 50 |
AHCYL2,PARD3 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.010e-02 | -3.50 | SH3 Domains | gene3d domains | 2.30.30.40 | 223 | 3 | 14470 | 44 |
NEBL,MACF1,SORBS1 |
3.028e-02 | -3.50 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 50 |
FGFR3,BMPR1B |
3.028e-02 | -3.50 | heart contraction | biological process | GO:0060047 | 99 | 2 | 18204 | 50 |
GJA1,ATP1A2 |
3.030e-02 | -3.50 | abdomen | COSMIC cancer mutations | abdomen | 603 | 5 | 16828 | 49 |
FGFR3,PREX2,ITPR2,LRIG1,CTNND2 |
3.034e-02 | -3.50 | response to wounding | biological process | GO:0009611 | 431 | 4 | 18204 | 50 |
NFIA,SLC1A3,SLC1A2,MACF1 |
3.035e-02 | -3.49 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 49 |
ATP1A2 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.040e-02 | -3.49 | PHACTR4 (phosphatase and actin regulator 4) | protein interactions | 65979 | 106 | 2 | 19454 | 50 |
GJA1,PARD3 |
3.040e-02 | -3.49 | USP6NL (USP6 N-terminal like) | protein interactions | 9712 | 106 | 2 | 19454 | 50 |
GJA1,PARD3 |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | UGT1A9 (UDP glucuronosyltransferase family 1 member A9) | protein interactions | 54600 | 12 | 1 | 19454 | 50 |
PON2 |
3.042e-02 | -3.49 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 50 |
ZNRF3 |
3.042e-02 | -3.49 | FAM222A (family with sequence similarity 222 member A) | protein interactions | 84915 | 12 | 1 | 19454 | 50 |
MEIS2 |
3.042e-02 | -3.49 | CTF1 (cardiotrophin 1) | protein interactions | 1489 | 12 | 1 | 19454 | 50 |
LIFR |
3.042e-02 | -3.49 | IL15 (interleukin 15) | protein interactions | 3600 | 12 | 1 | 19454 | 50 |
LRIG1 |
3.042e-02 | -3.49 | Pard6b (par-6 family cell polarity regulator beta) | protein interactions | 58220 | 12 | 1 | 19454 | 50 |
PARD3 |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 50 |
TNIK |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.049e-02 | -3.49 | LRRCT | pfam domains | PF01463 | 11 | 1 | 17795 | 50 |
LRIG1 |
3.079e-02 | -3.48 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 50 |
ATP1A2,SLC1A3,ATP13A4,RYR3 |
3.087e-02 | -3.48 | eye | COSMIC cancer mutations | eye | 606 | 5 | 16828 | 49 |
FGFR3,PREX2,CTNND2,CPE,MACF1 |
3.087e-02 | -3.48 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 38 |
ABLIM1 |
3.093e-02 | -3.48 | EFR3A (EFR3 homolog A) | protein interactions | 23167 | 107 | 2 | 19454 | 50 |
GJA1,PARD3 |
3.093e-02 | -3.48 | HTR3A (5-hydroxytryptamine receptor 3A) | protein interactions | 3359 | 107 | 2 | 19454 | 50 |
GPM6A,GJA1 |
3.093e-02 | -3.48 | EPHA3 (EPH receptor A3) | protein interactions | 2042 | 107 | 2 | 19454 | 50 |
PARD3,GJA1 |
3.093e-02 | -3.48 | TMEM86B (transmembrane protein 86B) | protein interactions | 255043 | 107 | 2 | 19454 | 50 |
GJA1,SFXN5 |
3.107e-02 | -3.47 | MCAM (melanoma cell adhesion molecule) | protein interactions | 4162 | 464 | 4 | 19454 | 50 |
CTNNA2,GJA1,TNIK,PARD3B |
3.124e-02 | -3.47 | LIM | smart domains | SM00132 | 71 | 2 | 9717 | 38 |
NEBL,ABLIM1 |
3.138e-02 | -3.46 | inositol 1,4,5 trisphosphate binding | molecular function | GO:0070679 | 12 | 1 | 18094 | 48 |
ITPR2 |
3.142e-02 | -3.46 | positive regulation of cold-induced thermogenesis | biological process | GO:0120162 | 101 | 2 | 18204 | 50 |
SFXN5,GJA1 |
3.147e-02 | -3.46 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 50 |
AHCYL2,GPM6A |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
MSI2,RYR3 |
3.147e-02 | -3.46 | SLC39A14 (solute carrier family 39 member 14) | protein interactions | 23516 | 108 | 2 | 19454 | 50 |
GJA1,PARD3 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.151e-02 | -3.46 | VCL (vinculin) | protein interactions | 7414 | 268 | 3 | 19454 | 50 |
MACF1,NEBL,SORBS1 |
3.157e-02 | -3.46 | calcium ion transport | biological process | GO:0006816 | 251 | 3 | 18204 | 50 |
GPM6A,RYR3,ITPR2 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.171e-02 | -3.45 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 21 |
TRPS1 |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.193e-02 | -3.44 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
SLC4A4,SPON1,MEIS2,NEBL,PARD3,ATP13A4,SFXN5,MACF1,NHSL1,SLC1A2,CTNND2,RFX4,PTPRZ1,NTM,LRIG1,GPC5,PON2,MSI2,NPAS3,SLC1A3,CPE,FBXL7,ABLIM1,LIFR,ITPR2,ATP1A2,CDH20,AHCYL2,NKAIN3,NFIA,TNIK,SPARCL1,SOX5,PREX2,PARD3B,LSAMP,RYR3 |
3.193e-02 | -3.44 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 37 | 16828 | 49 |
RFX4,PTPRZ1,SLC1A2,CTNND2,SFXN5,NHSL1,MACF1,PARD3,ATP13A4,MEIS2,SLC4A4,SPON1,NEBL,PREX2,TNIK,SPARCL1,SOX5,RYR3,LSAMP,PARD3B,AHCYL2,CDH20,NKAIN3,ITPR2,LIFR,ATP1A2,NFIA,ABLIM1,NPAS3,SLC1A3,CPE,FBXL7,LRIG1,NTM,GPC5,PON2,MSI2 |
3.200e-02 | -3.44 | ZNRF4 (zinc and ring finger 4) | protein interactions | 148066 | 109 | 2 | 19454 | 50 |
PON2,ITPR2 |
3.204e-02 | -3.44 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 44 |
RFX4 |
3.230e-02 | -3.43 | apical part of cell | cellular component | GO:0045177 | 471 | 4 | 19108 | 49 |
GJA1,TNIK,PARD3B,PARD3 |
3.248e-02 | -3.43 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 50 |
SLC1A3 |
3.248e-02 | -3.43 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 50 |
BMPR1B |
3.248e-02 | -3.43 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 50 |
SLC1A2 |
3.248e-02 | -3.43 | oligopeptide transmembrane transport | biological process | GO:0035672 | 12 | 1 | 18204 | 50 |
GJA1 |
3.248e-02 | -3.43 | regulation of gonadotropin secretion | biological process | GO:0032276 | 12 | 1 | 18204 | 50 |
GJA1 |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
PARD3B,BMPR1B |
3.255e-02 | -3.43 | cellular component assembly | biological process | GO:0022607 | 2472 | 12 | 18204 | 50 |
PARD3,RFX4,SORBS1,TNIK,NEBL,ABLIM1,SLC1A2,RYR3,CDH20,GPM6A,GJA1,AQP4 |
3.257e-02 | -3.42 | regulation of biomineral tissue development | biological process | GO:0070167 | 103 | 2 | 18204 | 50 |
GJA1,BMPR1B |
3.270e-02 | -3.42 | nervous system process | biological process | GO:0050877 | 1376 | 8 | 18204 | 50 |
PTPRZ1,CTNNA2,ATP1A2,LRIG1,MEIS2,SLC1A3,AQP4,ABLIM1 |
3.291e-02 | -3.41 | ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) | protein interactions | 8869 | 13 | 1 | 19454 | 50 |
PON2 |
3.291e-02 | -3.41 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 50 |
ZNRF3 |
3.291e-02 | -3.41 | TAS1R3 (taste 1 receptor member 3) | protein interactions | 83756 | 13 | 1 | 19454 | 50 |
GJA1 |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | MAB21L1 (mab-21 like 1) | protein interactions | 4081 | 13 | 1 | 19454 | 50 |
MEIS2 |
3.291e-02 | -3.41 | JAM2 (junctional adhesion molecule 2) | protein interactions | 58494 | 13 | 1 | 19454 | 50 |
PARD3 |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.302e-02 | -3.41 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 10 | 19108 | 49 |
GLUL,RYR3,ITPR2,AHCYL2,ATP13A4,FGFR3,SPARCL1,SPON1,ATP1A2,GJA1 |
3.302e-02 | -3.41 | FLOT2 (flotillin 2) | protein interactions | 2319 | 273 | 3 | 19454 | 50 |
SOX5,GJA1,PARD3 |
3.318e-02 | -3.41 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 50 |
SLC1A2,RYR3,AQP4 |
3.321e-02 | -3.40 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 50 |
CPE |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.363e-02 | -3.39 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 50 |
MACF1,TRPS1 |
3.373e-02 | -3.39 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 2 | 18204 | 50 |
NFIA,SOX5 |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.395e-02 | -3.38 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 48 |
ATP1A2 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.418e-02 | -3.38 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 7 | 19454 | 50 |
PITPNC1,NHSL1,PARD3,SORBS1,ABLIM1,PARD3B,MACF1 |
3.418e-02 | -3.38 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_leukaemia | 2081 | 11 | 16828 | 49 |
ATP1A2,SLC4A4,NFIA,SOX5,TRPS1,TNIK,BMPR1B,FGFR3,PTPRZ1,PREX2,DTNA |
3.418e-02 | -3.38 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 50 |
DTNA,ZNRF3 |
3.418e-02 | -3.38 | KIRREL1 (kirre like nephrin family adhesion molecule 1) | protein interactions | 55243 | 113 | 2 | 19454 | 50 |
PARD3,GJA1 |
3.425e-02 | -3.37 | signal transduction | biological process | GO:0007165 | 4637 | 19 | 18204 | 50 |
RYR3,GJA1,SPARCL1,ITPR2,PREX2,ZNRF3,FGFR3,ATP1A2,PARD3,TNIK,LIFR,BMPR1B,SORBS1,CTNND2,MACF1,NFIA,DTNA,PITPNC1,CPE |
3.425e-02 | -3.37 | ZDHHC17 (zinc finger DHHC-type palmitoyltransferase 17) | protein interactions | 23390 | 277 | 3 | 19454 | 50 |
NEBL,GPM6A,SLC1A3 |
3.439e-02 | -3.37 | ear | COSMIC cancer mutations | ear | 624 | 5 | 16828 | 49 |
ZBTB20,FGFR3,SPARCL1,LIFR,NPAS3 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.459e-02 | -3.36 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 49 |
SORBS1,ATP1A2 |
3.466e-02 | -3.36 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 38 |
SPARCL1 |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
MACF1,ZBTB20 |
3.496e-02 | -3.35 | response to organic substance | biological process | GO:0010033 | 2498 | 12 | 18204 | 50 |
ZBTB20,TNIK,LIFR,SORBS1,SLC1A2,GLUL,RYR3,GJA1,ITPR2,AQP4,SLC1A3,ATP1A2 |
3.500e-02 | -3.35 | Ion_trans_dom | interpro domains | IPR005821 | 109 | 2 | 18521 | 50 |
ITPR2,RYR3 |
3.505e-02 | -3.35 | cellular response to stimulus | biological process | GO:0051716 | 6307 | 24 | 18204 | 50 |
GLUL,GJA1,SLC1A3,ZNRF3,PREX2,AQP4,SPARCL1,FGFR3,ATP1A2,ZBTB20,TNIK,NFIA,PITPNC1,CPE,RYR3,ITPR2,PARD3,SORBS1,BMPR1B,LIFR,MACF1,CTNND2,DTNA,SLC1A2 |
3.514e-02 | -3.35 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 50 |
NFIA |
3.514e-02 | -3.35 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 50 |
ATP1A2 |
3.514e-02 | -3.35 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 50 |
CTNNA2 |
3.529e-02 | -3.34 | cellular component organization | biological process | GO:0016043 | 5636 | 22 | 18204 | 50 |
PARD3B,GPM6A,GJA1,PREX2,AQP4,SPARCL1,CTNNA2,RFX4,TNIK,PITPNC1,NFIA,CDH20,RYR3,PARD3,CTNND2,MACF1,PTPRZ1,SORBS1,BMPR1B,NEBL,ABLIM1,SLC1A2 |
3.530e-02 | -3.34 | DTNA (dystrobrevin alpha) | protein interactions | 1837 | 115 | 2 | 19454 | 50 |
GJA1,PARD3 |
3.530e-02 | -3.34 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 50 |
CTNND2,PARD3 |
3.530e-02 | -3.34 | SULF2 (sulfatase 2) | protein interactions | 55959 | 115 | 2 | 19454 | 50 |
PON2,SPON1 |
3.530e-02 | -3.34 | PLEKHA7 (pleckstrin homology domain containing A7) | protein interactions | 144100 | 115 | 2 | 19454 | 50 |
PARD3,GJA1 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.540e-02 | -3.34 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 1 | 19454 | 50 |
ZBTB20 |
3.540e-02 | -3.34 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 50 |
ZNRF3 |
3.540e-02 | -3.34 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 50 |
GPM6A |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | KRTAP22-1 (keratin associated protein 22-1) | protein interactions | 337979 | 14 | 1 | 19454 | 50 |
MEIS2 |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 50 |
AHCYL2 |
3.545e-02 | -3.34 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
GPC5,NPAS3,NFIA |
3.545e-02 | -3.34 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 3 | 16828 | 49 |
NPAS3,GPC5,NFIA |
3.553e-02 | -3.34 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 49 |
NPAS3,ABLIM1,NTM,SOX5,TNIK,LSAMP,ATP1A2,NKAIN3,AQP4,NFIA,PARD3,GLUL,SPON1,NEBL,CTNND2,SLC1A2,GJA1,FGFR3,PTPRZ1,BMPR1B,MACF1,ZBTB20,FBXL7,SLC1A3,CPE,TRPS1,GPC5,GPM6A,LRIG1,MSI2,SPARCL1,PREX2,PARD3B,RYR3,DTNA,ITPR2,LIFR,CDH20,AHCYL2,ATP13A4,ZNRF3,SLC4A4,MEIS2,RFX4,SFXN5,SORBS1,PITPNC1,NHSL1 |
3.554e-02 | -3.34 | MIP | prosite domains | PS00221 | 10 | 1 | 12186 | 44 |
AQP4 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.575e-02 | -3.33 | lung-carcinoma-large_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-large_cell_carcinoma | 849 | 6 | 16828 | 49 |
LRIG1,LIFR,FGFR3,BMPR1B,PTPRZ1,TNIK |
3.575e-02 | -3.33 | large_cell_carcinoma | COSMIC cancer mutations | large_cell_carcinoma | 849 | 6 | 16828 | 49 |
PTPRZ1,FGFR3,BMPR1B,TNIK,LIFR,LRIG1 |
3.576e-02 | -3.33 | LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 1) | protein interactions | 55004 | 714 | 5 | 19454 | 50 |
SLC1A3,DTNA,PARD3,TNIK,GJA1 |
3.581e-02 | -3.33 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 3 | 16828 | 49 |
FGFR3,PTPRZ1,MACF1 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.592e-02 | -3.33 | PRKACA (protein kinase cAMP-activated catalytic subunit alpha) | protein interactions | 5566 | 486 | 4 | 19454 | 50 |
TNIK,ITPR2,PARD3,SLC4A4 |
3.610e-02 | -3.32 | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-squamous_cell_carcinoma | 3507 | 16 | 16828 | 49 |
ATP1A2,LIFR,ZBTB20,MACF1,PTPRZ1,PREX2,CTNND2,RYR3,PARD3B,MEIS2,GPC5,SPON1,SLC4A4,LRIG1,PARD3,NPAS3 |
3.612e-02 | -3.32 | oesophagus-lower_third-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-lower_third-carcinoma-adenocarcinoma | 6302 | 25 | 16828 | 49 |
PREX2,SOX5,RYR3,PARD3B,AHCYL2,CDH20,AQP4,ITPR2,NPAS3,TRPS1,CPE,GPC5,PON2,PTPRZ1,GJA1,CTNND2,SORBS1,ZBTB20,MACF1,PARD3,ATP13A4,MEIS2,ZNRF3,SPON1,NEBL |
3.620e-02 | -3.32 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 50 |
ZNRF3,GPC5,CTNND2 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.642e-02 | -3.31 | ZMYND19 (zinc finger MYND-type containing 19) | protein interactions | 116225 | 117 | 2 | 19454 | 50 |
SPON1,CTNND2 |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.699e-02 | -3.30 | SIPA1L2 (signal induced proliferation associated 1 like 2) | protein interactions | 57568 | 118 | 2 | 19454 | 50 |
PARD3,GJA1 |
3.699e-02 | -3.30 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 50 |
TNIK,AHCYL2 |
3.715e-02 | -3.29 | MIP | interpro domains | IPR000425 | 14 | 1 | 18521 | 50 |
AQP4 |
3.715e-02 | -3.29 | Aquaporin-like | interpro domains | IPR023271 | 14 | 1 | 18521 | 50 |
AQP4 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.728e-02 | -3.29 | CLEC7A (Dectin-1) induces NFAT activation | REACTOME pathways | R-HSA-5607763 | 13 | 1 | 10285 | 30 |
ITPR2 |
3.728e-02 | -3.29 | Passive transport by Aquaporins | REACTOME pathways | R-HSA-432047 | 13 | 1 | 10285 | 30 |
AQP4 |
3.728e-02 | -3.29 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.745e-02 | -3.28 | DHFR2 (dihydrofolate reductase 2) | protein interactions | 200895 | 287 | 3 | 19454 | 50 |
SLC1A3,CPE,ITPR2 |
3.750e-02 | -3.28 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 49 |
GPC5,PARD3 |
3.754e-02 | -3.28 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 49 |
AQP4,SLC1A3,SLC4A4 |
3.756e-02 | -3.28 | ANKRD26 (ankyrin repeat domain containing 26) | protein interactions | 22852 | 119 | 2 | 19454 | 50 |
PARD3,GJA1 |
3.764e-02 | -3.28 | Ion_trans | pfam domains | PF00520 | 109 | 2 | 17795 | 50 |
RYR3,ITPR2 |
3.764e-02 | -3.28 | Carfentanil Action Pathway | SMPDB pathways | SMP0000414 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Remifentanil Action Pathway | SMPDB pathways | SMP0000416 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Pentazocine Action Pathway | SMPDB pathways | SMP0000686 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Buprenorphine Action Pathway | SMPDB pathways | SMP0000684 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alvimopan Action Pathway | SMPDB pathways | SMP0000685 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levomethadyl Acetate Action Action Pathway | SMPDB pathways | SMP0000677 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Methadyl Acetate Action Pathway | SMPDB pathways | SMP0000678 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Fentanyl Action Pathway | SMPDB pathways | SMP0000415 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ketobemidone Action Pathway | SMPDB pathways | SMP0000690 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dimethylthiambutene Action Pathway | SMPDB pathways | SMP0000680 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Procaine Action Pathway | SMPDB pathways | SMP0000402 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydromorphone Action Pathway | SMPDB pathways | SMP0000410 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxycodone Action Pathway | SMPDB pathways | SMP0000409 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Proparacaine Action Pathway | SMPDB pathways | SMP0000403 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Anileridine Action Pathway | SMPDB pathways | SMP0000674 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dezocine Action Pathway | SMPDB pathways | SMP0000676 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Benzocaine Action Pathway | SMPDB pathways | SMP0000392 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Prilocaine Action Pathway | SMPDB pathways | SMP0000401 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naltrexone Action Pathway | SMPDB pathways | SMP0000687 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Bupivacaine Action Pathway | SMPDB pathways | SMP0000393 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Mepivacaine Action Pathway | SMPDB pathways | SMP0000399 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Naloxone Action Pathway | SMPDB pathways | SMP0000688 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Diphenoxylate Action Pathway | SMPDB pathways | SMP0000675 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Sufentanil Action Pathway | SMPDB pathways | SMP0000417 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Alfentanil Action Pathway | SMPDB pathways | SMP0000413 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levallorphan Action Pathway | SMPDB pathways | SMP0000683 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levobupivacaine Action Pathway | SMPDB pathways | SMP0000397 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dihydromorphine Action Pathway | SMPDB pathways | SMP0000689 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxybuprocaine Action Pathway | SMPDB pathways | SMP0000400 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Oxymorphone Action Pathway | SMPDB pathways | SMP0000412 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Hydrocodone Action Pathway | SMPDB pathways | SMP0000411 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ethylmorphine Action Pathway | SMPDB pathways | SMP0000681 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Escitalopram Action Pathway | SMPDB pathways | SMP0000425 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Tramadol Action Action Pathway | SMPDB pathways | SMP0000671 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Ropivacaine Action Pathway | SMPDB pathways | SMP0000404 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | 3-Methylthiofentanyl Action Pathway | SMPDB pathways | SMP0000679 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Levorphanol Action Pathway | SMPDB pathways | SMP0000673 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Cocaine Action Pathway | SMPDB pathways | SMP0000395 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Chloroprocaine Action Pathway | SMPDB pathways | SMP0000394 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Propoxyphene Action Pathway | SMPDB pathways | SMP0000672 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.764e-02 | -3.28 | Dibucaine Action Pathway | SMPDB pathways | SMP0000396 | 26 | 1 | 1369 | 2 |
ATP1A2 |
3.771e-02 | -3.28 | protein localization to membrane | biological process | GO:0072657 | 462 | 4 | 18204 | 50 |
PARD3,CPE,TNIK,MACF1 |
3.779e-02 | -3.28 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | atrial cardiac muscle cell to AV node cell signaling | biological process | GO:0086026 | 14 | 1 | 18204 | 50 |
GJA1 |
3.779e-02 | -3.28 | oligopeptide transport | biological process | GO:0006857 | 14 | 1 | 18204 | 50 |
GJA1 |
3.779e-02 | -3.28 | cellular response to ethanol | biological process | GO:0071361 | 14 | 1 | 18204 | 50 |
ITPR2 |
3.779e-02 | -3.28 | adult heart development | biological process | GO:0007512 | 14 | 1 | 18204 | 50 |
GJA1 |
3.779e-02 | -3.28 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 50 |
ATP1A2 |
3.779e-02 | -3.28 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 50 |
RYR3 |
3.779e-02 | -3.28 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 50 |
SLC1A2 |
3.779e-02 | -3.28 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 50 |
SLC1A3 |
3.779e-02 | -3.28 | atrial cardiac muscle cell action potential | biological process | GO:0086014 | 14 | 1 | 18204 | 50 |
GJA1 |
3.779e-02 | -3.28 | positive regulation of myoblast proliferation | biological process | GO:2000288 | 14 | 1 | 18204 | 50 |
MEIS2 |
3.779e-02 | -3.28 | cerebrospinal fluid circulation | biological process | GO:0090660 | 14 | 1 | 18204 | 50 |
AQP4 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | TAFA5 (TAFA chemokine like family member 5) | protein interactions | 25817 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 1 | 19454 | 50 |
CPE |
3.788e-02 | -3.27 | TESPA1 (thymocyte expressed, positive selection associated 1) | protein interactions | 9840 | 15 | 1 | 19454 | 50 |
ITPR2 |
3.788e-02 | -3.27 | XIRP1 (xin actin binding repeat containing 1) | protein interactions | 165904 | 15 | 1 | 19454 | 50 |
NEBL |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.810e-02 | -3.27 | CEP128 (centrosomal protein 128) | protein interactions | 145508 | 289 | 3 | 19454 | 50 |
NEBL,SORBS1,ABLIM1 |
3.814e-02 | -3.27 | LRP6 (LDL receptor related protein 6) | protein interactions | 4040 | 120 | 2 | 19454 | 50 |
GJA1,ZNRF3 |
3.814e-02 | -3.27 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 50 |
NFIA,AHCYL2 |
3.840e-02 | -3.26 | KIF14 (kinesin family member 14) | protein interactions | 9928 | 1803 | 9 | 19454 | 50 |
SOX5,SLC1A3,MACF1,NEBL,ITPR2,MSI2,ABLIM1,PARD3,SORBS1 |
3.843e-02 | -3.26 | SREBF2 (sterol regulatory element binding transcription factor 2) | protein interactions | 6721 | 290 | 3 | 19454 | 50 |
GLUL,ABLIM1,SLC4A4 |
3.856e-02 | -3.26 | heart process | biological process | GO:0003015 | 113 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
3.864e-02 | -3.25 | MIP | pfam domains | PF00230 | 14 | 1 | 17795 | 50 |
AQP4 |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.881e-02 | -3.25 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 49 |
PARD3B,NEBL |
3.887e-02 | -3.25 | positive regulation of multicellular organismal process | biological process | GO:0051240 | 1691 | 9 | 18204 | 50 |
PARD3,SFXN5,MACF1,BMPR1B,PTPRZ1,SOX5,ZBTB20,GJA1,ATP1A2 |
3.900e-02 | -3.24 | germ_cell_tumour | COSMIC cancer mutations | germ_cell_tumour | 867 | 6 | 16828 | 49 |
MACF1,TRPS1,TNIK,FGFR3,PREX2,BMPR1B |
3.902e-02 | -3.24 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 44 |
TRPS1 |
3.907e-02 | -3.24 | Desipramine Action Pathway | SMPDB pathways | SMP0000423 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.907e-02 | -3.24 | Nalbuphine Action Pathway | SMPDB pathways | SMP0000691 | 27 | 1 | 1369 | 2 |
ATP1A2 |
3.908e-02 | -3.24 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 48 |
CPE |
3.908e-02 | -3.24 | tropomyosin binding | molecular function | GO:0005523 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | filamin binding | molecular function | GO:0031005 | 15 | 1 | 18094 | 48 |
NEBL |
3.908e-02 | -3.24 | efflux transmembrane transporter activity | molecular function | GO:0015562 | 15 | 1 | 18094 | 48 |
GJA1 |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
SLC4A4,PTPRZ1,ATP13A4 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
NHSL1,DTNA |
3.941e-02 | -3.23 | SQSTM1 (sequestosome 1) | protein interactions | 8878 | 984 | 6 | 19454 | 50 |
PARD3,MEIS2,GJA1,BMPR1B,FGFR3,ABLIM1 |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.947e-02 | -3.23 | pleura-pulmonary_blastoma | COSMIC cancer mutations | pleura-pulmonary_blastoma | 648 | 5 | 16828 | 49 |
BMPR1B,NTM,TRPS1,NEBL,ATP13A4 |
3.947e-02 | -3.23 | pulmonary_blastoma | COSMIC cancer mutations | pulmonary_blastoma | 648 | 5 | 16828 | 49 |
NTM,TRPS1,BMPR1B,ATP13A4,NEBL |
3.947e-02 | -3.23 | testis-germ_cell_tumour-seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-seminoma | 648 | 5 | 16828 | 49 |
PREX2,FGFR3,BMPR1B,TRPS1,TNIK |
3.949e-02 | -3.23 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 21 |
SLC4A4 |
3.970e-02 | -3.23 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 5 | 16828 | 49 |
TNIK,FGFR3,ABLIM1,PREX2,MACF1 |
3.971e-02 | -3.23 | gliogenesis | biological process | GO:0042063 | 275 | 3 | 18204 | 50 |
PTPRZ1,NFIA,PARD3 |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.975e-02 | -3.23 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 50 |
TNIK |
3.975e-02 | -3.23 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 50 |
ATP1A2 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.008e-02 | -3.22 | learning or memory | biological process | GO:0007611 | 276 | 3 | 18204 | 50 |
MEIS2,ATP1A2,PTPRZ1 |
4.008e-02 | -3.22 | telencephalon development | biological process | GO:0021537 | 276 | 3 | 18204 | 50 |
RFX4,SLC1A2,ATP1A2 |
4.010e-02 | -3.22 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 30 |
ABLIM1 |
4.027e-02 | -3.21 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 49 |
TNIK |
4.028e-02 | -3.21 | phospholipid binding | molecular function | GO:0005543 | 489 | 4 | 18094 | 48 |
PITPNC1,ITPR2,PARD3,PARD3B |
4.035e-02 | -3.21 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 50 |
ZNRF3 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 50 |
TNIK |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 50 |
ZBTB20 |
4.035e-02 | -3.21 | Sumo3 (small ubiquitin-like modifier 3) | protein interactions | 20610 | 16 | 1 | 19454 | 50 |
ITPR2 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | VGLL1 (vestigial like family member 1) | protein interactions | 51442 | 16 | 1 | 19454 | 50 |
MEIS2 |
4.035e-02 | -3.21 | NBL1 (NBL1, DAN family BMP antagonist) | protein interactions | 4681 | 16 | 1 | 19454 | 50 |
LRIG1 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CNTFR (ciliary neurotrophic factor receptor) | protein interactions | 1271 | 16 | 1 | 19454 | 50 |
LIFR |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.043e-02 | -3.21 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 50 |
SORBS1 |
4.043e-02 | -3.21 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 50 |
SLC1A2 |
4.043e-02 | -3.21 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 50 |
FGFR3 |
4.043e-02 | -3.21 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 50 |
RYR3 |
4.043e-02 | -3.21 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 50 |
NFIA |
4.043e-02 | -3.21 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 50 |
ATP1A2 |
4.043e-02 | -3.21 | columnar/cuboidal epithelial cell maturation | biological process | GO:0002069 | 15 | 1 | 18204 | 50 |
GJA1 |
4.043e-02 | -3.21 | atrial cardiac muscle cell to AV node cell communication | biological process | GO:0086066 | 15 | 1 | 18204 | 50 |
GJA1 |
4.043e-02 | -3.21 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 50 |
MACF1 |
4.043e-02 | -3.21 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 50 |
SOX5 |
4.050e-02 | -3.21 | Lidocaine (Local Anaesthetic) Action Pathway | SMPDB pathways | SMP0000398 | 28 | 1 | 1369 | 2 |
ATP1A2 |
4.069e-02 | -3.20 | LZTS2 (leucine zipper tumor suppressor 2) | protein interactions | 84445 | 506 | 4 | 19454 | 50 |
PARD3,SORBS1,GJA1,NEBL |
4.079e-02 | -3.20 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 3 | 19454 | 50 |
NFIA,TRPS1,SOX5 |
4.094e-02 | -3.20 | RHOU (ras homolog family member U) | protein interactions | 58480 | 507 | 4 | 19454 | 50 |
MACF1,AHCYL2,PARD3,GJA1 |
4.101e-02 | -3.19 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 50 |
NTM,LRIG1,LSAMP,FGFR3 |
4.106e-02 | -3.19 | SLAMF1 (signaling lymphocytic activation molecule family member 1) | protein interactions | 6504 | 125 | 2 | 19454 | 50 |
CPE,LIFR |
4.106e-02 | -3.19 | SCGB1D1 (secretoglobin family 1D member 1) | protein interactions | 10648 | 125 | 2 | 19454 | 50 |
CPE,LIFR |
4.106e-02 | -3.19 | STXBP1 (syntaxin binding protein 1) | protein interactions | 6812 | 125 | 2 | 19454 | 50 |
GJA1,GPM6A |
4.106e-02 | -3.19 | UACA (uveal autoantigen with coiled-coil domains and ankyrin repeats) | protein interactions | 55075 | 125 | 2 | 19454 | 50 |
PARD3,GJA1 |
4.106e-02 | -3.19 | TCHP (trichoplein keratin filament binding) | protein interactions | 84260 | 125 | 2 | 19454 | 50 |
GLUL,PARD3 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
4.121e-02 | -3.19 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
MACF1,LIFR,ATP1A2,BMPR1B,FGFR3,SPARCL1,PON2,MSI2,NEBL,MEIS2,NTM,SLC4A4,NPAS3,PARD3 |
4.121e-02 | -3.19 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
PARD3,NPAS3,MEIS2,SLC4A4,NTM,MSI2,PON2,NEBL,FGFR3,BMPR1B,SPARCL1,ATP1A2,LIFR,MACF1 |
4.131e-02 | -3.19 | extremity | COSMIC cancer mutations | extremity | 1876 | 10 | 16828 | 49 |
RYR3,ATP13A4,FGFR3,PREX2,PTPRZ1,PARD3,FBXL7,PITPNC1,NEBL,CDH20 |
4.134e-02 | -3.19 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 50 |
TNIK |
4.134e-02 | -3.19 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 50 |
ATP1A2 |
4.148e-02 | -3.18 | bicellular tight junction | cellular component | GO:0005923 | 126 | 2 | 19108 | 49 |
PARD3B,PARD3 |
4.163e-02 | -3.18 | water channel activity | molecular function | GO:0015250 | 16 | 1 | 18094 | 48 |
AQP4 |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
PITPNC1,GPM6A |
4.166e-02 | -3.18 | HTR2C (5-hydroxytryptamine receptor 2C) | protein interactions | 3358 | 126 | 2 | 19454 | 50 |
SFXN5,GJA1 |
4.171e-02 | -3.18 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 7 | 16828 | 49 |
ATP13A4,RYR3,SOX5,PARD3,SLC1A2,GPC5,CDH20 |
4.176e-02 | -3.18 | Glycerol uptake facilitator protein | gene3d domains | 1.20.1080.10 | 14 | 1 | 14470 | 44 |
AQP4 |
4.193e-02 | -3.17 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 50 |
TNIK,LIFR,SORBS1,BMPR1B,CTNND2,MACF1,FGFR3,CPE,NFIA,ZNRF3 |
4.193e-02 | -3.17 | Codeine Action Pathway | SMPDB pathways | SMP0000405 | 29 | 1 | 1369 | 2 |
ATP1A2 |
4.215e-02 | -3.17 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 19 |
BMPR1B |
4.215e-02 | -3.17 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 19 |
RYR3 |
4.225e-02 | -3.16 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 44 |
SPARCL1,RYR3,MACF1 |
4.226e-02 | -3.16 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.250e-02 | -3.16 | lung-middle_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-middle_lobe-carcinoma-adenocarcinoma | 1368 | 8 | 16828 | 49 |
CTNND2,CPE,ATP13A4,PARD3B,RYR3,ATP1A2,ITPR2,MACF1 |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | FLRT3 (fibronectin leucine rich transmembrane protein 3) | protein interactions | 23767 | 17 | 1 | 19454 | 50 |
GJA1 |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | DENND5B (DENN domain containing 5B) | protein interactions | 160518 | 17 | 1 | 19454 | 50 |
GJA1 |
4.282e-02 | -3.15 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 50 |
SOX5 |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.286e-02 | -3.15 | FARP1 (FERM, ARH/RhoGEF and pleckstrin domain protein 1) | protein interactions | 10160 | 128 | 2 | 19454 | 50 |
PARD3,GJA1 |
4.286e-02 | -3.15 | TEAD2 (TEA domain transcription factor 2) | protein interactions | 8463 | 128 | 2 | 19454 | 50 |
TRPS1,ZBTB20 |
4.286e-02 | -3.15 | ATG5 (autophagy related 5) | protein interactions | 9474 | 128 | 2 | 19454 | 50 |
GJA1,FGFR3 |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.286e-02 | -3.15 | ATF7IP (activating transcription factor 7 interacting protein) | protein interactions | 55729 | 128 | 2 | 19454 | 50 |
SOX5,MACF1 |
4.286e-02 | -3.15 | SH3BP4 (SH3 domain binding protein 4) | protein interactions | 23677 | 128 | 2 | 19454 | 50 |
PARD3,GJA1 |
4.304e-02 | -3.15 | SH3DOMAIN | prints domains | PR00452 | 83 | 2 | 5227 | 21 |
NEBL,SORBS1 |
4.307e-02 | -3.14 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 50 |
CPE |
4.307e-02 | -3.14 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 50 |
ATP1A2 |
4.307e-02 | -3.14 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 50 |
AHCYL2 |
4.307e-02 | -3.14 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 50 |
SLC1A2 |
4.307e-02 | -3.14 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 50 |
CPE |
4.307e-02 | -3.14 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 50 |
SLC1A3 |
4.307e-02 | -3.14 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 50 |
ZNRF3 |
4.307e-02 | -3.14 | glutamine family amino acid biosynthetic process | biological process | GO:0009084 | 16 | 1 | 18204 | 50 |
GLUL |
4.321e-02 | -3.14 | C3orf52 (chromosome 3 open reading frame 52) | protein interactions | 79669 | 304 | 3 | 19454 | 50 |
GJA1,ITPR2,ZNRF3 |
4.334e-02 | -3.14 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 5 | 16828 | 49 |
SPARCL1,LIFR,TNIK,FGFR3,BMPR1B |
4.336e-02 | -3.14 | Imipramine Action Pathway | SMPDB pathways | SMP0000422 | 30 | 1 | 1369 | 2 |
ATP1A2 |
4.346e-02 | -3.14 | SLC38A2 (solute carrier family 38 member 2) | protein interactions | 54407 | 129 | 2 | 19454 | 50 |
GJA1,PARD3 |
4.346e-02 | -3.14 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 50 |
ZBTB20,SOX5 |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.352e-02 | -3.13 | homeostatic process | biological process | GO:0042592 | 1456 | 8 | 18204 | 50 |
SLC1A3,ATP13A4,AQP4,ATP1A2,RYR3,ZBTB20,GJA1,SLC4A4 |
4.377e-02 | -3.13 | developmental maturation | biological process | GO:0021700 | 286 | 3 | 18204 | 50 |
NFIA,GJA1,FGFR3 |
4.379e-02 | -3.13 | export from cell | biological process | GO:0140352 | 485 | 4 | 18204 | 50 |
CPE,GJA1,SLC4A4,ATP1A2 |
4.388e-02 | -3.13 | Z disc | cellular component | GO:0030018 | 130 | 2 | 19108 | 49 |
RYR3,NEBL |
4.400e-02 | -3.12 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 49 |
AQP4,SLC4A4,SLC1A3 |
4.415e-02 | -3.12 | ossification | biological process | GO:0001503 | 287 | 3 | 18204 | 50 |
FGFR3,GJA1,BMPR1B |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.428e-02 | -3.12 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 5 | 16828 | 49 |
SPARCL1,LIFR,TNIK,FGFR3,BMPR1B |
4.468e-02 | -3.11 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.468e-02 | -3.11 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 50 |
SOX5,NFIA |
4.479e-02 | -3.11 | Fluoxetine Action Pathway | SMPDB pathways | SMP0000426 | 31 | 1 | 1369 | 2 |
ATP1A2 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.507e-02 | -3.10 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 49 | 16828 | 49 |
LRIG1,GPM6A,GPC5,MSI2,TRPS1,FBXL7,SLC1A3,CPE,CDH20,AHCYL2,ITPR2,LIFR,PREX2,SPARCL1,RYR3,DTNA,PARD3B,MEIS2,SLC4A4,ZNRF3,ATP13A4,SORBS1,SFXN5,PITPNC1,NHSL1,RFX4,NTM,PON2,ABLIM1,NPAS3,AQP4,NKAIN3,ATP1A2,NFIA,TNIK,SOX5,LSAMP,SPON1,NEBL,PARD3,GLUL,ZBTB20,MACF1,BMPR1B,FGFR3,PTPRZ1,GJA1,SLC1A2,CTNND2 |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | SHISA2 (shisa family member 2) | protein interactions | 387914 | 18 | 1 | 19454 | 50 |
GJA1 |
4.529e-02 | -3.09 | ACAP1 (ArfGAP with coiled-coil, ankyrin repeat and PH domains 1) | protein interactions | 9744 | 18 | 1 | 19454 | 50 |
NEBL |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.530e-02 | -3.09 | PHLDB2 (pleckstrin homology like domain family B member 2) | protein interactions | 90102 | 132 | 2 | 19454 | 50 |
GJA1,PARD3 |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.557e-02 | -3.09 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 6 | 18094 | 48 |
ABLIM1,NEBL,SORBS1,CTNNA2,MACF1,GJA1 |
4.558e-02 | -3.09 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 19 |
RYR3 |
4.560e-02 | -3.09 | action potential | biological process | GO:0001508 | 124 | 2 | 18204 | 50 |
ATP1A2,GJA1 |
4.560e-02 | -3.09 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 50 |
SORBS1,ZBTB20 |
4.560e-02 | -3.09 | regulation of ossification | biological process | GO:0030278 | 124 | 2 | 18204 | 50 |
BMPR1B,GJA1 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.570e-02 | -3.09 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 50 |
SLC1A2 |
4.570e-02 | -3.09 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 50 |
ATP1A2 |
4.570e-02 | -3.09 | regulation of trophoblast cell migration | biological process | GO:1901163 | 17 | 1 | 18204 | 50 |
GJA1 |
4.570e-02 | -3.09 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 50 |
RYR3 |
4.570e-02 | -3.09 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 50 |
NFIA |
4.570e-02 | -3.09 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 50 |
TNIK |
4.570e-02 | -3.09 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 50 |
SORBS1 |
4.570e-02 | -3.09 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 50 |
CTNNA2 |
4.574e-02 | -3.08 | SH3 | prosite domains | PS50002 | 222 | 3 | 12186 | 44 |
MACF1,NEBL,SORBS1 |
4.596e-02 | -3.08 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 38 |
TRPS1 |
4.596e-02 | -3.08 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 38 |
NFIA |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 44 |
CPE |
4.596e-02 | -3.08 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 44 |
CPE |
4.615e-02 | -3.08 | cell cortex | cellular component | GO:0005938 | 313 | 3 | 19108 | 49 |
PARD3,PARD3B,ITPR2 |
4.622e-02 | -3.07 | Methadone Action Pathway | SMPDB pathways | SMP0000408 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Nicotine Action Pathway | SMPDB pathways | SMP0000431 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.622e-02 | -3.07 | Citalopram Action Pathway | SMPDB pathways | SMP0000424 | 32 | 1 | 1369 | 2 |
ATP1A2 |
4.623e-02 | -3.07 | ion binding | molecular function | GO:0043167 | 6007 | 22 | 18094 | 48 |
PON2,RYR3,GLUL,ITPR2,ABLIM1,SPON1,TRPS1,SPARCL1,SLC1A2,MACF1,BMPR1B,ZNRF3,SLC1A3,ATP1A2,PARD3,ATP13A4,DTNA,ZBTB20,TNIK,PITPNC1,CPE,FGFR3 |
4.626e-02 | -3.07 | actomyosin structure organization | biological process | GO:0031032 | 125 | 2 | 18204 | 50 |
NEBL,SORBS1 |
4.631e-02 | -3.07 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 50 |
NFIA,SOX5,BMPR1B,FGFR3 |
4.634e-02 | -3.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 28 | 16828 | 49 |
PON2,LRIG1,NPAS3,TRPS1,SLC1A3,ABLIM1,ITPR2,LIFR,ATP1A2,NKAIN3,PARD3B,DTNA,RYR3,TNIK,SOX5,SPARCL1,PREX2,NEBL,SLC4A4,ATP13A4,GLUL,PARD3,MACF1,ZBTB20,SORBS1,CTNND2,PTPRZ1,FGFR3 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.715e-02 | -3.05 | DVL2 (dishevelled segment polarity protein 2) | protein interactions | 1856 | 531 | 4 | 19454 | 50 |
MACF1,ZNRF3,PARD3,LIFR |
4.716e-02 | -3.05 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 50 |
SOX5,NFIA |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
AHCYL2,CDH20,ITPR2,LIFR,DTNA,RYR3,PARD3B,PREX2,SPARCL1,MSI2,GPC5,GPM6A,LRIG1,CPE,SLC1A3,FBXL7,TRPS1,PITPNC1,NHSL1,SFXN5,SORBS1,RFX4,MEIS2,ZNRF3,SLC4A4,ATP13A4,NFIA,NKAIN3,AQP4,ATP1A2,LSAMP,SOX5,TNIK,PON2,NTM,ABLIM1,NPAS3,ZBTB20,MACF1,BMPR1B,PTPRZ1,FGFR3,CTNND2,SLC1A2,GJA1,NEBL,SPON1,GLUL,PARD3 |
4.752e-02 | -3.05 | Leu-rich_rpt_4 | interpro domains | IPR025875 | 18 | 1 | 18521 | 50 |
LRIG1 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.764e-02 | -3.04 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 49 |
TNIK |
4.764e-02 | -3.04 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 49 |
ATP1A2 |
4.774e-02 | -3.04 | PCDH19 (protocadherin 19) | protein interactions | 57526 | 19 | 1 | 19454 | 50 |
GJA1 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | DEFB125 (defensin beta 125) | protein interactions | 245938 | 19 | 1 | 19454 | 50 |
GJA1 |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | GCHFR (GTP cyclohydrolase I feedback regulator) | protein interactions | 2644 | 19 | 1 | 19454 | 50 |
NEBL |
4.774e-02 | -3.04 | OSM (oncostatin M) | protein interactions | 5008 | 19 | 1 | 19454 | 50 |
LIFR |
4.774e-02 | -3.04 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 50 |
ZBTB20 |
4.774e-02 | -3.04 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 50 |
ATP1A2 |
4.775e-02 | -3.04 | brain development | biological process | GO:0007420 | 724 | 5 | 18204 | 50 |
SLC1A2,RFX4,ATP1A2,MEIS2,CTNNA2 |
4.779e-02 | -3.04 | NIBAN2 (niban apoptosis regulator 2) | protein interactions | 64855 | 136 | 2 | 19454 | 50 |
GJA1,GLUL |
4.793e-02 | -3.04 | skin-back-malignant_melanoma | COSMIC cancer mutations | skin-back-malignant_melanoma | 280 | 3 | 16828 | 49 |
PREX2,ATP1A2,TNIK |
4.832e-02 | -3.03 | dicarboxylic acid catabolic process | biological process | GO:0043649 | 18 | 1 | 18204 | 50 |
GLUL |
4.832e-02 | -3.03 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 50 |
PARD3 |
4.832e-02 | -3.03 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 50 |
ATP1A2 |
4.832e-02 | -3.03 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 50 |
CTNND2 |
4.832e-02 | -3.03 | cardiac myofibril assembly | biological process | GO:0055003 | 18 | 1 | 18204 | 50 |
NEBL |
4.832e-02 | -3.03 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 50 |
ZNRF3 |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.842e-02 | -3.03 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 50 |
NFIA,SOX5 |
4.842e-02 | -3.03 | CDC42BPA (CDC42 binding protein kinase alpha) | protein interactions | 8476 | 137 | 2 | 19454 | 50 |
GJA1,PARD3 |
4.848e-02 | -3.03 | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | REACTOME pathways | R-HSA-2173791 | 17 | 1 | 10285 | 30 |
PARD3 |
4.848e-02 | -3.03 | Elevation of cytosolic Ca2+ levels | REACTOME pathways | R-HSA-139853 | 17 | 1 | 10285 | 30 |
ITPR2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.875e-02 | -3.02 | Nitrogen metabolism | KEGG pathways | hsa00910 | 17 | 1 | 7161 | 21 |
GLUL |
4.875e-02 | -3.02 | Nitrogen metabolism | KEGG pathways | ko00910 | 17 | 1 | 7161 | 21 |
GLUL |
4.894e-02 | -3.02 | response to organophosphorus | biological process | GO:0046683 | 129 | 2 | 18204 | 50 |
RYR3,ITPR2 |
4.907e-02 | -3.01 | Trichlormethiazide Action Pathway | SMPDB pathways | SMP0000121 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Torsemide Action Pathway | SMPDB pathways | SMP0000118 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hartnup Disorder | SMPDB pathways | SMP0000189 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Methyclothiazide Action Pathway | SMPDB pathways | SMP0000081 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Indapamide Action Pathway | SMPDB pathways | SMP0000110 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorthalidone Action Pathway | SMPDB pathways | SMP0000122 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Cystinuria | SMPDB pathways | SMP0000723 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Cyclothiazide Action Pathway | SMPDB pathways | SMP0000103 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Quinethazone Action Pathway | SMPDB pathways | SMP0000091 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Iminoglycinuria | SMPDB pathways | SMP0000193 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance (LPI) | SMPDB pathways | SMP0000585 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Spironolactone Action Pathway | SMPDB pathways | SMP0000134 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Furosemide Action Pathway | SMPDB pathways | SMP0000115 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Eplerenone Action Pathway | SMPDB pathways | SMP0000135 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Kidney Function | SMPDB pathways | SMP0000483 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Chlorothiazide Action Pathway | SMPDB pathways | SMP0000078 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Ethacrynic Acid Action Pathway | SMPDB pathways | SMP0000097 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Lysinuric Protein Intolerance | SMPDB pathways | SMP0000197 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Glucose Transporter Defect (SGLT2) | SMPDB pathways | SMP0000184 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bendroflumethiazide Action Pathway | SMPDB pathways | SMP0000090 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Metolazone Action Pathway | SMPDB pathways | SMP0000105 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydroflumethiazide Action Pathway | SMPDB pathways | SMP0000108 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Polythiazide Action Pathway | SMPDB pathways | SMP0000080 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Bumetanide Action Pathway | SMPDB pathways | SMP0000088 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Amiloride Action Pathway | SMPDB pathways | SMP0000133 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Hydrochlorothiazide Action Pathway | SMPDB pathways | SMP0000100 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Blue Diaper Syndrome | SMPDB pathways | SMP0000583 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.907e-02 | -3.01 | Triamterene Action Pathway | SMPDB pathways | SMP0000132 | 34 | 1 | 1369 | 2 |
ATP1A2 |
4.924e-02 | -3.01 | water transmembrane transporter activity | molecular function | GO:0005372 | 19 | 1 | 18094 | 48 |
AQP4 |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.924e-02 | -3.01 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 48 |
ATP1A2 |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
SORBS1,DTNA,MACF1 |
4.941e-02 | -3.01 | LRR_4 | pfam domains | PF12799 | 18 | 1 | 17795 | 50 |
LRIG1 |
4.987e-02 | -3.00 | ligand-gated monoatomic cation channel activity | molecular function | GO:0099094 | 135 | 2 | 18094 | 48 |
ITPR2,RYR3 |